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Streptococcus pneumoniae é uma bactéria de Gram-positivo considerada um 
agente patogénico oportunista, pois coloniza de forma assintomática a nasofaringe 
humana, sendo a colonização um pré-requisito para causar uma infeção localizada 
ou sistémica. O uso disseminado de antimicrobianos diminuiu drasticamente a 
morbilidade e mortalidade a nível global da doença pneumocócica. No entanto, a 
resistência aos antibióticos surgiu rapidamente após o seu uso inicial. Atualmente, 
S. pneumoniae apresenta resistência a um grande número de antibióticos, 
incluindo β-lactâmicos e quinolonas. Assim, para prevenir infeções pneumocócicas e 
devido à emergência de estirpes resistentes aos antimicrobianos, foram 
desenvolvidas vacinas utilizando os polissacáridos capsulares pneumocócicos. 
Existem dois tipos de vacinas, as estritamente polissacarídicas e as conjugadas. 
Nas vacinas polissacarídicas apenas são incluídos os polissacáridos, enquanto nas 
vacinas conjugadas os polissacáridos estão unidos a uma proteína transportadora. 
Atualmente, em Portugal, uma vacina polissacarídica 23-valente (PPV23) e duas 
vacinas conjugadas pneumocócicas (PCV), uma com 10 serotipos (PCV10) e outra 
com 13 serotipos (PCV13) estão disponíveis no mercado. A PCV13 substituiu a 
vacina conjugada 7-valente (PCV7) aumentando a proteção conferida pela vacina 
para 13 serotipos. A PCV7 foi a primeira vacina conjugada introduzida em Portugal 
e causou uma alteração na distribuição dos serotipos, tanto na colonização como na 
doença invasiva pneumocócica (IPD). Os serotipos vacinais na IPD em crianças 
diminuíram e, de forma menos pronunciada, também diminuíram na IPD em 
adultos. A diminuição da incidência dos serotipos incluídos na PCV7 deu origem à 
expansão dos serotipos não-vacinais (NVT) que aumentaram em frequência na IPD. 
Os genotipos que apresentam serotipos incluídos nas vacinas também podem 
escapar à sua proteção alterando a sua cápsula através da recombinação genética 
dos seus genes capsulares, um processo denominado troca capsular.  
A plasticidade do genoma bacteriano é essencial para a adaptação rápida a 
ambientes em mudança e para a colonização de novos nichos ecológicos. Os 
mecanismos moleculares responsáveis pela plasticidade do genoma podem ser 
mutações pontuais, rearranjos genómicos, elementos genéticos móveis ou a 




por transdução. A transferência horizontal de genes e a recombinação são 
importantes porque distribuem e fixam mutações benéficas e também são 
responsáveis pela aquisição de novos elementos genéticos, tendo um papel essencial 
no desenvolvimento de resistência a antibióticos, troca capsular e na aquisição de 
fatores de virulência. Entre os mecanismos de transferência genética horizontal, a 
transformação genética natural tem sido a mais estudada em S. pneumoniae e é 
crucial para a plasticidade genética desta bactéria. O estado de competência 
necessário para que a transformação genética natural ocorra nos pneumococos é 
rigidamente controlado por um sistema de quorum-sensing. O produto do gene 
comC é processado e secretado por um transportador ABC (ComAB) resultando na 
acumulação extracelular de um péptido de 17 aminoácidos, o péptido estimulador 
da competência (CSP). Um sistema de dois componentes, consistindo de uma 
histidina cinase (ComD) e o seu regulador de resposta (ComE), é responsável por 
detetar a concentração extracelular de CSP e despoletar a cascata de reações que 
induzem a competência através da ativação de um conjunto de genes precoces, 
incluindo o gene comX. O produto do gene comX é um fator sigma alternativo que 
desencadeia a expressão de genes tardios necessários à competência. Foram 
identificados vários alelos do gene comC em S. pneumoniae, dando origem a pelo 
menos 3 CSPs diferentes. No entanto, a maioria das estirpes apresenta apenas um 
dos dois principais alelos: CSP1 (≈70 % das estirpes) ou CSP2 (≈30 % das estirpes). 
Cada estirpe possui apenas uma cópia do gene comC e responde especificamente ao 
CSP produzido devido à especificidade mostrada pelo domínio sensor de ComD. 
Assim sendo, os pneumococos podem ser divididos em subpopulações tendo em 
conta o CSP a que respondem, definindo o ferótipo de uma estirpe (frequentemente 
o ferótipo CSP1 ou CSP2). A designação de ferótipo foi escolhida porque o CSP 
comporta-se como uma feromona. 
O objetivo principal desta tese foi estudar os ferótipos de S. pneumoniae, que 
são definidos pela resposta específica de uma estirpe a uma variante do CSP, e o 
impacto da diversidade do ferótipo na estrutura genética da população 
pneumocócica. Para atingir este objetivo, a diversidade e a abundância dos 
ferótipos foram determinadas em estirpes recolhidas de infeções pneumocócicas 
invasivas ocorridas em Portugal. Para identificar os determinantes estruturais da 
especificidade dos ferótipos, tentámos obter a estrutura 3D do domínio sensor de 
ComD mediante cristalografia de raios X e, posteriormente, cristalizá-lo em 




ferótipos poderiam ser observadas em detalhe usando esta técnica. Para aplicar 
esta técnica fiz um estágio no laboratório do Dr. Juan Hermoso no Instituto 
Química Física Rocasolano, CSIC, Madrid. Também foi escolhido o serogrupo 6, 
cujos serotipos apresentam ferótipos diferentes, para avaliar se a recombinação 
entre as estirpes foi influenciada ou não. O estudo do serogrupo 6 também teve 
como objetivo avaliar a evolução clonal e dos serotipos durante 14 anos (1999-2012) 
e verificar se os novos serotipos identificados recentemente no serogrupo 6 estavam 
presentes na nossa coleção.  
Foi realizado um estudo detalhado da diversidade genética do operão 
comCDE de uma amostra de estirpes responsáveis por infeções pneumocócicas 
invasivas em Portugal. Foram identificados 30 perfis únicos dos alelos comCDE. 
Três variantes de CSP foram identificadas correspondendo aos ferótipos CSP1, 
CSP2 e CSP3. No entanto, os CSPs encontrados neste estudo já eram conhecidos, 
não tendo sido identificadas novas variantes do CSP. A diversidade do gene comD 
foi relacionada com o ferótipo, não acontecendo o mesmo com o gene comE. A maior 
parte da divergência genética estava localizada na região que codifica o CSP e o 
domínio sensor de ComD. O gene comD apresentou a maior diversidade, enquanto 
o comE era mais conservado, apresentando apenas 5 variantes proteicas. Foi a 
primeira vez que o alelo comC-3 e, portanto, o ferótipo CSP3 foram identificados em 
pneumococos isolados em Portugal. ComC-1.1 (CSP1), ComD-1.1 e ComE-1 foram 
as variantes proteicas mais frequentemente identificadas nestas estirpes. 
Utilizou-se uma extensa coleção de estirpes (n=903) responsáveis por infeções 
pneumocócicas invasivas em crianças (<18 anos) durante um período de 14 anos 
para identificar a abundância de cada um dos ferótipos e avaliar a sua evolução, 
usando um novo esquema de PCR para identificar o ferótipo. Também foram 
realizadas associações entre o ferótipo e outras características epidemiológicas. O 
ferótipo mais abundante foi o CSP1 (n=681, 75,4 %), seguido pelo CSP2 (n=192, 
21,3 %) e depois pelo CSP3 (n=20, 2,2 %). As proporções dos ferótipos 
permaneceram estáveis, apesar das mudanças ocorridas na distribuição dos 
serotipos. Os ferótipos CSP1 e CSP2 apresentaram o mesmo grau de diversidade 
em relação ao serotipo, ST e CC. Este trabalho confirmou que o ferótipo CSP3 não é 
frequente mas está distribuído em diversas linhagens genéticas.  
Outro objetivo desta tese foi estudar a especificidade do domínio sensor de 
ComD em relação ao CSP através da sua caracterização estrutural por 




desenhadas e produzidas com as etiquetas de afinidade 6x His e LSL150 e inseridas 
nas estirpes E. coli BL21(DE3) e E. coli JM109(DE3). A produção do sensor de 
ComD não foi alcançada em nenhuma das condições testadas e não foram 
realizadas experiências adicionais com esta proteína. ComD poderia apresentar 
uma topologia semelhante à proteína AgrC, um recetor de membrana do tipo 
histidina cinase de Staphylococcus aureus, com o seu domínio sensor inserido na 
membrana através de 7 segmentos transmembranares conectados por pequenas 
regiões extra e intracelulares. Muitas das substituições de aminoácidos entre 
ComD1, ComD2 e ComD3 poderiam estar localizadas nos segmentos 
transmembranares. A presença de tantas hélices membranares pode ter sido a 
razão pela qual a produção do sensor de ComD não foi bem-sucedida.  
O serogrupo 6 foi escolhido para avaliar a influência do ferótipo na 
recombinação entre os serotipos deste serogrupo, uma vez que estes apresentaram 
distintos ferótipos. Observou-se uma diminuição da variante 6B-2 na doença 
pneumocócica invasiva (IPD), mas não de 6B-1, após a introdução da vacina 
conjugada, sustentada por uma diminuição das estirpes do CC273. O serotipo 6C 
foi associado com a IPD em adultos e aumentou nesta faixa etária apresentando 
duas linhagens genéticas (CC315 e CC395), enquanto em crianças as mesmas 
linhagens expressaram outros serotipos do serogrupo 6. Em conjunto, estes 
resultados sugerem uma potencial proteção cruzada das PCVs contra o serotipo 6C 
entre as crianças vacinadas, mas não entre adultos. O serotipo 6A tornou-se o 
serotipo mais importante do serogrupo 6 em crianças, mas diminuiu na IPD em 
adultos. Não foram detetados outros serotipos do serogrupo 6, portanto, os ensaios 
fenotípicos disponíveis ou os ensaios genotípicos simples permanecem adequados 
para distinguir os serotipos dentro das estirpes do serogrupo 6. A influência do 
ferótipo na recombinação entre as estirpes do serogrupo 6 foi avaliada através da 
análise dos possíveis casos de troca capsular. No entanto, devido ao baixo número 
destes casos, o serogrupo 6 não proporcionou uma conclusão clara sobre este tema. 
Assim, foi utilizada uma coleção maior de estirpes isoladas de crianças com doença 
invasiva pneumocócica (n=903) e foram feitos testes de fluxo de genes e 
diferenciação genética entre populações com um ferótipo diferente usando os dados 
de MLST destas estirpes. No entanto, a influência do ferótipo na estrutura genética 





S. pneumoniae apresenta um polimorfismo nos genes comC e comD e a 
interação dos seus produtos pode ser como um mecanismo de chave e fechadura. 
Foi visto que estes genes estão sob seleção positiva e, por isso, se ocorrerem 
mutações nesta região, estas poderiam diminuir consideravelmente a eficiência da 
indução de competência. A proporção dos ferótipos parece ser 70:28:2 
(CSP1:CSP2:CSP3) e também parece que é mantida em populações provenientes de 
diversos locais e de datas diferentes. Porém, o mecanismo que mantém estas 
proporções continua por esclarecer, embora o facto das estirpes do ferótipo CSP1 
apresentarem uma melhor capacidade do que as estirpes do ferótipo CSP2 para 
formar biofilmes e produzir transformantes possa explicar a maior proporção do 
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Streptococcus pneumoniae is a Gram-positive bacterium and is considered an 
opportunistic pathogen because it colonizes asymptomatically the human 
nasopharynx and colonization is a pre-requisite for local and systemic disease. 
The widespread use of antimicrobials decreased dramatically the global 
burden of pneumococcal disease. However, resistance to antibiotics quickly arose 
after its initial use. Nowadays, S. pneumoniae has high frequency of resistance to a 
large group of antibiotics, including β-lactams and quinolones. In order to prevent 
pneumococcal infections and with the advent of antimicrobial resistance, vaccines 
have been developed using capsular polysaccharides as immunogens. There are two 
types of vaccines, strictly polysaccharide and conjugate vaccines. The first is 
constituted only by polysaccharides whereas in the latter polysaccharides are 
linked to a carrier protein.  Currently, in Portugal the two types of vaccines are 
licensed, the 23-valent polysaccharide vaccine (PPV23) and two pneumococcal 
conjugate vaccines (PCV), one with 10 serotypes (PCV10) and another with 13 
serotypes (PCV13). PCV13 replaced the 7-valent conjugate vaccine (PCV7) 
increasing vaccine protection to 13 serotypes. PCV7 was the first conjugate vaccine 
introduced in Portugal and caused a change in the distribution of serotypes both in 
colonization and in invasive pneumococcal disease (IPD). Vaccine serotypes 
responsible for IPD in children decreased and, in a less pronounced way, also 
decreased in adults. The decrease in the incidence of serotypes included in PCV7 
resulted in the expansion of non-vaccine serotypes (NVT) that increased in 
frequency in IPD. Genotypes that display serotypes included in the vaccines may 
also escape vaccine pressure by altering their capsule through the genetic 
recombination of their capsular genes, a process called capsular switching. 
Bacterial genome plasticity is essential for rapid adaptation to changing 
environments and colonization of new niches. The molecular mechanisms 
responsible for genome plasticity are point mutations, genomic rearrangements, 
mobile genetic elements and horizontal gene transfer either by natural genetic 




important because they distribute and fix beneficial mutations and are also 
responsible for the acquisition of novel genetic information, having an essential 
role in the development of antibiotic resistance, capsular switching and the 
acquisition of virulence determinants. Among the mechanisms of horizontal gene 
transfer, natural genetic transformation has been the most studied in S. 
pneumoniae and it is crucial for genetic plasticity in pneumococci. Pneumococci 
undergo genetic transformation through natural competence which is tightly 
controlled by a quorum-sensing-like system. The product of the comC gene is 
processed and secreted by an ABC transporter (ComAB) resulting in the 
accumulation of a 17-aminoacid peptide pheromone, the competence-stimulating 
peptide (CSP), into the medium. A two-component system, consisting of a histidine 
kinase receptor (ComD) and its cognate response regulator (ComE), is responsible 
for sensing CSP concentration and triggering the competence response by 
activating a set of early genes including comX. The product of the comX gene is an 
alternative sigma factor that triggers the expression of late genes necessary for 
competence. 
In pneumococci, several alleles of the comC gene have been identified 
producing at least 3 different mature CSPs. However, most strains present only 
one of two main alleles: CSP1 (≈70 % of the strains) or CSP2 (≈30 % of the strains). 
Each strain has only one copy of a comC allele and responds specifically to the CSP 
produced due to the specificity shown by the sensor domain of ComD. 
Consequently, pneumococci can be divided into subpopulations according to the 
CSP they respond to, defining the pherotype of an isolate (usually pherotype CSP1 
or CSP2). It was termed pherotype because CSP behaves like a pheromone. 
The main purpose of this thesis was to study pneumococcal pherotypes, the 
mechanism underlying the specific response of a given isolate to a CSP variant, 
and the impact of pherotype diversity on the genetic structure of the pneumococcal 
population. To achieve this goal, pherotype diversity and abundance were 
determined in pneumococcal isolates recovered from IPD in Portugal. To determine 
the structural determinants of pherotype specificity we attempted to study the 3D 
structure of the ComD sensor by X-ray crystallography and, ultimately, to 
crystallize it in complex with CSP. Specific interactions between ComD and CSP of 
each pherotype could be observed in detail using this technique. To perform these 
experiments, I visited Dr. Juan Hermoso’s lab in Instituto Química Física 




associated with different pherotypes, to see if recombination was restricted or not 
between the isolates. Study of serogroup 6 also had the aim of evaluating their 
clonal and serotype evolution during 14 years (1999-2012) and to check if the newly 
identified serogroup 6 serotypes were present in our pneumococcal collection. 
It was performed a comprehensive study of the genetic diversity of the 
comCDE locus of a sample of invasive pneumococci recovered in Portugal. A total of 
30 unique profiles of comCDE alleles were identified. Three CSP variants were 
identified corresponding to pherotypes CSP1, CSP2 and CSP3. However, the CSPs 
found in this study were already known, thus new variants of CSP were not 
discovered. The diversity of comD was associated with pherotype but that was not 
the case for comE. The majority of the genetic divergence was located in the region 
coding the mature CSP and the sensor domain of ComD. The gene comD was the 
most diverse while comE was more conserved presenting just 5 protein variants. It 
was the first time that the comC-3 allele and therefore the CSP3 pherotype were 
identified in pneumococcal isolates recovered in Portugal. ComC-1.1 (CSP1), 
ComD-1.1 and ComE-1 were the most frequent protein variants produced in these 
isolates. 
We used an extensive pneumococcal invasive isolate collection (n=903) 
recovered from children (<18 years) during a period of 14 years to identify the 
abundance of each pherotype and evaluate their evolution, using a new PCR 
scheme to identify pherotype. Then, associations between pherotype and other 
characteristics were tested. The most abundant pherotype was CSP1 (n=681, 75.4 
%), followed by CSP2 (n=192, 21.3 %) and then by CSP3 (n=20, 2.2 %). Pherotype 
proportions remained stable despite the changes that occurred in serotype 
distribution and pherotype CSP1 and CSP2 presented the same degree of diversity 
regarding serotype, ST and CC. This work confirmed that pherotype CSP3 was 
infrequent but it was distributed throughout several genetic backgrounds. 
Another goal of this thesis was to study the specificity of ComD sensor 
domain towards CSP through the structural characterization by X-ray 
crystallography. Four constructs of parts of the ComD sensor were designed and 
produced with 6x His and LSL150 affinity tags and inserted into the E. coli strains 
BL21(DE3) and JM109(DE3). Production of the ComD sensor was not achieved in 
any of the conditions tested and further experiments were not performed with this 
protein. ComD could present a topology similar to AgrC, a histidine kinase 




embedded sensor with 7 transmembrane segments connected by small 
extracellular regions, where many of the amino acid substitutions between ComD1, 
ComD2 and ComD3 could be located in transmembrane domains. The presence of 
so many membrane helices could be the reason why the production of ComD sensor 
was a not achieved. 
We also chose serogroup 6 to see if pherotype was influencing recombination 
between serogroup 6 serotypes since they present distinct serotypes. It was seen a 
decrease of the 6B-2 variant among invasive pneumococcal disease (IPD), but not 
6B-1, post conjugate vaccine introduction, underpinned by a decrease of CC273 
isolates. Serotype 6C was associated with adult IPD and increased in this age 
group representing two lineages (CC315 and CC395), while the same lineages 
expressed other serogroup 6 serotypes in children. Taken together, these findings 
suggest a potential cross-protection of PCVs against serotype 6C IPD among 
vaccinated children but not among adults. Serotype 6A became the most important 
serogroup 6 serotype in children but it decreased in adult IPD. No other serogroup 
6 serotypes were detected, so available phenotypic or simple genotypic assays 
remain adequate for distinguishing serotypes within serogroup 6 isolates. Influence 
of pherotype on the recombination between serogroup 6 isolates was evaluated by 
analyzing the cases of possible capsular switching events. However, due to the low 
number of these events, serogroup 6 did not provide a clear evidence to clarify this. 
Thus, a large collection of pneumococci causing IPD in children (n=903) was used 
and gene flow and genetic differentiation tests were performed using their MLST 
data. However, the influence of pherotype on the genetic structure of S. 
pneumoniae was not clear, even when considering all the information collected. 
S. pneumoniae presents a polymorphism in the genes comC and comD and 
the interaction of their products might function as a lock and key mechanism. 
These genes are under positive selection and mutations in this region could 
decrease the efficiency of competence induction. Pherotype abundance in a 70:28:2 
ratio (CSP1:CSP2:CSP3) seems to be maintained in populations from diverse 
geographic origins and isolation dates. However, the mechanism maintaining it 
remains to be elucidated, although the better capacity of CSP1 strains to form 
biofilms and yield more transformants than CSP2 strains may contribute to 








AU: absorbance units 
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The main purpose of this thesis was to study pneumococcal pherotypes, the 
mechanism underlying the specific response of a given isolate to a variant of the 
competence-stimulating peptide (CSP) and the impact of pherotype diversity in 
pneumococcal population genetic structure. 
 
This thesis was divided into 4 parts: 
  
 Part I – Introduction: it is an introductory part and consists of: 
o Chapter 1 - Background: in this chapter is presented a review of 
the literature providing the essential information to read this 
thesis. 
o Chapter 2 – Aims of the thesis: the questions pursued in this 
work to achieve the goals established are presented in this chapter. 
o Chapter 3 – Pneumococcal isolates and typing methods: the 
common materials and methods, transversal to all chapters, are 
presented here. Specific procedures of the studies performed are 
presented in their respective chapter.  
 
 Part II – Pherotype diversity and abundance: this part presents an initial 
description of pherotype characteristics such as their genetic diversity and 
abundance among pneumococci populations. Two studies were performed and 
are presented in the following chapters: 
o Chapter 4 – Diversity of the comCDE locus: a genetic analysis 
of the pherotype-defining and competence-regulating genes was 
performed to check and compare the comCDE diversity of the 
pneumococci lineages circulating in Portugal with other studies. 
o Chapter 5 – Pherotype abundance: it was studied the 
proportion of pherotypes over a 14 years period when conjugate 
vaccines were introduced and substantial changes occurred in 
serotype distribution. 
 
 Part III – Pherotype specificity and influence on the genetic structure: 
the work presented in this part addressed the specificity of pherotypes and its 
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consequences for the evolution of S. pneumoniae. This is the last section 
presenting results, which are divided into two chapters: 
o Chapter 6 – Structural study of pherotype specificity by X-
ray crystallography: production of the ComD sensor for 
crystallization experiments was attempted during my visit to Dr. 
Juan Hermoso lab in Instituto Química Física Rocasolano, CSIC, 
Madrid. The goal was to study the specific interaction between 
CSP and ComD through their 3D structure. 
o Chapter 7 – Serogroup 6 and influence of pherotype in 
genetic recombination: this chapter presents the work 
performed to address the consequences of pherotype diversity on 
the genetic recombination among pneumococci. We focused on 
serogroup 6 to address this question and part of this work was 
published on the following article: 
 
J. Diamantino-Miranda, S.I. Aguiar, J.A. Carriço, J. Melo-Cristino 
and M. Ramirez. (2017). Clonal and serotype dynamics of serogroup 6 isolates 
causing invasive pneumococcal disease in Portugal: 1999-2012. PLoS One, 
12(2):e0170354. doi: 10.1371/journal.pone.0170354. 
 
 Part IV – Final remarks and future perspectives: this is the final part of 
this thesis and a final reflection discussing the importance of the results of this 
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CHAPTER 1.                       BACKGROUND 
 
1.1. Pneumococcus discovery and identification 
 
Streptococcus pneumoniae, also known as pneumococcus, was first isolated 
simultaneous and independently by George Sternberg and Louis Pasteur in 1881 
(Watson et al., 1993). After its identification, it was confirmed to be an 
asymptomatically carried agent that could cause disease in humans and other 
mammalian hosts. The first name assigned to this bacterium was Diplococcus 
pneumoniae in 1920, which was later, changed to Streptococcus pneumoniae in 
1974 (Grabenstein and Klugman, 2012). S. pneumoniae is a Gram-positive 
bacterium with a genome containing a high AT content. Morphologically, 
pneumococci typically present in pairs of cells with a lancet-shape. Phylogenetic 
studies placed S. pneumoniae in the Mitis group with Streptococcus 
pseudopneumoniae and Streptococcus mitis being the closest relatives of the 
pneumococcus (Kilian et al., 2008).  
The first approach to microbiological identification of S. pneumoniae consists 
in the detection of α-haemolytic colonies on blood agar plates, cell lysis by bile and 
susceptibility to optochin (Werno and Murdoch, 2008). Regarding cell lysis by bile, 
the major pneumococcal autolytic enzyme LytA is activated in the presence of the 
bile salt deoxycholate (Mosser and Tomasz, 1970). This feature distinguishes S. 
pneumoniae from other α-haemolytic streptococci. Another test to differentiate 
pneumococci from commensal streptococci is the susceptibility to optochin (also 
known as ethylhydrocupreine) because this antibiotic is able to inhibit the 
pneumococcal F0F1-ATPase (Angulo et al., 2011). However, resistance to 
deoxycholate and to optochin was already reported (Aguiar et al., 2006, Obregón et 
al., 2002, Pikis et al., 2001), making each of these phenotypic tests separately not 
fully conclusive for identification of pneumococci.  
 
1.2. Colonization and disease 
 
S. pneumoniae is considered an opportunistic pathogen because it colonizes 
asymptomatically the human nasopharynx and colonization is required before local 
and systemic disease. It is assumed that the human nasopharynx is the main 
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reservoir of pneumococci, especially in children where up to almost 70 % can be 
colonized (Sá-Leão et al., 2009). Colonization starts with exposure to the bacteria 
and their attachment to epithelium. Then, bacteria replicate by obtaining nutrients 
and finally they persist by evading the host immune system. The cycle is complete  
with transmission to a new host (Siegel and Weiser, 2015). Colonization of the 
upper respiratory tract can not only evolve into disease but also drives the 
evolution of S. pneumoniae (Siegel and Weiser, 2015). 
Mucus is an important physical barrier to colonization and infection. The 
pneumococcal polysaccharide capsule is the main virulence factor of S. pneumoniae 
and possibly evolved to allow survival in the mucus. Pneumococci undergo phase 
variation, a process that regulates capsule production. A thick capsule is produced 
to pass through the mucus by anionic interactions because most capsules are 
negatively charged. However, the presence of a thick capsule hampers attachment 
to the epithelium because the capsular polysaccharide masks the structures at the 
cell surface mediating adherence to host cells. For this reason, capsule production 
is downregulated to enable attachment to host surface carbohydrates. Pneumococci 
present several adhesion factors, for example NanA, a lectin-like protein, PspC also 
known as CbpA, and pili, the later divided into two major isoforms (Aguiar et al., 
2012, Horácio et al., 2016). After adhesion to the epithelium, pneumococci form a 
biofilm, a highly-structured community of cells that produce an extracellular 
matrix and adhere to abiotic or biological surfaces (Figure 1.1). Forming biofilms 
during colonization may serve as protection against the host, by reducing 
production of inflammation inducing factors, and also promotes closeness between 
cells to facilitate the exchange of genetic material (Chao et al., 2014). 
Pneumococci interact with the host mucosal immune system and must evade 
it to persist. Capsule is a major player in this interaction because it limits 
opsonisation by complement and antibody. Pneumococci also possess an IgA1 
protease which cleaves human immunoglobulin A1, the dominant IgA present in 
the human respiratory tract. During colonization, pneumococci face not only the 
host immune system but also need to compete with the indigenous host microbiota 
or other opportunistic pathogens.  Haemophilus influenzae outcompetes S. 
pneumoniae by promoting its clearance (Lysenko et al., 2005) while pneumococcal 
colonization protects against Staphylococcus aureus colonization (Bogaert et al., 
2004). Co-infection with Influenza virus is beneficial to pneumococci because it 
increases its replication in the nasopharynx (Siegel et al., 2014). Pneumococci also 
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compete with other pneumococcal strains by producing bacteriocins that target 
them or strains of closely related species (Dawid et al., 2007). 
Colonizing pneumococci may progress to disease causing a range of infections. 
However, pneumococcal infections do not promote spread to new hosts and are 
therefore believed not to be a major selective pressure in the evolution of these 
bacteria. In contrast, the pressures to successfully colonize the host lead to the 
development of virulence factors that ultimately contribute to disease (Weiser, 
2009). The range of infections may be from local and mild like acute otitis media, 
sinusitis and conjunctivitis, to systemic and severe like pneumonia, septicaemia or 
meningitis, with associated mortality rates around 5 %, 20 % and 30 %, 
respectively (Henriques-Normark and Tuomanen, 2013). The pneumococcal 
infections in which pneumococci invade a normally sterile body site such as blood 
and cerebrospinal fluid (CSF) are considered invasive pneumococcal disease (IPD). 
Annual IPD burden is around 14.5 million cases resulting in 800 000 deaths in 
children under the age of 5 and more than 20 % of the cases in the elderly result in 
death (Heron, 2012, Naucler et al., 2013, O'Brien et al., 2009). These data show 
that children and the elderly are the main groups at increased risk for 
pneumococcal infection followed by immunocomprised people. 
 
 
Figure 1.1 – Scanning electron microscopy image of S. pneumoniae biofilms formed on the 
nasal septum of a mouse. Mice were experimentally colonized 7 days prior. Biofilms are the non-
contiguous aggregates on the left. Adapted from Gilley and Orihuela (Gilley and Orihuela, 2014). 
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1.3. Antimicrobial resistance 
 
The widespread use of antimicrobials decreased dramatically the global 
burden of pneumococcal disease. However, resistance to antibiotics quickly arose 
after its initial use. Since the identification of the first S. pneumoniae strain with 
reduced susceptibility to penicillin (Hansman and Bullen, 1967), antibiotic 
resistance among S. pneumoniae has increased and it has become a global issue 
(Appelbaum, 1987). Moreover, at this point S. pneumoniae has inherent resistance 
to a large group of antibiotics, including β-lactams, macrolides, aminoglycosides 
and first-generation quinolones (El Moujaber et al., 2017). Below is presented a 
brief review of the molecular mechanisms underlying resistance to the 
antimicrobials for which susceptibility was tested in this thesis: penicillin and 
cefotaxime (β-lactams), erythromycin (macrolide), clindamycin (lincosamide), 
tetracycline, chloramphenicol, co-trimoxazole (sulfonamide), levofloxacin 




-lactam antibiotics inhibit cell-wall synthesis through the binding to specific 
enzymes called penicillin-binding proteins (PBPs) (Neu and Gootz, 1996). S. 
pneumoniae presents a total of six PBPs but only three (PBP1a, PBP2x and PBP2b) 
are associated with resistance (Table 1.1). 
The main -lactam resistance mechanism in S. pneumoniae is the acquisition 
of altered PBP genes, or of gene fragments which are recombined with the native 
genes, from related species such as S. mitis and Streptococcus oralis through 
genetic transformation (Jensen et al., 2015). On the one hand, studies show that a 
high resistance level is achieved through the presence in the same strain of three 
altered PBPs: PBP1a, PBP2b and PBP2x.  On the other hand, a low level of 
penicillin resistance could be based mainly on modifications of PBP2x and PBP2b, 
resulting in penicillin non-susceptible S. pneumoniae (PNSP) (El Moujaber et al., 
2017). MurM and MurN, encoded by the murMN operon, have also been associated 
with penicillin resistance (Filipe and Tomasz, 2000, Garcia-Bustos and Tomasz, 
1990). These proteins are responsible for an irregularity in cell-wall synthesis 
because of the substitution of linearized muropeptides by atypical branched ones. 
However, MurM alone is insufficient to induce penicillin resistance, although it is 
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crucial to get the highest level of resistance to penicillin and cephalosporins, 
another class of -lactams antimicrobials (Smith and Klugman, 2001). 
 
Table 1.1 – Mutations associated with β-lactam resistance. Table adapted from (El Moujaber et 
al., 2017). 
 Mutation Resistance 
pbp2x Thr550Ala Cefotaxime 
T338A Penicillin 
pbp2b Thr446Ala Piperacillin 
T451A Penicillin 
pbp1a Mosaic gene Penicillin and cephalosporin 
cpoA Gly12Val Piperacillin 
ciaH Thr230Pro Cefotaxime 
Ala203Val 
murM Mosaic gene Penicillin and cephalosporin 
 
1.3.2. Macrolide, lincosamide and streptogramin B 
 
Resistance to macrolides in pneumococci can be due to modification of the 
ribosome and it was the first resistance mechanism described in S. pneumoniae. 
Ribosomal alteration is caused by the erm gene frequently located in the 
transposons Tn1545 (Courvalin and Carlier, 1986) and Tn917  (McDougal et al., 
1998). A methylase is encoded by ermB which is responsible for the dimethylation 
of the adenine A2058 in the domain V of 23S rRNA, reducing its affinity to 
macrolides (Arthur et al., 1987). In addition, ermA, another methylase, was also 
implicated in macrolide resistance (Syrogiannopoulos et al., 2001) and both ermA 
and ermB provide resistance to the macrolide-lincosamide-streptogramin B 
families (MLSB phenotype) (McDougal et al., 1998, Syrogiannopoulos et al., 2001). 
This kind of resistance can be displayed in two distinct forms, either constitutive 
(cMLSB) or inducible (iMLSB). These resistance phenotypes are defined by the 
regulatory region and not by a specific gene type (Leclercq and Courvalin, 1991). 
Moreover, at the end of the 1990s it was identified a different resistance pattern. In 
this case, it was observed resistance to macrolides in the absence of ermA and 
ermB genes but vulnerability to clindamycin and streptogramin B. This phenotype, 
known as the M phenotype, was recognized in both S. pneumoniae and 
Streptococcus pyogenes (Sutcliffe et al., 1996). Shortly after, mefE was identified as 
a key factor in conferring resistance with this phenotype (Tait-Kamradt et al., 
1997). The mefE gene encodes an efflux pump which expels the macrolide antibiotic 
from the cell (Sutcliffe et al., 1996). Furthermore, it was identified a transposon, 
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Tn2010, which carried both mefE and ermB, making it a dual-macrolide resistance 




Tetracycline resistance is mostly associated with the presence of tet genes 
that encode efflux proteins, like tetA, tetB, tetC and tet31, and proteins related with 
ribosomal protection, like tetM, tetO, tetT and tetW, being tetM the dominant 
tetracycline resistance gene found in S. pneumoniae (Chopra and Roberts, 2001). 
These genes were shown to be carried in a transposon together with another 
resistance gene conferring chloramphenicol resistance: cat (Shoemaker et al., 
1979). This genetic element was called Tn5253 (Ayoubi et al., 1991) and found to be 
composed of two distinct conjugative transposons: the tet-carrier Tn5251 inserted 
within Tn5252, the carrier of the cat gene. Moreover, other transposons were also 
recognized as transporters of tetM, such as Tn1545 (Courvalin and Carlier, 1986), 
Tn2009 (Del Grosso et al., 2004), Tn3872, Tn2010 and Tn2017 (Roberts and 
Mullany, 2009). Nevertheless, several works described tetracycline susceptibility 
among tetM-harbouring strains (Varaldo et al., 2009). The reason for the low 
transcription level of tetM and consequently the susceptible profile was the 
occurrence of frame shift mutations originated by either a deletion or an insertion 
(Grohs et al., 2012). Finally, a recent study revealed another tetracycline resistance 
mechanism in S. pneumoniae in the absence of tet genes (Lupien et al., 2015). In 
this case, resistance was conferred by mutations in the rpsJ gene, which encodes 
the ribosomal protein S10 close to the tetracycline site of action, in parallel with 




The main mechanism of chloramphenicol resistance among bacteria, 
including S. pneumoniae, is the acquisition of chloramphenicol acetyltransferase 
(Cat) encoded by the cat gene. This protein is responsible for chloramphenicol 
acetylation generating O-acetoxy chloramphenicol products which decreases the 
binding of the antimicrobial to ribosomes (Dang-Van et al., 1978, Yunis, 1988) . As 
referred before, in S. pneumoniae the cat gene is transported by the composite 
transposon Tn5253 (Ayoubi et al., 1991). 





Some studies have shown that the major increase in resistance to 
trimethoprim and trimethoprim-sulfamethoxazole (also known as co-trimoxazole) 
was caused by a single amino acid substitution (Ile100Leu) in dihydrofolate 
reductase (Adrian and Klugman, 1997, Schmitz et al., 2001). This mutation can be 
accompanied by other mutations in this protein that result in increases of 
resistance. In the absence of the substitution in position 100, it was described 
another substitution, Asp92Ala, in more than 30 % of co-trimoxazole resistant 
pneumococci (Cornick et al., 2014). Co-trimoxazole resistance also requires 




Several mutations in the genes gyrA, gyrB, parC and parE have been 
identified as the main reason of quinolone resistance in S. pneumoniae. The level of 
fluoroquinolone resistance depends on the mutations that occurred. While 
mutations in parC alone confer low-level quinolone resistance, when they are 
accompanied by mutations in gyrA the resistance level is higher. Moreover, gyrA or 
parC mutations can also propitiate further substitutions increasing the resistance 
level (Gillespie et al., 2003). Mutations in gyrB and parE were also observed but 
they conferred a lowest level of resistance than mutations in either gyrA or parC 
(Hooper, 2000). 
It was thought that target modification was the only mechanism responsible 
for quinolone resistance. However, pmrA, a pneumococcal multidrug resistance 
gene, coding for an efflux pump, was associated with fluoroquinolone resistance 
and displayed more than 20 % similarity to the Bacillus subtilis multidrug 
resistance (bmr) and S. aureus norfloxacin efflux pump (norA) genes (El Moujaber 
et al., 2017). Additionally, the overexpression of patA and patB genes was 
connected with fluoroquinolone resistance in clinical isolates of S. pneumoniae 
since they become susceptible to this antimicrobial after inactivation of these genes 
(Garvey et al., 2011). Both genes are located in the same operon and they interact 
together as a heterodimer forming an ABC transporter. However, the regulatory 
mechanisms controlling expression of these genes are still unknown (Baylay et al., 
2015, Baylay and Piddock, 2015). 





Vancomycin resistance has not yet been found in S. pneumoniae. However, a 
mutation in the histidine kinase vncS gene was reported in vancomycin-tolerant 
pneumococci (Henriques Normark et al., 2001, Sung et al., 2006). This mutation 
was regarded to be the main mechanism of vancomycin tolerance causing the 
suppression of the autolytic activity. It was also seen that a vncS mutant was 
capable of developing tolerance to other antibiotics such as quinolones and β-




Oxazolidinones are a new class of synthetic antibiotics and linezolid was the 
first oxazolidinone to become available. Linezolid is effective against Gram-positive 
bacteria but has limited activity against Gram-negative bacteria (Diekema and 
Jones, 2001). Linezolid is one of the few truly new antibiotics that have been 
introduced in many years, as most of the antibiotics recently released are 
derivatives of existing drugs. FDA approved linezolid to be used against S. 
pneumoniae because of the increase of PNSP. Although the mode of action of 
oxazolidinones is not completely clear, they act as protein synthesis inhibitors by 
binding to the ribosomal peptidyl transferase center and stopping the growth of 
bacteria (Bozdogan and Appelbaum, 2004, Long and Vester, 2012). It was observed 
that oxazolidinones bind to the 50S ribosomal subunit but they have no affinity to 
the 30S subunit (Zhou et al., 2002). Oxazolidinones compete with chloramphenicol 
and lincomycin for binding to the 50S subunit, which indicates that they have a 
close binding site (Lin et al., 1997). The effect of oxazolidinones binding to 50S is 
inhibition of initiation complex formation and of 70S formation (Aoki et al., 1997, 
Bobkova et al., 2003, Swaney et al., 1998). When 70S is already formed, binding of 
oxazolidinones inhibits translocation of the peptide chain from A site to P site 
during peptide bond formation. The mechanism of action of oxazolidinones is 
similar to those of other antibiotics binding to the ribosomal peptidyl transferase 
center. 
One of the resistance mechanisms to linezolid is target modification and 
transferable resistance has not been described yet for oxazolidinones. The other 
nonribosomal resistance mechanism reported is due to mutations causing an 
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increased expression of ABC transporter genes in S. pneumoniae (Billal et al., 
2011, Feng et al., 2009). Linezolid resistant S. pneumoniae strains selected in vitro 
carried mutations in the peptidyl transferase centre of 23S rRNA (Bozdogan and 
Appelbaum, 2004). Linezolid resistance in clinical isolates of S. pneumoniae was 
firstly reported for two S. pneumoniae isolates that presented a minimum 
inhibitory concentration (MIC) of 4 µg/mL (Farrell et al., 2004). These isolates 
presented two separate mutations, A2059G in combination with G2057A in the 23S 




In order to prevent pneumococcal infections and with the advent of 
antimicrobial resistance, vaccines have been developed, using capsular 
polysaccharides as immunogenic agents. However, these pneumococcal vaccines 
only confer protection against the serotypes included in their composition. 
The known serotypes are not equally prevalent among the isolates causing 
IPD and only a few serotypes are responsible for most of these infections. Their 
distribution also varies according to the age group considered and there are also 
differences in their prevalence in respect to colonization. Thus, some serotypes 
seem to have an enhanced invasive capacity, while others are more frequently 
found in colonization (Sá-Leao et al., 2011). Serotype prevalence also varies over 
time and there are differences in their distribution between several countries 
(Hausdorff, 2002). For this reason, it is important to monitor strains in circulation 
in the population at the local level. At present, epidemiological surveillance of IPD 
makes it possible to evaluate the effect of vaccines on the distribution of serotypes 
in different countries and whether new formulations of vaccines are needed. 
There are two types of vaccines, polysaccharide and conjugate vaccines. In the 
first only polysaccharides are included whereas in the latter polysaccharides are 
linked to a carrier protein. Currently, in Portugal, the two types of vaccines are 
licensed, the 23-valent polysaccharide vaccine (PPV23) and two pneumococcal 
conjugate vaccines (PCV), one with 10 serotypes (PCV10) and another with 13 
serotypes (PCV13). PPV23 was introduced in Portugal in 1996, while the PCV10 
and PCV13 vaccines were licensed by the European Medicines Agency in March 
and December 2009 (Aguiar et al., 2010b), respectively, and were introduced in 
Portugal on the same date. PCV13 replaced the 7-valent conjugate vaccine (PCV7) 
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increasing vaccine protection to 13 serotypes. PCV7 was available for pediatric 
vaccination in Portugal through the private sector from June 2001 onwards and its 
uptake slowly increased over the years (Horácio et al., 2016). In 2012, PCV13 
received approval for use also in adults >50 years of age with an extension being 
made to all ages in 2013. Additionally, PCV13 entered the Portuguese National 
Immunization Program in June 2015 for children born from January 2015 onwards 
(Horácio et al., 2016). The serotypes included in the vaccines (Table 1.2) were 
chosen because they represented the majority of cases of IPD at the time they were 
implemented, although the serotypes included in PCV7 were based mainly in the 
serotype distribution of USA while PCV10 and PCV13 also took into consideration 
other geographical areas. Some of the vaccine serotypes were associated with 
antimicrobial resistance. 
Conjugate vaccines are recommended for children under 2 years of age and 
for children up to 6 years of age who have a medical condition that increases the 
risk of pneumococcal infection (Nuorti and Whitney, 2010). Polysaccharides that 
are conjugated to a protein induce a thymus-dependent response, so conjugate 
vaccines are effective in children younger than 2 years old because their immune 
system is able to mount this type of response efficiently. Thus, after three doses in 
the first year, these vaccines induce the activation of memory cells and their 
protection is prolonged. Conjugate vaccines also confer immunity in the mucosa 
(Nurkka et al., 2001), preventing colonization of the nasopharynx by vaccine 
serotypes (Klugman, 2001). 
PCV7 was the first conjugate vaccine introduced in Portugal and caused a 
change in the distribution of serotypes both in colonization (Sá-Leão et al., 2009) 
and in IPD (Aguiar et al., 2010b, Aguiar et al., 2008). Vaccine serotypes responsible 
for IPD in children decreased and, in a less pronounced way, also decreased in 
adults (Aguiar et al., 2008). Thus, this vaccine proved to be very effective in the 
prevention of pneumococcal infections by vaccine serotypes and in the USA there 
was a decline in the incidence of IPD in all age groups (Pilishvili et al., 2010). 
However, in United Kingdom PCV7 introduction also reduced the incidence of IPD 
but its effect was quickly mitigated by serotype replacement which happened faster 
than in USA (Choi et al., 2011, Miller et al., 2011). The effect observed in adults, 
which is an unvaccinated group, was probably due to the interruption of the 
transmission of the vaccine serotypes by the vaccinated children. This protective 
effect exerted on the non-vaccinated groups is called herd effect. 
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The decrease in the incidence of serotypes included in PCV7 resulted in the 
expansion of non-vaccine serotypes (NVT) that increased their frequency in IPD. 
This replacement was due to the reduction or even elimination of nasopharyngeal 
colonization by vaccine serotypes, which allowed the expansion of non-vaccine 
serotypes in this ecological niche (Dagan, 2009b). Among NVT, serotype 19A 
showed the greatest expansion following PCV7 use, both in the USA (Pilishvili et 
al., 2010) and in Europe (Ardanuy et al., 2009, Miller et al., 2011). This serotype 
also increased in areas where PCV7 was not implemented, therefore, PCV7 only 
strengthened or accelerated the expansion of serotype 19A (Aguiar et al., 2010c). 
Genotypes that display serotypes included in the vaccine may also escape vaccine 
pressure by altering their capsule through genetic recombination of the capsular 
locus, a process called capsular switching. It has been documented in the USA that 
a genotype associated with serotype 4 obtained serotype 19A capsular genes, 
evading PCV7 (Brueggemann et al., 2007). PCV7 includes serotypes associated 
with antimicrobial resistance and, shortly after its introduction, the frequency of 
resistant strains decreased. However, resistance to antibiotics has increased again, 
as some of the NVT that have expanded are associated with resistance, as was the 
case of serotype 19A (Dagan, 2009a). 
The use of PCV13 in the vaccination of adults aged 50 years and over has 
recently been authorized by the European Medicines Agency. PCV13 has been 
shown to be more immunogenic than PPV23 for most of the serotypes shared by 
both vaccines and is well tolerated in healthy adults (Scott et al., 2007). The use of 




Table 1.2 – Serotype composition of pneumococcal vaccines. 
Vaccine Included Serotypes  
PCV7    4   6B    9V    14   18C  19F   23F  
PCV10a 1   4 5  6B 7F   9V    14   18C  19F   23F  
PCV13b 1  3 4 5 6A 6B 7F   9V    14   18C 19A 19F   23F  
PPV23c 1 2 3 4 5  6B 7F 8 9N 9V 10A 11A 12F 14 15B 17F 18C 19A 19F 20 22F 23F 33F 
aPCV10 has all serotypes of PCV7 plus serotypes 1, 5 and 7F. 
bPCV13 has all PCV10 serotypes plus serotypes 3, 6A and 19A. 
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1.5. Genetic transformation 
 
Bacterial genome plasticity is essential for rapid adaptation to changing 
environments and colonization of new niches. The molecular mechanisms 
responsible for genome plasticity are point mutations, genome rearrangements, 
mobile genetic elements and horizontal gene transfer either by natural genetic 
transformation or transduction (Straume et al., 2015). 
Horizontal gene transfer and recombination are important because they 
distribute and fix beneficial mutations and are also responsible for the gain of new 
genetic information. Between the mechanisms of horizontal gene transfer, natural 
genetic transformation has been the most studied in S. pneumoniae and is crucial 
for genetic plasticity in pneumococci (Chewapreecha et al., 2014, Croucher et al., 
2011). Although it is recognized that pneumococcus is a highly transformable 
bacterium, there is a great variation in transformation frequencies among the 
pneumococcal population and it does not correlate with genetic relatedness (Evans 
and Rozen, 2013). 
Natural genetic transformation is a phenomenon where cells are in a state of 
competence being able to recognize and bind to double-stranded DNA fragments 
present in the external environment, independent of their origin. These fragments 
are then transported through the membrane as single-stranded DNA and can be 
integrated into the genome through genetic recombination often leading to 
permanent modification of the cell genotype (Claverys and Havarstein, 2002). This 
mechanism was discovered in S. pneumoniae when, in 1928, Griffith found that 
non-virulent and non-capsulated strains were able to acquire a polysaccharide 
capsule and cause deadly infections in mice if they were administered 
concomitantly with encapsulated and virulent strains previously killed by heat 
(Griffith, 1928). It is now known that S. pneumoniae is not the only naturally 
competent species, with more than 60 other species found to be naturally 
transformable (Johnsborg et al., 2007). Competence in S. pneumoniae is temporary, 
reaching a maximum about twenty minutes after the beginning of the process and 
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1.5.1. Competence regulation 
 
The mechanism of competence regulation is a form of intercellular 
communication that is called quorum-sensing because it allows monitoring the 
population density through the concentration of an extracellular peptide, the 
competence-stimulating peptide (CSP). A large number of bacterial species present 
this type of communication, which reveals the importance of quorum-sensing in the 
adaptation and survival of these microorganisms. Coordination of competence was 
among the first examples of intercellular communication between bacteria 
(Claverys et al., 2006). The process of competence regulation is schematized in 









Figure 1.2 – Pneumococcal quorum-sensing-like system of competence regulation for 
natural genetic transformation. The products of the operons comAB and comCDE are the main 
constituents of the two-component signaling system regulating competence in S. pneumoniae. 
Secretion and processing of the product of comC by the ABC transporter ComAB results in the 
accumulation of the mature CSP in the medium until it reaches a critical concentration to trigger 
competence. This peptide is sensed by the transmembrane histidine kinase ComD, which 
autophosphorylates upon CSP binding, transferring the phosphoryl group to the response regulator 
ComE. Then this protein becomes activated and, after dimerization, induces the expression of the 
early competence genes, including comAB, comCDE, comX and comM, resulting in an amplification of 
the production of CSP and driving the cells into the competent state. ComX is an alternative sigma 
factor that upon association with the RNA polymerase activates the expression of the late competence 
genes involved in fratricide, DNA-uptake and recombination of homologous DNA. ComM protein 
provides immunity against CbpD induced lysis. Thus, CbpD, a secreted murein hydrolase, induces the 
lysis of non-competent pneumococci by enhancing the activity of the peptidoglycan hydrolases LytA 
and LytC in the process termed fratricide. The DNA released from the lysed bacteria can be taken up 
by competent cells and integrated into their genomes. 
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1.5.2. Pherotypes determined by competence-stimulating peptide (CSP) 
 
In the 1960s it was discovered that competence was induced in a coordinated 
way when the cultures reached a defined cell density and that the sterile filtered 
medium of competent cultures contained a proteinaceous compound that induced 
competence in non-competent cultures (Johnsborg and Havarstein, 2009). 
However, this protein was purified and identified only in 1995 and was found to be 
a small unaltered peptide consisting of 17 amino acid residues, which was named 
CSP (Havarstein et al., 1995). The amino acid sequence of this peptide was used to 
identify the gene that produces it. This gene, termed comC, encodes a precursor of 
CSP with 41 amino acids, of which 24 belong to the N-terminal leader peptide 
(Figure 1.3). At the processing site this peptide contains two glycine residues 
which are characteristic of double-glycine leader peptides. Several alleles of the 
comC gene have been identified producing at least 3 different mature CSPs (Pozzi 
et al., 1996, Ramirez et al., 1997, Whatmore et al., 1999). However, most strains 
present only one of the two main alleles: CSP1 (≈70 % of the strains) or CSP2 (≈30 
% of the strains) (Carrolo et al., 2009). The third variant of CSP is not very well 
studied because of its rarity and its nomenclature varies among the studies that 
report it (Ramirez et al., 1997, Whatmore et al., 1999). Here in this thesis, this 
third variant will be called CSP3. Each strain has only one copy of a comC allele 
and responds specifically to the CSP produced due to the specificity shown by the 
sensor domain of ComD (see next section). Consequently, pneumococci can be 
divided into subpopulations regarding the CSP they respond to, defining the 
pherotype of an isolate (usually pherotype CSP1 or CSP2). It was termed pherotype 
because CSP behaves like a pheromone. 
Prior to CSP identification, two genes (comA and comB, Figure 1.2) were 
identified which were essential for the presence of this peptide in the supernatant 
of S. pneumoniae cultures (Chandler and Morrison, 1988). ComA was later found to 
belong to a family of ABC (ATP-binding cassette) transporters specific for double-
glycine leader peptides (Claverys and Havarstein, 2002, Hui and Morrison, 1991, 
Hui et al., 1995) and which, together with ComB, specifically exported CSP. The 
CSP precursor is cleaved after the two glycine residues and its continuous export 
leads to its accumulation in the medium (Figure 1.2). 
 




Figure 1.3 – comC1 gene sequence and respective encoded amino acid residues. Residues 
that form CSP1 are underlined and the processing site formed by two glycine residues is pointed out. 
Adapted from Håvarstein et al., 1995 (Havarstein et al., 1995). 
 
1.5.3. ComD and ComE, a histidine kinase receptor and a response regulator 
protein 
 
The comC gene belongs to an operon containing two other genes, comD and 
comE (Figure 1.2). These encode two proteins, ComD and ComE, which form a 
two-component sensor system that monitors the external concentration of CSP and 
controls the expression of specific genes. ComD is a histidine kinase and has been 
identified as the CSP-specific receptor (Havarstein et al., 1996). Like most histidine 
kinases, ComD has a sensor domain at the N-terminus associated with the 
membrane and a cytoplasmic C-terminal kinase domain containing the histidine 
residue that is phosphorylated. This protein has some diversity in its binding 
domain (Havarstein et al., 1997) which, together with the variation of a 
hydrophobic domain in each CSP variant (Johnsborg et al., 2006), is thought to be 
responsible for the specific interaction between these two proteins. Thus, each 
strain synthesizes a receptor specific for the CSP variant it produces, thereby 
defining different pherotypes. 
The binding of CSP to ComD is believed to induce a conformational change in 
its transmembrane domain which activates its cytoplasmic kinase domain. This 
activation leads to the phosphorylation of the respective response regulator, the 
ComE protein. In its phosphorylated state this protein induces the transcription of 
several genes by binding to a specific sequence in their promoters (Martin et al., 
2010, Ween et al., 1999). Among these genes are the comCDE and comAB operons 
and the comX gene. With the induction of the comCDE and comAB operons, 
extracellular CSP and intracellular levels of phosphorylated ComE rapidly increase 
in an autocatalytic process allowing the coordinated induction of competence across 
the population. However, genes encoding proteins required for genetic 
transformation, such as dprA, sssB and recA (Claverys et al., 2009), are not directly 
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induced by ComE, and the comX gene has been shown to be responsible for this 
induction (Lee and Morrison, 1999). Thus, we can divide the genes of the cascade of 
competence into two classes, early (comCDE, comAB and comX) and late (dprA, 
sssB and recA) (Figure 1.2), whose difference of expression time was confirmed by 
DNA microarray studies (Peterson et al., 2004). 
 
1.5.4. ComX, the alternative sigma factor 
 
Genes belonging to the late class, which include all those encoding the 
proteins required for the acquisition and recombination of exogenous DNA, share 
in the -10 region a consensus sequence (TACGAATA) named com-box and a 
thymine-rich site in the -25 region (Campbell et al., 1998). The com-box is not 
present in ComE-activated genes and is different from the standard Pribnow box, 
suggesting that an alternative sigma factor is responsible for the regulation of the 
genes that contain this motif (Claverys and Havarstein, 2002). In fact, it was 
demonstrated that the product of the comX gene was the regulating factor of these 
genes. ComX is a sigma factor (σX) that associates with the RNA polymerase during 
the period of competence (Figure 1.2) (Lee and Morrison, 1999, Luo et al., 2003). It 
has also been found that there are two copies of the comX gene (designated comX1 
and comX2) in the S. pneumoniae genome and that both are functional. 
Although ComX is the only link between early competence genes and the 
genes required for genetic transformation, it was later found that another factor 
was necessary for the efficient development of competence and accumulation of 
ComX.  The expression of this factor was induced by ComE and, therefore, it 
belongs to the early class (Luo et al., 2003). This competence-positive regulator is 
encoded by the comW gene and acts post-transcriptionally on ComX (Luo et al., 
2004). The ClpEP complex is the major protease responsible for the degradation of 
ComX when competence declines and ComW was shown to protect σX from 
proteolysis (Piotrowski et al., 2009, Sung and Morrison, 2005). Thus, the presence 
of ComW is essential for S. pneumoniae to develop and maintain the state of 
competence. Furthermore, regulation of ComX by ComW ensures that competence 
is not induced at a wrong time due to basal transcription of comX when the RNA 
polymerase overcomes the terminator of transcription of the genes upstream of 
comX or when there are mutations affecting the expression or function of ComX 
(Sung and Morrison, 2005). 





The number of genes induced by CSP is high, with 105 genes being identified 
in one study (Dagkessamanskaia et al., 2004) and 124 in another study (Peterson et 
al., 2004). However, only 7 early and 14 late class genes are required for the 
genetic transformation process to occur (Eldholm et al., 2009), indicating that CSP 
can regulate other physiological processes. In fact, it was discovered a molecular 
mechanism induced during competence that causes lysis of non-competent cells 
with the consequent active release of DNA into the medium (Moscoso and Claverys, 
2004, Steinmoen et al., 2002, Steinmoen et al., 2003). As this mechanism kills cells 
genetically similar to the attacking cells it was termed fratricide (murder of brother 
or sister) (Figure 1.2) and it was shown that cell lysis occurs by contact between 
cells and not by diffusion in the medium of the lytic factors (Steinmoen et al., 2003). 
Proteins possessing choline binding domains (CBDs) have the ability to bind 
non-covalently to the phosphorylcholine residues present in the teichoic and 
lipoteichoic acids on the cell surface of S. pneumoniae (Kausmally et al., 2005). Of 
the various choline-binding proteins encoded by S. pneumoniae, three of them have 
been described as important for competence-induced lysis and all are murein 
hydrolases: LytA, LytC and CbpD (Eldholm et al., 2009, Guiral et al., 2005, 
Kausmally et al., 2005, Moscoso and Claverys, 2004, Steinmoen et al., 2002). 
The lytA gene encodes the major autolysin of S. pneumoniae and the lytC 
gene synthesizes the LytC lysozyme. The lytA gene, as the lytC, is constitutively 
transcribed but, unlike lytC, during competence its expression increases because it 
belongs to the CSP-induced cinA-recA-dinF operon (Mortier-Barriere et al., 1998, 
Rimini et al., 2000). The CbpD protein is only produced during competence and its 
gene belongs to the late class (Kausmally et al., 2005, Peterson et al., 2004). 
The action of CbpD is essential in fratricide because in strains without this 
protein the lysis of non-competent cells is absent (Eldholm et al., 2009, Kausmally 
et al., 2005). However, strains with a double mutation in the lytA and lytC genes 
are practically unable to lyse cells during the competence, i.e., CbpD alone does not 
have sufficiently effective hydrolytic activity (Eldholm et al., 2009, Kausmally et 
al., 2005, Moscoso and Claverys, 2004) and the presence of LytA or LytC 
significantly increases cell lysis. Thus, when CbpD is present, LytA and LytC 
assume an important role in the lytic process (Eldholm et al., 2009). 
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CbpD is only produced by the competent cells but LytA and LytC are 
synthesized by both the attacking and the target cells. It was discovered that the 
proteins produced by the non-competent cells resulted in greater lysis than the 
same proteins produced by the attacking cells (Eldholm et al., 2009). LytC can be 
found in the supernatant medium while LytA is not detected in the medium, 
therefore LytC is secreted and LytA is an intracellular protein thought to be 
associated with the membrane (Eldholm et al., 2009). Cleavage of the 
peptidoglycan by CbpD facilitates the hydrolysis of these chains by LytC (Perez-
Dorado et al., 2010). Thus, during the fratricide, the attacking cells through the 
production of CbpD are able to activate LytC and, after membrane degradation, 
LytA is released from the non-competent cells and consequently also becomes 
active. The more cells are lysed, the greater the concentration of active LytC and 
LytA, and this amplification effect allows fratricide to be efficient at a reduced cost 
to the attacking cells. 
Attacking cells must have a mechanism of protection against their own 
lysins. The protein conferring protection to competent cells has already been 
identified and is named ComM (Havarstein et al., 2006). Strains that do not 
produce ComM are susceptible to the action of CbpD, LytA and LytC even though 
they are in the competent state. The comM gene belongs to the early class, being 
expressed before the cbpD gene, and its product is a transmembrane protein. 
Although the competent cell immunity factor is already known, the mechanism 
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CHAPTER 2.                         AIMS OF THE THESIS 
 
The aim of this thesis was to strengthen the current knowledge on horizontal 
gene transfer and its importance for the evolution of S. pneumoniae, focusing in the 
pherotypes variants that exist in this population. The specific goals of each study 
presented in this thesis were the following: 
 
Part II – Pherotype diversity and abundance: the general aim of this part was 
to characterize the isolates recovered in IPD in Portugal regarding their pherotype 
diversity and abundance. 
 Chapter 4 – Diversity of the comCDE locus: the aim of this study was 
to evaluate the genetic diversity of the pherotype-defining region comCDE 
of a sample of isolates recovered from IPD in Portugal during 1999-2001, 
a period before introduction of PCV7. Thus, we wanted to report the 
diversity present in Portuguese isolates and compare our results with 
other studies of isolates recovered in other geographical locations. 
Another aim was to detect possible new variants of CSP.  
 Chapter 5 – Pherotype abundance: the proportion of pherotypes is 
well described in the literature and CSP1 is always the dominant 
pherotype over CSP2 in a proportion close to 70:30. A few isolates were 
reported to present a different pherotype, here named CSP3, suggesting 
that this pherotype is very uncommon. It was previously noted that there 
was an association between serotype and pherotype. From this scenario, 
the main goal of this study was to evaluate the evolution of pherotype 
abundance over a 14 years period where conjugate vaccines were 
introduced and dramatic changes occurred in serotype distribution. 
Another aim was to reliably identify the abundance of CSP3 in natural 
populations of S. pneumoniae by using a large collection (n=903). 
 
Part III – Pherotype specificity and influence on the genetic structure: the 
aim of the work performed in this part was to describe the structural determinants 
of the specificity of pherotypes and if there are any consequences of this specificity 
affecting the evolution of S. pneumoniae by influencing recombination among 
pneumococci. 
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 Chapter 6 – Structural study of pherotype specificity by X-ray 
crystallography: our strategy to determine the structural determinants 
of pherotype specificity was to study the 3D structure of the ComD sensor 
by X-ray crystallography and, ultimately, to crystallize it in complex with 
CSP. Specific interactions between ComD and CSP of each pherotype 
could be observed in detail using this technique. To perform this 
experiment, I visited Dr. Juan Hermoso lab in Instituto Química Física 
Rocasolano, CSIC, Madrid. His team has an extensive experience in 
studying protein 3D structures by X-ray crystallography.  
 Chapter 7 – Serogroup 6 and influence of pherotype in genetic 
recombination: phenotypic differences among pherotypes were observed 
regarding their capacity to form biofilms and their recombination 
efficiency (Carrolo et al., 2014). Thus, the main goal of this work was to 
evaluate possible effects of pherotype diversity on the evolution of S. 
pneumoniae. We wanted to elucidate if pherotype has any influence on the 
recombination between isolates that share or not the same pherotype. To 
achieve this goal, we focused on serogroup 6, whose serotypes present 
different pherotypes, to see if recombination was restricted or not between 
isolates. Study of serogroup 6 also had the aim to evaluate their clonal 
and serotype evolution during 14 years (1999-2012) and to check if newly 
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CHAPTER 3. PNEUMOCOCCAL ISOLATES AND TYPING 
METHODS 
 
This chapter describes the general procedures that are common to all studies 
presented in this thesis. 
 
3.1. Pneumococcal isolates 
 
Since 1999 the isolates of S. pneumoniae responsible for infections in 
Portugal have been monitored by the Portuguese Group for the Study of 
Streptococcal Infections. This surveillance is carried out by more than 30 hospital 
laboratories located in all regions of Portugal, including the Autonomous Regions of 
Azores and Madeira. These laboratories collect isolates from patients with 
pneumococcal infections which are then sent to the Institute of Microbiology of the 
Faculty of Medicine of the University of Lisbon. 
The largest collection studied in this study was composed of isolates that 
caused IPD in children (<18 years) during the years 1999 and 2012 in Portugal. 
Although the laboratories were contacted periodically, no audit was carried out to 
ascertain whether all the collected isolates were sent. In cases where there was 
more than one invasive isolate from the same patient only one was included in the 
study, giving preference to isolates collected from the CSF. 
 
3.2. Storing, identification and growing of isolates 
 
The isolates, on arrival at the Institute of Microbiology, were inoculated onto 
blood agar plates (Tryptone Soy Agar, Oxoid, Hampshire, England, supplemented 
with 5 % (v/v) sheep blood, Probiológica, Belas, Portugal) and incubated overnight 
at 35 °C with an atmosphere enriched with 5 % CO2. Laboratory identification of S. 
pneumoniae consisted of an analysis of the colony morphology, hemolysis type after 
growth in solid medium enriched with blood, susceptibility to optochin and 
solubility in bile salts. 
Colonies of S. pneumoniae are round, non-pigmented, and exhibit a 
characteristic central depression of this species resulting from self-induced cell 
lysis. Some isolates have a mucous aspect which is due to the increased production 
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of the polysaccharide capsule. In blood-containing media, S. pneumoniae colonies 
are α-hemolytic with a green pigmentation around the growth due to partial 
erythrocyte degradation and consequent haemoglobin degradation. However, other 
viridans streptococci are also α-hemolytic, making it difficult to distinguish from S. 
pneumoniae. In the laboratory, this distinction is made by the susceptibility test to 
optochin, in which viridans streptococci are resistant and S. pneumoniae is 
susceptible. 
The optochin susceptibility test was performed by placing a filter paper disc 
with 5 μg of optochin (Oxoid, Hampshire, England) on the blood agar plate. 
Inhibition halos were measured after incubation. The isolates were identified as 
sensitive when their halo was equal to or greater than 14 mm. Isolates showing 
halos less than 14 mm or that did not even have inhibition halos were tested for 
solubility in bile salts because isolates of S. pneumoniae resistant to optochin have 
already been described (Aguiar et al., 2006). The bile solubility test was done by 
suspending the bacterial cultures in 0.5 mL of 0.85 % (w/v) NaCl with an 
approximate turbidity of McFarland 1 and by adding an equal volume of 2 % (w/v) 
sodium deoxycholate (DOC), which is a salt present in bile, or 0.85 % (w/v) NaCl as 
control. The isolates were incubated at 35 °C for 15 min and the turbidity of the 
DOC suspension was compared to the turbidity of the control. S. pneumoniae cells 
lyse in the presence of bile salts due to the activation of the autolysin LytA, while 
the cells of other species remain intact. Thus, if the DOC suspension was clear or 
substantially less turbid than the control it was indicative of S. pneumoniae. In the 
case where no differences were detected, the suspensions were further incubated at 
35 °C for up to 2 h. If lysis did not occur after this incubation time, the isolate was 
not considered S. pneumoniae. 
After confirmation of the species, the isolates were stored at -70 °C in 
Tryptone Soy Broth medium (Oxoid, Hampshire, England) with 15 % (v/v) glycerol. 
Every time the isolates were thawed they were plated onto blood agar plates and 












The serotype of the isolates was determined by the capsular reaction test (or 
Quellung reaction) in which the capsular polysaccharides react with specific 
antibodies. When there is reaction, agglutination is either observed 
macroscopically, upon observation under the optical microscope (the bacteria are 
aggregated) or by the capsule becoming visible because its refractive index is 
altered by the immunoprecipitation with specific serum (Quellung reaction) 
(Sorensen, 1993). This test was performed with a kit of sera (Statens Serum 
Institut, Copenhagen, Denmark) that is divided into pools (identifying several 
serogroups or serotypes), sera that identify serogroups and sera that identify 
serotypes. Testing of each serum was performed on a microscopy slide by mixing 
about 1 μL of serum with about 3 μL of a suspension of the test strain. 
Agglutination was a sign of a positive reaction. Due to the high number of existing 
serotypes, a “chessboard” system (Table 3.1) was used to optimize serotyping 
(Sorensen, 1993). 
Sera from the new pool set (serum P to T) containing the serotypes included 
in vaccines were first sequentially tested. Upon a positive reaction, sera from the 
existing pool set (sera A-F and H) were tested to determine the serotype or 
serogroup in common with the serum that tested positive. In the absence of 
agglutination with sera from P to T, sera containing the serotypes or serogroups 
not included in the vaccines (C-I sera) were tested. The identified serotype (or 
serogroup) was confirmed with the corresponding specific serum. When a serogroup 
was found, the serotype was determined by testing specific sera according to a table 
provided by Statens Serum Institut at http://www.ssi.dk. 
Table 3.1 – Chessboard system used for serotyping S. pneumoniae isolates. Adapted from 
(Sorensen, 1993). 
Pool 
Serotype or serogroup with  a new poola 
NVT serotypes or serogroupsa 
P Q R S T 
A  1 18* 4 5   2  
B 19*  6* 3 8   
C  7*    20 24*, 31, 40 
D    9*    11* 16*, 36, 37 
E   12* 10*   33* 21, 39  
F    17*   22* 27, 32*, 41* 
H 14 23*  15*  13, 28* 
Gb      29, 34, 35*, 42, 47* 
Ib      25*, 38, 43, 44, 45, 46, 48 
aThe serogroups are marked with an asterisk and the serotypes or serogroups included in vaccines are in bold. 
bSera G and I do not react with any vaccine serotype and therefore are not included in the chessboard system. 
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3.4. Multilocus Sequence Typing (MLST) 
 
The internal fragments of seven conserved polymorphic genes were amplified 
by PCR and sequenced. Each isolate was inoculated into Brain Heart Infusion 
(BHI) (Becton Dickinson, Maryland, EUA) and incubated in a water bath at 37 °C 
until reaching an OD600 of at least 0.80. To prepare the DNA, 9 μL of culture was 
boiled in 441 μL of water for 2 min and then immediately placed on ice for 5 min. 
For each gene the following amplification mixture was prepared: 20 μL of boiled 
DNA; 0.02 U/μL GoTaq® DNA polymerase (Promega, Wisconsin, USA); 1x buffer 
suitable for the enzyme and supplied by the manufacturer; 2 mM magnesium 
chloride (Promega, Wisconsin, USA); 0.2 mM deoxyribonucleotide triphosphates 
(dNTPs) (Fermentas, Vilnius, Lithuania); 0.4 pmol/μL of each primer (up and dn) of 
the gene to be amplified and 10.8 μL of water purified by the Milli-Q system 
(Millipore, Massachusetts, USA), completing a final volume of 50 μL.  
The sequences of the primers used, as well as the size of the generated 
fragment of each gene, are shown in Table 3.2. Each primer contains a tail 
upstream of the gene-specific sequence. This tail is a universal primer, in this case 
M13 phage, which makes it possible to sequence several genes in a single plate, 
allowing optimization of sequencing. The fragments were amplified in the 
thermocycler MyCycler® (Bio-Rad, California, USA). To amplify all fragments, 
except for the recP gene, the following program was used: denaturation at 95 °C (5 
min); 4 cycles of denaturation at 95 °C (1 min), hybridization at 48 °C (45 s) and 
elongation at 72 °C (1 min); 29 cycles of denaturation at 95 °C (1 min), 
hybridization at 65 °C (45 s) and elongation at 72 °C (1 min); elongation at 72 °C (5 
min). The primers used have a lower DNA binding specificity due to the presence of 
the tail, so the lower annealing temperature of the initial 4 cycles allowed 
hybridization with less specificity, facilitating the initiation of amplification of the 
target sequence. The recP gene fragments were amplified with the following 
program: denaturation at 95 °C (4 min); 30 cycles of denaturation at 95 °C (30 s), 
hybridization at 58 °C (30 s) and elongation at 72 °C (30 s); elongation at 72 °C (10 
min). Amplification products were visualized on a 1 % (w/v) agarose gel in 0.5x 
TBE buffer with 0.5 μg/mL ethidium bromide and purified using the commercial 
kit High Pure PCR Product Purification Kit (Roche, Mannheim, Germany) 
according to the manufacturer's instructions. After purification, the amplification 
products were sequenced by GATC Biotech (Constance, Germany) using the 
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universal primer M13F (Table 3.2). When new alleles were identified and when 
there were doubts in the visual inspection of the chromatogram, the results were 
confirmed by sequencing the other strand with the universal primer M13R-pUC 
(Table 3.2). 
The sequences obtained were analyzed through BioNumerics®, where an 
allele number was assigned to each of the genes and the sequence type (ST) to each 
allelic profile by comparison with the database available at 
https://pubmlst.org/spneumoniae/. The newly identified alleles and STs were 
submitted to the database curator for assignment of a new number. The analysis of 
the genetic relationship between the STs found was made through the software 
PHYLOViZ that uses the algorithm goeBURST (Francisco et al., 2009). To perform 
clustering of the isolates into clonal complexes (CCs), the complete database (all 
STs currently identified) was used. This clustering in CCs was done at the single 
locus variant (SLV) level, i.e. all STs within a clonal complex are linked to at least 
one of their SLV. Otherwise, the conditions to define CCs in PHYLOViZ are 
described in the appropriate section if the method performed differs from this 
procedure. 
 
Table 3.2 – Primers used in MLST. 
Primera Sequence (5'→ 3')b Size (bp)c,d Fragment size (bp)d 
aroe_up M13F – CGT TTA GCT GCA GTT GTT GC  38 
405 
aroe_dn M13R-pUC – CCC ACA CTG GTG GCA TTA AC 38 
ddl_up M13F – TTG CCA TGG ATA AAA TCA CGA C 40 
441 
ddl_dn M13R-pUC – CGC GCT TGT CAA AAC TTT CC  38 
gdh_up M13F – GTG CTG AAA AGA TTA AGG TCT 39 
460 
gdh_dn M13R-pUC – TGC TTC CAG CTT TAT AGT CAT C 40 
gki_up M13F – GGC ATT GGA ATG GGA TCA CC 38 
483 
gki_dn M13R-pUC – TCT CCC GCA GCT GAC AC 35 
recP_up M13F – GCC AAC TCA GGT CAT CCA GG 38 
450 
recP_dn M13R-pUC – GCT TCC AAG TCT GTT CCA TTT TC  41 
spi_up M13F – CGC TTA GAA AGG TAA GTT ATG 39 
474 
spi_dn M13R-pUC – AGG CTG AGA TTG GTG ATT CTC 39 
xpt_up M13F – GGA GGT CTT ATG AAA TTA TTA G 40 
486 
xpt_dn M13R-pUC – AGA TCT GCC TCC TTA AAT AC 38 
M13F TGT AAA ACG ACG GCC AGT 18  
M13R-pUC CAG GAA ACA GCT ATG ACC 18  
aThe universal primers of phage M13 are shaded. 
bAll the up and dn genes have the sequence of M13F and M13R-pUC at the beginning, respectively. 
cThe size of the primers is the sum of the nucleotides of the tail with those of the specific sequence for the gene. 
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3.5. Antimicrobial susceptibility 
 
The choice of antimicrobials to be tested was based on their clinical use, their 
importance as resistance markers and the fact that it is possible to compare them 
with previous studies. Thus, susceptibility profiles to penicillin and cefotaxime 
were determined by Etest® (BioMérieux, Marcy l'Etoile, France) according to the 
manufacturer's instructions (Melo-Cristino et al., 2003). The susceptibility profiles 
for erythromycin, clindamycin, tetracycline, levofloxacin, co-trimoxazole, 
chloramphenicol, vancomycin and linezolid were determined using the Kirby-Bauer 
method (Bauer et al., 1966), each with a defined concentration, according to the 
standards of the Clinical and Laboratory Standards Institute (CLSI) (C.L.S.I., 
2009). Briefly, to determine the susceptibility to the antimicrobials chosen, 
suspensions of the isolates were prepared in 0.85 % (w/v) NaCl with a turbidity of 
McFarland 0.5. This standardization of the inoculum is important for the 
reproducibility of the results. Thus, Mueller-Hinton plates (Oxoid, Hampshire, 
England) supplemented with 5 % (v/v) sheep blood (Probiológica, Belas, Portugal) 
were uniformly inoculated with these suspensions and discs or strips of Etest® of 
each antimicrobial were placed onto the plate. The plates were incubated at 35 °C 
with 5 % CO2 for 24 h. After incubation, the inhibition halos were measured around 
the discs and MIC values were read in the Etest® strips. In order to classify the 
susceptibility of the isolates, the diameter of the halos and MIC values were 
interpreted according to CLSI (C.L.S.I., 2014). In 2008 a change was introduced in 
the CLSI breakpoint for resistance to penicillin, establishing different values for 
cases of meningitis and non-meningitis. To facilitate comparison with previous 
epidemiological studies, the 2007 CLSI indications (C.L.S.I., 2007) were used to 
define levels of susceptibility to penicillin. Thus, MIC values of >0.06 to <2 μg/mL 
defined intermediate resistance and values ≥2 μg/mL defined high-level resistance. 
Multidrug resistance (MDR) was defined by non-susceptibility to at least three 
classes of antibiotics. 
To validate the results obtained, the reference strain S. pneumoniae ATTC 
49619 was used as a control and susceptibility testing for this strain was regularly 
performed with the antimicrobials used in this study. The results were validated by 
making sure the values obtained fell within the ranges indicated in the CLSI 
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II. PHEROTYPE DIVERSITY AND ABUNDANCE 
 
In this section we will describe the diversity of pherotypes found in invasive 
isolates from Portugal and also a report of their abundance. Pherotype diversity 
was determined by a genetic study of the comCDE locus of a collection of 
pneumococcal invasive isolates recovered before conjugate vaccines were 
introduced (Chapter 4), while pherotype abundance was evaluated by identifying 
the pherotype of a large collection of invasive isolates recovered from children over 
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CHAPTER 4.              DIVERSITY OF THE COMCDE LOCUS 
 
This chapter presents a comprehensive study of the genetic diversity of the 
comCDE locus of an invasive pneumococcal sample recovered in Portugal. There 
are two major published studies about the genetic diversity of the comC gene 
(Ramirez et al., 1997, Whatmore et al., 1999) and one of them also included the 
comD gene (Whatmore et al., 1999). However, in those studies the complete 
sequence of comD and also of the comE gene was not analyzed. Furthermore, in 
contrast to those studies, the sample studied in this work had more isolates and 
these were recovered in the same period and geographical site, allowing us to 
evaluate diversity in the same population. 
The aim of this study was to sequence the comCDE locus of a collection of 
invasive pneumococcal isolates and identify the genetic profiles of this locus 
present in Portugal. Then, these profiles were compared with published comCDE 
sequences and related with other isolate characteristics, such as serotype and 
genetic lineage. This study also enabled the identification of potential new variants 
of CSP. 
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4.1. Materials and methods 
4.1.1. Bacterial isolates 
 
To evaluate the genetic diversity of the comCDE locus, the same invasive 
pneumococcal sample studied previously by our laboratory was chosen (Carrolo et 
al., 2009). This sample was composed of isolates recovered from invasive infections 
from all age groups and isolated between 1999 and 2001, representing the diversity 
of genetic lineages circulating in Portugal in a period when the effects of conjugate 
vaccination had not been felt yet. The initially chosen sample included a total of 90 
pneumococcal invasive isolates but one of them was not recovered when isolates 
were recovered from storage, making a total of 89 isolates available for this study. 
The serotype and MLST data of these isolates were described previously by our 
laboratory (Serrano et al., 2005, Serrano et al., 2004).  
 
4.1.2. Sequencing of comCDE locus 
 
An analysis of the public sequences of comCDE locus was required to identify 
conserved regions as targets for designing primers for sequencing. Thus, a BLAST 
search of the nucleotide database was performed in February 2013 using as query 
the sequence of comD gene of strain R6 (accession no. AE007317), restricting the 
results to the species Streptococcus pneumoniae. After downloading the resulting 
complete original1 sequences, an analysis of the comCDE locus was restricted only 
to complete sequences of this operon, resulting in a total of 31 comCDE sequences 
(Table 4.1). These sequences were aligned with the exception of the isolates 
gamPNI0373 and AP200 because they presented a deletion in the gene comE and 
an insertion in the gene comC, respectively. Then, the primers comC-fw, comD-fw, 
comD-rv and comE-rv (Table 4.2) were designed in conserved regions in the 
alignment (Figure 4.1) as universal primers to be used in our screening.  
While all primers were used to sequence the comCDE locus, only the primer 
pair comC-fw and comE-rv were used in the PCR reaction to yield the product of 
interest in a first step. However, some isolates did not yield a PCR product with 
sufficient quality for sequencing, making it necessary the use of the inner primers 
                                               
1The complete original sequences were the entire sequence of the matching accession 
number, for example, it was entire genomes in the case where the match was from a 
complete or draft genome. 
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(Figure 4.1). The DNA of the isolates was extracted using CTAB (Wilson, 2001) 
because extraction from boiled cells did not yield good results. PCR products were 
sequenced by GATC Biotech (Constance, Germany) using the four primers 
indicated. 
 
The PCR reaction (V=50 µl) for the amplification of comCDE locus was 
composed of: 
- 0.05 U/µl GoTaq® DNA polymerase (Promega, Wisconsin, USA); 
- 1x enzyme’s buffer provided by manufacturer; 
- 2 mM magnesium chloride; 
- 0.4 mM dNTPs; 
- 0.4 pmol/µl of each primer (comC-fw and comE-rv); 
- 4 ng/µl of template DNA. 
 
With the following PCR program:  
- 5 min at 95 ºC; 
- 30x (30 s at 95 ºC, 30 s at 50 ºC and 3 min at 72 ºC) 




Figure 4.1 – Primers used for sequencing the comCDE locus. The first base of comC was used 
as reference to assign positions numbers. Small triangles represent primers and their direction. 
Dashed lines represent the expected size of the region sequenced from each primer (800 bp). Gene’s 
length is at scale. 
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Table 4.1 – Strains with complete comCDE locus sequence in the public database and 
comparison with the alleles found in Portugal. The alleles of these strains were not included in 
the allele classification described in the section 4.2. Results. 
Accession no. Strain Pherotype comC comD comE 
AE005672 TIGR4 CSP2 comC-2.1 comD-2.8 comE-10 
AE007317 R6 CSP1 comC-1.1 comD-1.1 comE-15 
AF067659 A66 CSP2 comC-2.1 comD-2.1 comE-5 
CM001835 PCS8235 CSP1 comC-1.1 comD-1.1 comE-2 
CP000410 D39 CSP1 comC-1.1 comD-1.1 comE-15 
CP000918 70585 CSP1 comC-1.2 comD-1.5 No matchb 
CP000919 JJA CSP2 comC-2.2 No matchb comE-7 
CP000920 P1031 CSP1 comC-1.1 No matchb comE-15 
CP000921 Taiwan19F-14 CSP1 comC-1.1 comD-1.1 comE-2 
CP000936 Hungary19A-6 CSP1 comC-1.1 comD-1.1 No matchb 
CP001015 G54 CSP1 comC-1.1 No matchb comE-1 
CP001033 CGSP14 CSP1 comC-1.1 comD-1.1 comE-2 
CP001845 gamPNI0373 CSP1 comC-1.1 No matchb Deletion of 555 bp 
No matchb 
CP001993 TCH8431/19A CSP1 No matchb comD-1.1 comE-2 
CP002121 AP200 NDa Insertion of 1248 bp 
No matchb 
No matchb comE-1 
CP002176 670-6B CSP1 comC-1.1 comD-1.1 comE-4 
CP003357 ST556 CSP1 comC-1.1 comD-1.1 comE-2 
CP006844 A026 CSP1 No matchb comD-1.1 comE-2 
FM211187 ATCC 700669 CSP2 comC-2.2 comD-2.2 comE-7 
FQ312027 OXC141 CSP1 comC-1.2 comD-1.3 comE-8 
FQ312029 INV200 CSP1 comC-1.1 comD-1.1 comE-2 
FQ312030 INV104 CSP2 comC-2.1 Deletion of 9 bp  
No matchb 
comE-10 
FQ312039 SPN032672 CSP1 comC-1.1 comD-1.1 comE-2 
FQ312041 SPN994038 CSP1 comC-1.2 comD-1.5 comE-8 
FQ312042 SPN033038 CSP1 comC-1.1 comD-1.1 comE-2 
FQ312043 SPN034183 CSP1 comC-1.2 comD-1.5 comE-8 
FQ312044 SPN994039 CSP1 comC-1.2 comD-1.5 comE-8 
FQ312045 SPN034156 CSP1 comC-1.2 No matchb comE-8 
HE983624 SPNA45 CSP1 comC-1.2 No matchb No matchb 
U33315 CP1200 CSP1 comC-1.1 comD-1.1 comE-15 
U76218 R6x CSP1 comC-1.1 No matchb No matchb 
aND – Not determined because an insertion was found in comC of the strain AP200. 
bNo match with the alleles found in this study. 
 
Table 4.2 – Sequence of the primers used for sequencing the comCDE locus. 
Primer Sequence (5'→ 3') Size (bp) 
comC-fw GTACACTTTGGGAGAAAAAAATGA 24 
comD-fw TTTACAGAATTACACAGATGAAATT 25 
comD-rv CTATGTTGTTCAAATCAAAGTAAGT 25 
comE-rv CCCCTTGACCAACGGACCTTC 21 
 
4.1.3. Analysis of comCDE locus 
 
The analysis of the sequences was performed in Geneious Pro (version 5.3.6). 
For each isolate, the comCDE sequence was obtained by assembling the reads from 
the four sequencing primers using as reference the comCDE locus of R6 strain. 
Then, the genes comC, comD and comE were identified and translated to amino 
acid sequence. DNA and protein sequences were aligned using MUSCLE algorithm 
with default settings and then alleles and comCDE profiles were determined. 
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Alignments of the alleles were performed using MUSCLE algorithm with 
default settings in Geneious and were edited in BioEdit (version 7.2.5). The matrix 
BLOSUM62 was used to define similar amino acids. The alignments were used to 
build phylogenetic trees by neighbor-joining method and resampling was done by 
bootstrap for 1000 times. 
 
  




4.2.1. Pneumococcal invasive isolates and allele classification 
 
The sequence of the comCDE locus was obtained for n=89 invasive isolates 
recovered in 1999 (n=26), 2000 (n=33) and 2001 (n=30) from all age groups (<18 
years, n=21; ≥18 years, n=68). These isolates presented a total of 27 serotypes and 
57 STs (Figure 4.2) and were recovered from blood (n=76), CSF (n=12) and pleural 
fluid (n=1). The alleles of comC, comD and comE of these isolates were identified, 
translated into protein and classified. The alleles of the strains with complete 
comCDE locus sequence in the public database were not taken into account in this 
classification. However, a comparison was performed with the alleles found in this 
study (Table 4.1).  
The following criteria were used for allele classification. In the case of the 
genes comC and comD, numbers were attributed to them including the 
corresponding pherotype followed by a number identifying their frequency rank in 
the current study. For example, the comD-1.3 and comD-2.2 alleles presented 
pherotype CSP1 and CSP2 alleles, respectively, and were the third and second 
most frequent allele of their pherotype, respectively. However, for the comE gene, 
classification was done only considering their frequency because a correlation with 
pherotype was not obvious. Protein alleles inherited the name of their respective 
DNA allele and when more than one allele yielded the same protein sequence, the 
name of the most frequent was chosen. 
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4.2.2. Gene comC 
 
A total of 6 alleles of the gene comC were identified among the isolates 
(Table 4.3 and Figure 4.3). These alleles could be divided into three groups 
representing pherotypes CSP1, CSP2 and CSP3. Pherotype CSP1 (n=66, 74.2 %) 
was the most abundant among the isolates, followed by CSP2 (n=21, 23.6 %) and 
CSP3 (n=2, 2.2 %). Translation of these alleles yielded a total of 5 variants of the 
precursor of CSP (Figure 4.4) because the comC-1.2 allele presented the silent 
mutation T82C (position 97 in Figure 4.3) in relation to comC-1.1, producing the 
same protein variant. However, looking only at the mature exported CSPs, which 
are represented by the sequence after the double glycine cleavage site, only 3 
distinct protein sequences were identified, each representing a distinct pherotype. 
Thus, one of each of the ComC variants of the pherotypes CSP1 and CSP2 
presented an amino acid substitution in the signal peptide, while the mature CSP 
was conserved. 
Regarding the comC-3 allele, the main feature observed was its higher 
genetic diversity and larger size in comparison with comC-1 and comC-2 alleles 
(141 bp vs. 126 bp, respectively). Translation of comC-3 allele showed a precursor 
of CSP3 with a signal peptide of the same size, albeit with one amino acid 
alteration relative to the other signal peptides, but the mature CSP3 presented 22 
amino acids while CSP1 and CSP2 mature peptides were composed of 17 amino 
acids. As far as we know, it was the first time the comC-3 allele and therefore the 
CSP3 pherotype were identified in pneumococcal isolates recovered in Portugal. 
 




Figure 4.3 – DNA sequence of comC alleles. Black boxes highlight SNPs.  
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comC-1.1 A T GA A A A A C A C A G T T A A A T T GGA A C A G T T T G T A GC T T T GA A GGA A A A A GA C T T A C A A A A GA T T A A A GG T GGGGA GA T GA G - - - - - - - - - - - - - - - G T T G T C A A A A T T C T T C C G T GA T T T T A T T T T A C A A A GA A A A A A G T A A
comC-1.2 A T GA A A A A C A C A G T T A A A T T GGA A C A G T T T G T A GC T T T GA A GGA A A A A GA C T T A C A A A A GA T T A A A GG T GGGGA GA T GA G - - - - - - - - - - - - - - - GC T G T C A A A A T T C T T C C G T GA T T T T A T T T T A C A A A GA A A A A A G T A A
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comC-2.2 A T GA A A A A C A C A G T T A A A T T GGA A C A G T T T G T A GC T T T GA A GGA A A A A GA C T T A C A A A A T A T T A A A GG T GGGGA GA T GA G - - - - - - - - - - - - - - - GA T T T C A A GA A T C A T C C T T GA T T T T C T T T T C C T A C GA A A A A A G T A A
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ComC-1.1 MK N T V K L E Q F V A L K E K D L QK I K GG E MR L S - - - - - K F F R D F I L QR K K
ComC-1.3 MK N T V K L E Q F V T L K E K D L QK I K GG E MR L S - - - - - K F F R D F I L QR K K
ComC-2.1 MK N T V K L E Q F V A L K E K D L QK I K GG E MR I S - - - - - R I I L D F L F L R K K
ComC-2.2 MK N T V K L E Q F V A L K E K D L QN I K GG E MR I S - - - - - R I I L D F L F L R K K
ComC-3 MK N T V K L E Q F V A L K E K D L QN I QGG E MR K MN E K S F N I F N F F N F F R R R
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Table 4.3 – Alleles of the genes comC, comD and comE and respective serotypes and STs. 
Allele n Pherotype Serotype ST 
comC-1.1 56 CSP1 14 (n=10); 1 (n=6); 9V (n=5); 7F, 
23F (n=4 each); 4, 11A, 12B, 33F 
(n=3 each); 6B, 8, 18C, 22F (n=2 
each); 6A, 13, 15B, 16F, 19F, 20,  
35F (n=1 each) 
156 (n=6); 191, 557 (n=4 each); 306, 338, 1221 (n=3 
each); 53, 218, 408, 1012, 1367 (n=2 each); 15, 62, 
100, 228, 273, 304, 347, 350, 414, 574, 644, 717, 790, 
838, 1026, 1224, 1225, 1233, 1365, 1368, 1369, 1371, 
1706 (n=1 each) 
comC-1.2 9 CSP1 3 (n=5); 5, 19A (n=2 each) 180, 458, 1223 (n=2 each); 199, 876, 1230 (n=1 
each) 
comC-1.3 1 CSP1 22F (n=1) 1372 (n=1) 
comC-2.1 16 CSP2 3 (n=5); 4 (n=3); 19F (n=2); 6B, 
6C, 8, 10A, 10F, 12B (n=1 each)  
260 (n=3); 247, 1220 (n=2 each); 177, 273, 391, 395, 
404, 989, 1222, 1231, 1649 (n=1 each) 
comC-2.2 5 CSP2 19A, 23F (n=2 each); 9N (n=1) 81 (n=3); 66, 276 (n=1 each) 
comC-3 2 CSP3 19A, 35F (n=1 each) 1201, 1366 (n=1 each) 
comD-1.1 51 CSP1 14 (n=10); 1 (n=6); 9V (n=5); 23F 
(n=4); 4, 11A, 12B, 22F, 33F (n=3 
each); 6B, 18C (n=2 each); 6A, 
8, 13, 15B, 16F, 20, 35F (n=1 
each) 
156 (n=6); 557 (n=4); 306, 338, 1221 (n=3 each); 
218, 408, 1012, 1367 (n=2 each); 15, 53, 62, 100, 228, 
273, 304, 350, 414, 574, 644, 717, 790, 838, 1026, 
1224, 1225, 1233, 1365, 1368, 1369, 1371, 1372, 1706 
(n=1 each) 
comD-1.2 4 CSP1 7F (n=4) 191 (n=4) 
comD-1.3 3 CSP1 3 (n=3) 180 (n=2); 1230 (n=1) 
comD-1.4 2 CSP1 19A (n=2) 199, 876 (n=1 each) 
comD-1.5 2 CSP1 5 (n=2) 1233 (n=2) 
comD-1.6 1 CSP1 19F (n=1) 347 (n=1) 
comD-1.7 1 CSP1 8 (n=1) 53 (n=1) 
comD-1.8 2 CSP1 3 (n=2) 458 (n=2) 
comD-2.1 5 CSP2 3 (n=4); 4 (n=1) 260, 1220 (n=2 each); 1222 (n=1) 
comD-2.2 4 CSP2 23F (n=2); 9N, 19A (n=1 each) 81 (n=3); 66 (n=1) 
comD-2.3 3 CSP2 19F (n=2); 10F (n=1)  177, 391, 1649 (n=1 each) 
comD-2.4 1 CSP2 8 (n=1) 404 (n=1) 
comD-2.5 1 CSP2 6C (n=1) 395 (n=1) 
comD-2.6 1 CSP2 12B (n=1) 989 (n=1) 
comD-2.7 1 CSP2 6B (n=1) 273 (n=1) 
comD-2.8 1 CSP2 10A (n=1) 1231 (n=1) 
comD-2.9 1 CSP2 19A (n=1) 276 (n=1) 
comD-2.10 2 CSP2 4 (n=2) 247 (n=2) 
comD-2.11 1 CSP2 3 (n=1) 260 (n=1) 
comD-3.1 1 CSP3 19A (n=1) 1201 (n=1) 
comD-3.2 1 CSP3 35F (n=1) 1366 (n=1) 
comE-1 18 CSP1, CSP2 11A, 33F (n=3 each); 8, 18C, 19F, 
22F (n=2 each); 6C, 10F, 13, 20 
(n=1 each) 
53, 408, 1012, 1367 (n=2 each); 62, 100, 177, 391, 
395, 574, 717, 1026, 1233, 1649 (n=1 each) 
comE-2 16 CSP1 1 (n=6); 7F (n=4); 4 (n=3); 14, 
16F, 19F (n=1 each) 
191 (n=4); 306, 1221 (n=3 each); 15, 228, 304, 347, 
350, 414 (n=1 each) 
comE-3 15 CSP1 14 (n=9); 9V (n=5); 12B (n=1) 156 (n=6); 557 (n=4); 218, 644, 790, 838, 1225 (n=1 
each) 
comE-4 7 CSP1, CSP2 5, 6B (n=2 each); 4, 6A, 12B (n=1 
each) 
1223 (n=2); 273, 989, 1222, 1224, 1369 (n=1 each) 
comE-5 5 CSP2 3 (n=5) 260 (n=3); 1220 (n=2) 
comE-6 5 CSP1 23F (n=4); 15B (n=1) 338 (n=3); 1371, 1706 (n=1 each) 
comE-7 4 CSP2 19A, 23F (n=2 each) 81 (n=3); 276 (n=1) 
comE-8 3 CSP1 3 (n=3) 180 (n=2); 1230 (n=1) 
comE-9 3 CSP1, CSP2 19A (n=2); 8 (n=1) 199, 404, 876 (n=1 each) 
comE-10 3 CSP2 4 (n=2); 6B (n=1) 247 (n=2); 273 (n=1) 
comE-11 2 CSP1 12B (n=2) 218, 1365 (n=1 each) 
comE-12 2 CSP1 3 (n=2) 458 (n=2) 
comE-13 2 CSP3 19A, 35F (n=1 each) 1201, 1366 (n=1 each) 
comE-14 1 CSP2 9N (n=1) 66 (n=1) 
comE-15 1 CSP1 22F (n=1) 1372 (n=1) 
Insertion of 
1274 bp 
1 CSP1 35F (n=1) 1368 (n=1) 
Insertion of 
1246 bp 
1 CSP2 10A (n=1) 1231 (n=1) 
 
4.2.3. Gene comD 
 
The genetic diversity observed in the gene comD was higher with a total of 21 
alleles identified, resulting in 17 ComD variants (Table 4.3, Figure 4.5 and 4.6). 
The majority of the genetic diversity was observed in the N-terminus corresponding 
to the sensor domain and, similarly to the gene comC, comD alleles could also be 
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divided into three major groups, each representing a pherotype: comD-1, comD-2 
and comD-3. This relation with pherotype was still observed when alleles were 
translated into protein (Figure 4.7). The division into three groups is due to the 
sensor domain because the kinase domain located in the C-terminus was more 
conserved and an association with pherotype could not be observed for this domain.  
A total of 8 alleles were identified in comD-1 group and all produced different 
ComD1 proteins. The allele comD-1.8 presented a deletion of 24 bp which 
translated in a protein with a deletion of 8 amino acids (Figure 4.5 and 4.6). 
Analyzing the phylogenetic tree built with the sequences of ComD proteins, it could 
be observed that ComD1 variants clearly formed two subgroups: canonical (ComD-
1.1, ComD-1.2, ComD-1.6 and ComD-1.7) and non-canonical (ComD-1.3, ComD-1.4, 
ComD-1.5 and ComD-1.8) (Figure 4.7). 
Regarding comD-2 group, 11 alleles were observed resulting in 7 protein 
variants of ComD2. The comD-2.10 and comD-2.11 alleles presented an insertion 
and a deletion of 1 bp, respectively (Figure 4.5), resulting in truncated proteins of 
29 bp and 135 bp length, respectively, and for this reason they were not included in 
the protein variants analysis. The comD-2.6, comD-2.7 and comD-2.8 alleles 
produced the same protein. 
The two alleles of comD-3 and their respective protein variants presented the 
highest genetic variation in relation to comD-1 and comD-2 groups, resembling the 
results observed in comC. 
Analyzing the protein sequence, ComD1 variants shared His21, Phe47, Leu51 
and Ile53 as exclusive amino acids residues whereas ComD2 variants shared 
Arg27, Tyr34, Glu48, Ser50, Lys58 and Ile59 and ComD3 presented 13 exclusive 
amino acids in the first 200 bases. ComD3 also shared Ala62 with all the variants 
from the non-canonical ComD1 subgroup. The canonical ComD1 variants presented 
Phe22 as an exclusive amino acid. These positions could be candidates to be the 
determinants of specificity between ComD receptors and CSPs. 





Figure 4.5 – DNA sequence of comD alleles. Black boxes highlight SNPs.  
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comD-1.3 A T GGA T T T A T T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A GC T A C C A T T T A A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-1.8 A T GGA T T T A T T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A GC T A C C A T T T A A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-1.5 A T GGA T T T A T T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A GC T A C C A T T T A A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-1.4 A T GGA T T T A T T T GGA T T T GGGA C A G T T A T T G T T C A T C T T T T A A T T A T T A G T C A C A A C T A C C A T T T A A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-1.1 A T GGA T T T A T T T GGA T T T GGGA C GG T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C A T T T T A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-1.2 A T GGA T T T A T T T GGA T T T GGGA C GG T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C A T T T T A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-1.7 A T GGA T T T A T T T GGA T T T GGGA C GG T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C A T T T T A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-1.6 A T GGA T T T A C T T GGA T T T GGGA C GG T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C A T T T T A T T T G T A A A GG T C A A A T A A - A T A GA A A A GA A T T A T T C G T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A T
comD-2.10 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A T A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.8 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.7 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.6 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.5 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.1 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.11 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.4 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.2 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C A T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.3 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C G T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-2.9 A T GGA T T T A C T T GGA T T T GGGA C A G T T A T T G T T C A T T T T T T A A T T A T T A G T C A C A G T T A C C G T T T A A T T T G T A A A GG T C GA A T A A - A T A GA A A A GA A T T A T A C A T T T T T GG T GC T T A T A C A T T A C T A A C T GA A A T A G T A C
comD-3.1 A T GGA T T T T T T C T T A T T A G T A GA T T T GA T A T T A T A T T T T T T A A T T A T T A G T C A T A G T T A C C G T T T A A T T T G T A A A GA T C A A A T A A - A T A GA A A A GA A T T A T T C T T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A C
comD-3.2 A T GGA T T T T T T C T T A T T A G T A GA T T T GA T A T T A T A T T T T T T A A T T A T T A G T C A T A G T T A C C G T T T A A T T T G T A A A GA T C A A A T A A - A T A GA A A A GA A T T A T T C T T T T T T GG T GC T T A T A C A T T A C T A A C A GA A A T A G T A C
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comD-1.3 T T GA T T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GC A A C A T T T T T A T T T C C T T T GGGC C T A T A T T C C T A T T T T C GA T GGA T A A A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-1.8 T T GA C T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GC A A C A T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA T T A T T C C T A A G T T T A C T A C T A T C T
comD-1.5 T T GA T T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GC A A C A T T T T T A T T T C C T T T GGGC C T A T A T T C C T A T T T T C GA T GGA T A A A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-1.4 T T GA T T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GC A A T A T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-1.1 T T GA T T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGA T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-1.2 T T GA T T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGA T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-1.7 T T GA T T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGA T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-1.6 T T GA T T T T C C C T T A T A T A T T C T A T A T T T A GA T GGG T T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGA T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.10 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.8 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.7 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.6 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.5 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.1 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.11 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.4 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.2 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.3 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-2.9 T T GA A T T T T C C T T T T A T C T T C T A T A T T T A GA T A A A A T A GGGA T T GA A A GA T T T T T A T T T C C T T T GGGC T T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T C C T A A G T T T A C T A C T A T C T
comD-3.1 T T GA T T T T C C C T T C T A T C T T C T A T A T T T A GA T GGG T T A GGGA T T GC A A C A T T T T T A T T T C C T T T GGGC C T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T T C T A A G T T T A C T A C T A T C T
comD-3.2 T T GA T T T T C C C T T C T A T C T T C T A T A T T T A GA T GGG T T A GGGA T T GC A A C A T T T T T A T T T C C T T T GGGC C T A T A T T C C T A T T T T C GA T GGA T GA A A C A G T A T GA GA GGGA T A GA GGA C T A T T T C T A A G T T T A C T A C T A T C T





Figure 4.5 – DNA sequence of comD alleles (continued).  
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comD-1.3 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T GC C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T GA C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-1.8 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-1.5 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T GA C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-1.4 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-1.1 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-1.2 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-1.7 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-1.6 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.10 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A T T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.8 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A T T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.7 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A T T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.6 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A T T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.5 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A T T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.1 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.11 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A - T T T G T T A C A T T A A A A A T C A T T T A
comD-2.4 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.2 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.3 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-2.9 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C C T C T A T A A C A GGA GA T A A T T T T G T T T T A C A A T A T C A T T T C C C A T T C T T T T T C G T T G T GA C GG T G T T A A C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-3.1 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C T T C T A T A A C A GGA GA C A A T T T T G T T T T A C A G T A T T A T GGC C T A T T C T T T T T C G T T G T GA C GG T G T T GA C C T A T T T T G T T A C A T T A A A A A T C A T T T A
comD-3.2 C T T T T A T A T GA GA GC A C T C A T A A C T T T C T G T C C G T A A C T T T C T C T T C T A T A A C A GGA GA C A A T T T T G T T T T A C A G T A T T A T GGC C T A T T C T T T T T C G T T G T GA C GG T G T T GA C C T A T T T T G T T A C A T T A A A A A T C A T T T A
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comD-1.3 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-1.8 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-1.5 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-1.4 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-1.1 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C GA GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-1.2 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C GA GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-1.7 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C GA GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-1.6 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C GA GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.10 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.8 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.7 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.6 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.5 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.1 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C GA GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.11 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C GA GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.4 C T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.2 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.3 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-2.9 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C T T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-3.1 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C A A GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T
comD-3.2 T T A T T T C C A T T T GGA A C T A GC C T A T T T T GA C GA GGA C T A C C T T T A T C C T T T C T T GA A A A A A G T A T T T T T T GC T T T A C T A T T GC T A C A T A T T G T A T C T T T C G T T T C A GA T A T GG T A A G T A C GA T T A A A C A T T T GA A T A G T T





Figure 4.5 – DNA sequence of comD alleles (continued).  
570 580 590 600 610 620 630 640 650 660 670 680 690 700
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comD-1.3 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-1.8 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-1.5 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-1.4 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-1.1 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-1.2 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-1.7 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-1.6 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.10 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.8 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.7 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.6 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.5 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.1 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.11 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.4 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T A C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.2 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.3 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-2.9 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-3.1 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T T T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
comD-3.2 T T GGA A G T A T T T T G T C A T C T A T T G T C T T T A T C T C T C T C C T T T T GA C C T T C T T T GC A A T GA A T T C T C A T A A A G T T C A A A T GGA GA A A GA GA T T GC T T T GA A GC A GA A GA A A T T T GA A C A GA A A C A T T T A C A GA A T T A C A C A
710 720 730 740 750 760 770 780 790 800 810 820 830 840
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comD-1.3 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-1.8 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC - - - - - - - - - - - - - - - - - - - - - - - - A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-1.5 GA T GA A A T T G T C GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGGA T GC T T G T C A G T A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA G T T T A C A A T GA A G T T T T GG T C A A A GC
comD-1.4 GA T GA A A T T G T C GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGGA T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-1.1 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-1.2 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T A G T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-1.7 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GA
comD-1.6 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.10 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.8 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.7 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A C GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.6 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.5 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.1 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.11 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.4 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.2 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.3 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-2.9 GA T GA A A T T G T T GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA A T T T A C A A T GA A G T T T T A G T C A A A GC
comD-3.1 GA T GA A A T T G T C GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA G T T T A C A A T GA A G T T T T GG T C A A A GC
comD-3.2 GA T GA A A T T G T C GG T C T G T A T A A T GA A A T C C G T GG T T T T C GA C A T GA T T A T GC T GGA A T GC T T G T C A GC A T GC A GA T GGC A A T T GA C A G T GG T A A T T T A C A GGA A A T T GA C A GA G T T T A C A A T GA A G T T T T GG T C A A A GC





Figure 4.5 – DNA sequence of comD alleles (continued).  
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comD-1.3 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-1.8 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-1.5 A A A T C A T A A A C T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA T T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-1.4 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-1.1 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-1.2 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-1.7 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-1.6 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.10 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.8 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.7 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.6 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.5 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.1 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.11 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.4 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.2 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.3 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-2.9 A A A T C A T A A A T T GC G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA C T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-3.1 A A A T C A T A A A C T A C G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA T T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
comD-3.2 A A A T C A T A A A C T A C G T T C A GA T A A G T A C A C T T A C T T T GA T T T GA A C A A C A T A GA A GA T T C A GC T T T A C GA A G T T T GG T T GC T C A G T C A A T T G T C T A T GC T C GA A A T A A T GG T G T A GA G T T T A C A C T GGA A G T A A A A GA T A
990 1000 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100 1110 1120
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comD-1.3 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-1.8 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-1.5 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-1.4 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-1.1 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-1.2 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-1.7 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-1.6 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.10 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.8 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.7 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.6 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.5 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.1 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.11 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.4 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.2 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.3 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-2.9 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T GG T T C G T A T C A T GA GC G T T T T A T T GA A T A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-3.1 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T A G T GC G T A T C A T GA GC G T T T T A T T GA A C A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
comD-3.2 C GA T T A C C A A GC T T C C A A T T GA A C T A T T GGA T T T A G T GC G T A T C A T GA GC G T T T T A T T GA A C A A T GC T G T C GA A GGA T C GGC T GA T A GC T A T A A A A A GC A GA T GGA A G T A GC A G T T A T T A A GA T GGA A A C T GA A A C A G T T
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comD-1.3 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-1.8 A T GG T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-1.5 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-1.4 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T T C C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-1.1 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-1.2 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-1.7 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-1.6 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.10 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.8 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.7 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.6 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC T T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.5 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T A A C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A T A A C A A T A T T A T
comD-2.1 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.11 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.4 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T T C C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.2 A T GG T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.3 A T GG T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-2.9 A T GG T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A T A T T A T
comD-3.1 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A C A T T A T
comD-3.2 A T T G T GA T T C A GA A T T C A T G T A A A A T GA C GA T GA C T C C T T C A GGA GA T C T A T T T GC C T T A GGA T T C T C C A C T A A GGGA A GA A A T C GC GGA G T C GGA T T A A A T A A T G T GA A A GA A C T A C T A GA T A A G T A C A A C A A C A T T A T
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comD-1.3 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-1.8 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-1.5 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-1.4 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-1.1 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-1.2 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-1.7 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-1.6 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.10 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.8 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.7 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.6 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.5 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.1 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.11 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.4 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.2 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.3 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-2.9 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGGA A T T T GA A T GA
comD-3.1 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGA A A T T T GA A T GA
comD-3.2 T T T A GA A A C A GA GA T GGA A GGC A G T A C A T T T A GA C A A A T C A T T A GA T T T A A GA GGA A A T T T GA A T GA





Figure 4.6 – Protein sequence of ComD variants. Black boxes highlight SNPs and grey boxes highlight similar amino acids. 
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ComD-1.4 MD L F G F G T V I V H L L I I S H N Y H L I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I A I F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-1.3 MD L F G F G T V I V H F L I I S H S Y H L I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I A T F L F P L G L Y S Y F RW I K QY E R D R G L F L S L L L S L L Y E S T H N F L P V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-1.5 MD L F G F G T V I V H F L I I S H S Y H L I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I A T F L F P L G L Y S Y F RW I K QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-1.8 MD L F G F G T V I V H F L I I S H S Y H L I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I A T F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-1.6 MD L L G F G T V I V H F L I I S H S Y H F I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-1.2 MD L F G F G T V I V H F L I I S H S Y H F I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-1.7 MD L F G F G T V I V H F L I I S H S Y H F I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-1.1 MD L F G F G T V I V H F L I I S H S Y H F I C K GQ I N R K E L F V F GA Y T L L T E I V F D F P L Y I L Y L D G L G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-2.3 MD L L G F G T V I V H F L I I S H S Y R L I C K GR I N R K E L Y V F GA Y T L L T E I V L E F S F Y L L Y L D K I G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-2.9 MD L L G F G T V I V H F L I I S H S Y R L I C K GR I N R K E L Y I F GA Y T L L T E I V L E F S F Y L L Y L D K I G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-2.2 MD L L G F G T V I V H F L I I S H S Y R L I C K GR I N R K E L Y I F GA Y T L L T E I V L E F S F Y L L Y L D K I G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-2.4 MD L L G F G T V I V H F L I I S H S Y R L I C K GR I N R K E L Y V F GA Y T L L T E I V L E F S F Y L L Y L D K I G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-2.1 MD L L G F G T V I V H F L I I S H S Y R L I C K GR I N R K E L Y V F GA Y T L L T E I V L E F S F Y L L Y L D K I G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-2.5 MD L L G F G T V I V H F L I I S H S Y R L I C K GR I N R K E L Y V F GA Y T L L T E I V L E F S F Y L L Y L D K I G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V I F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-2.6 MD L L G F G T V I V H F L I I S H S Y R L I C K GR I N R K E L Y V F GA Y T L L T E I V L E F S F Y L L Y L D K I G I E R F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V I F S S I T GD N F V L QY H F P F F F V V T V L T Y F V T L K I I Y
ComD-3.1 MD F F L L V D L I L Y F L I I S H S Y R L I C K D Q I N R K E L F F F GA Y T L L T E I V L D F P F Y L L Y L D G L G I A T F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY Y G L F F F V V T V L T Y F V T L K I I Y
ComD-3.2 MD F F L L V D L I L Y F L I I S H S Y R L I C K D Q I N R K E L F F F GA Y T L L T E I V L D F P F Y L L Y L D G L G I A T F L F P L G L Y S Y F RWMK QY E R D R G L F L S L L L S L L Y E S T H N F L S V T F S S I T GD N F V L QY Y G L F F F V V T V L T Y F V T L K I I Y
150 160 170 180 190 200 210 220 230 240 250 260 270 280
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ComD-1.4 Y F H L E L A Y F D K D Y L Y P F L K K V F F A L L L L H I V S F V S D MV S T I K H L N S F GS I L S S I V F I S L L L T F F A MN S H K V QM E K E I A L K QK K F E QK H L QN Y T D E I V G L Y N E I R G F R H D Y A GM L V S MQMA I D S GN L Q E I D R I Y N E V L V K A
ComD-1.3 Y F H L E L A Y F D K D Y L Y P F L K K V F F A L L L L H I V S F V S D MV S T I K H L N S F GS I L S S I V F I S L L L T F F A MN S H K V QM E K E I A L K QK K F E QK H L QN Y T D E I V G L Y N E I R G F R H D Y A GM L V S MQMA I D S GN L Q E I D R I Y N E V L V K A
ComD-1.5 Y F H L E L A Y F D K D Y L Y P F L K K V F F A L L L L H I V S F V S D MV S T I K H L N S F GS I L S S I V F I S L L L T F F A MN S H K V QM E K E I A L K QK K F E QK H L QN Y T D E I V G L Y N E I R G F R H D Y A GM L V S MQMA I D S GN L Q E I D R V Y N E V L V K A
ComD-1.8 Y F H L E L A Y F D K D Y L Y P F L K K V F F A L L L L H I V S F V S D MV S T I K H L N S F GS I L S S I V F I S L L L T F F A MN S H K V QM E K E I A L K QK K F E QK H L QN Y T D E I V G L Y N E I R G F R H D Y A GM L V S MQMA - - - - - - - - I D R I Y N E V L V K A
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ComD-1.5 L E T E M E GS T F R Q I I R F K R E F E
ComD-1.8 L E T E M E GS T F R Q I I R F K R E F E
ComD-1.6 L E T E M E GS T F R Q I I R F K R E F E
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ComD-3.1 L E T E M E GS T F R Q I I R F K R K F E
ComD-3.2 L E T E M E GS T F R Q I I R F K R K F E




Figure 4.7 – Phylogenetic tree of ComD variants. Tree built by neighbor-joining method and 
resampling was done by bootstrap for 1000 times. 
 
4.2.4. Gene comE 
 
The comE gene presented a total of 15 alleles, however, two isolates 
presented an insertion sequence of >1200 bp in this gene and they were excluded 
from this analysis (Table 4.3, Figure 4.8). The insertion sequence was ISSpn8 
(IS1239) from the family IS30 according to ISfinder database available at 
https://www-is.biotoul.fr (Siguier et al., 2006). This IS was inserted in the positions 
721 and 749 of these alleles, i.e., close to the end of the comE gene, but in a 
different orientation.  
II. Pherotype diversity and abundance 4. Diversity of the comCDE locus 
 
61 
The alleles could not be grouped and related with pherotype because in some 
cases the same allele was identified in different pherotypes (Table 4.3). The 
majority of the SNPs must have originated by point mutations because many were 
silent mutations resulting in only 5 protein variants of ComE (Figure 4.9). The 
allele comE-1 produced the same protein as all the other alleles except comE-5, 
comE-9, comE-12 and comE-13 which produced a different ComE variant. 
Nevertheless, the ComE variants were conserved presenting only 6 positions with 
amino acid substitutions. 
The comE-13 and comE-14 alleles presented the highest genetic diversity. 
This could be expected for comE-13, because it is the allele presented by CSP3 
isolates, but the case of comE-14 was special because it presented 16 silent 
mutations in relation to the allele comE-1, producing the same protein. Thus, the 
allele comE-14 could be defined as a case of stabilizing selection. 
 






Figure 4.8 – DNA sequence of comE alleles. Black boxes highlight SNPs.  
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comE-5 A A A T GA T GA A G T A A A T C A GC T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-6 A A A T GA T GA A G T A A A T C A GC T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-7 A A A T GA T GA A G T A A A T C A GC T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T T G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-8 A A A T GA T GA A G T A A A T C A A C T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-9 A A A T GA T GA A G T A A A T C A GC T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A G T T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-10 A A A T GA T GA A G T A A A T C A GC T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-11 A A A T GA T GA A G T A A A T C A A C T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-12 A A A T T A T GA A G T A A A T C A A C T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A G T T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-13 A A A T GA T GA A G T A A A T C A A C T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T T GC T C A A C T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C C A G T C GA T C A GA G T T T G
comE-14 A A A T GA T GA A G T A A A T C A GC T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T T G T C T T T A T C A C T A G T C GA T C A GA G T T T G
comE-15 A A A T GA T GA A G T A A A T C A GC T T T A T T T C C T A GA T A T C GA T A T T C A T GGA A T T GA GA A A A A GGGA T T T GA A G T GGC T C A GC T C A T T C G T C A T T A C A A T C C T T A C GC T A T T A T C G T C T T T A T C A C T A G T C GA T C A GA G T T T G
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comE-1 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-2 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-3 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-4 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-5 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-6 C GA C T C T A A C C T A T A A A T A T C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-7 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-8 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-9 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-10 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-11 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-12 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-13 C GA C T C T GA C C T A T A A A T A C C A GA T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A C GA T GA GA T G T T T A A GA A GC GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-14 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-15 C GA C T C T A A C A T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
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comE-1 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-2 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-3 T A T T T C GA C T A C A A T T A C A A A GGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-4 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-5 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-6 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-7 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-8 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-9 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-10 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-11 T A T T T C GA C T A C A A T T A C A A A GGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-12 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-13 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C GA C A GGA G T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-14 T A T T T T GA T T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C GA C A GGA G T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC C A A A GA G T T T T A C GG T A C C A T GA C A GA
comE-15 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA






Figure 4.8 – DNA sequence of comE alleles (continued). 
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comE-1 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-2 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-3 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-4 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-5 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-6 C GA C T C T A A C C T A T A A A T A T C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-7 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-8 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-9 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-10 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-11 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-12 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-13 C GA C T C T GA C C T A T A A A T A C C A GA T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A C GA T GA GA T G T T T A A GA A GC GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-14 C GA C T C T A A C C T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
comE-15 C GA C T C T A A C A T A T A A A T A C C A GG T A T C A GC C C T A GA T T T T G T T GA T A A GGA T A T C A A T GA T GA GA T G T T T A A GA A GA GA A T T GA GC A A A A T A T C T T C T A C A C GA A GA G T A T G T T A C T T GA A A A T GA A GA T G T T G T A GA T
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comE-1 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-2 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-3 T A T T T C GA C T A C A A T T A C A A A GGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-4 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-5 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-6 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-7 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-8 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-9 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-10 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-11 T A T T T C GA C T A C A A T T A C A A A GGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-12 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-13 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C GA C A GGA G T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
comE-14 T A T T T T GA T T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C GA C A GGA G T C T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC C A A A GA G T T T T A C GG T A C C A T GA C A GA
comE-15 T A T T T C GA C T A C A A T T A C A A GGGA A A T GA T T T A A A A A T T C C T T A C C A T GA T A T T T T G T A T A T T GA A A C A A C A GGGG T A T C T C A T A A A T T GC GC A T T A T T GG T A A GA A T T T T GC A A A A GA G T T T T A T GG T A C C A T GA C A GA
570 580 590 600 610 620 630 640 650 660 670 680 690 700
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comE-1 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-2 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-3 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-4 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-5 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-6 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-7 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-8 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-9 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-10 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GG T A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-11 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-12 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-13 T A T T C A GGA A A A GGA C A A A C A T GC T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-14 T A T T C A GGA A A A GGA C A A A C A T A C C C A A C GA T T T T A T T C T C C T C A T A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A T C T A GA A A T T G T T T T C T A T GA A GA C C A T C GC T G T C C T A T T T C A A
comE-15 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
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. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . .
comE-1 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-2 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-3 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-4 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-5 GA T T A A A A A T T GGA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-6 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-7 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-8 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-9 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-10 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-11 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-12 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-13 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-14 GG T T A A A A A T T A GA A A A T T GA A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-15 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
570 580 590 600 610 620 630 640 650 660 670 680 690 700
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comE-1 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-2 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-3 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-4 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-5 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-6 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-7 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-8 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-9 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-10 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GG T A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-11 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-12 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-13 T A T T C A GGA A A A GGA C A A A C A T GC T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
comE-14 T A T T C A GGA A A A GGA C A A A C A T A C C C A A C GA T T T T A T T C T C C T C A T A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A T C T A GA A A T T G T T T T C T A T GA A GA C C A T C GC T G T C C T A T T T C A A
comE-15 T A T T C A GGA A A A GGA C A A A C A T A C T C A GC GA T T T T A T T C T C C T C A C A A G T C A T T T T T GG T A A A T A T A GGC A A T A T C A GA GA A A T T GA T C GA A A A A A C T T A GA A A T T G T T T T C T A T GA A GA C C A T C G T T G T C C T A T T T C A A
710 720 730 740 750
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comE-1 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-2 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-3 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-4 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-5 GA T T A A A A A T T GGA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-6 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-7 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-8 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-9 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-10 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-11 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-12 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-13 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-14 GG T T A A A A A T T A GA A A A T T GA A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA
comE-15 GA T T A A A A A T T A GA A A A T T A A A A GA T A T T T T A GA GA A A A A A T C T C A A A A G T GA




Figure 4.9 – Protein sequence of ComE variants. Black boxes highlight SNPs and grey boxes highlight similar amino acids. 
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comE-1 MK V L I L E D V I E H QV R L E R I L D E I S K E S N I P I S Y K T T GK V R E F E E Y I E N D E V N Q L Y F L D I D I H G I E K K G F E V A Q L I R H Y N P Y A I I V F I T S R S E F A T L T Y K Y QV S A L D F V D K D I N D E M F K K R I E QN I F Y T K S M L L E N E D V V D
comE-5 MK V L I L E D V I E H QV R L E R I L D E I S K E S N I P I S Y K T T GK V R E F E E Y I E N D E V N Q L Y F L D I D I H G I E K K G F E V A Q L I R H Y N P Y A I I V F I T S R S E F A T L T Y K Y QV S A L D F V D K D I N D E M F K K R I E QN I F Y T K S M L L E N E D V V D
comE-9 MK V L I L E D V I E H QV R L E R I L D E I S K E S N I P I S Y K T T GK V R E F E E Y I E N D E V N Q L Y F L D I D I H G I E K K G F E V A Q F I R H Y N P Y A I I V F I T S R S E F A T L T Y K Y QV S A L D F V D K D I N D E M F K K R I E QN I F Y T K S M L L E N E D V V D
comE-12 MK V L I L E D V I E H QV R L E R I L D E I S K E S N I P I S Y K T T GK V R E F E E Y I E N Y E V N Q L Y F L D I D I H G I E K K G F E V A Q F I R H Y N P Y A I I V F I T S R S E F A T L T Y K Y QV S A L D F V D K D I N D E M F K K R I E QN I F Y T K S M L L E N E D V V D
comE-13 MK V L I L E D V I E H QV R L E R I L D E I S K E S N T P I S Y K T T GK V R E F E E Y I E N D E V N Q L Y F L D I D I H G I E K K G F E V A Q L I R H Y N P Y A I I V F I T S R S E F A T L T Y K Y Q I S A L D F V D K D I N D E M F K K R I E QN I F Y T K S M L L E N E D V V D
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comE-1 Y F D Y N Y K GN D L K I P Y H D I L Y I E T T GV S H K L R I I GK N F A K E F Y G T M T D I Q E K D K H T QR F Y S P H K S F L V N I GN I R E I D R K N L E I V F Y E D H R C P I S R L K I R K L K D I L E K K S QK
comE-5 Y F D Y N Y K GN D L K I P Y H D I L Y I E T T GV S H K L R I I GK N F A K E F Y G T M T D I Q E K D K H T QR F Y S P H K S F L V N I GN I R E I D R K N L E I V F Y E D H R C P I S R L K I GK L K D I L E K K S QK
comE-9 Y F D Y N Y K GN D L K I P Y H D I L Y I E T T GV S H K L R I I GK N F A K E F Y G T M T D I Q E K D K H T QR F Y S P H K S F L V N I GN I R E I D R K N L E I V F Y E D H R C P I S R L K I R K L K D I L E K K S QK
comE-12 Y F D Y N Y K GN D L K I P Y H D I L Y I E T T GV S H K L R I I GK N F A K E F Y G T M T D I Q E K D K H T QR F Y S P H K S F L V N I GN I R E I D R K N L E I V F Y E D H R C P I S R L K I R K L K D I L E K K S QK
comE-13 Y F D Y N Y K GN D L K I P Y H D I L Y I E T T GV S H K L R I I GK N F A K E F Y G T M T D I Q E K D K H A QR F Y S P H K S F L V N I GN I R E I D R K N L E I V F Y E D H R C P I S R L K I R K L K D I L E K K S QK
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4.2.5. Profiles of comCDE 
 
After concatenating the sequences of the three genes, a total of 30 unique 
profiles of comCDE alleles were identified, including the isolates with the two 
comE alleles with ISSpn8 (IS1239) (Table 4.4). The canonical subgroup of comD1 
alleles was correlated with comC-1.1 and comC-1.3 alleles, while comC-1.2 allele 
presented only non-canonical comD1 alleles. The comC-2.1 and comC-2.2 alleles 
also presented their own comD alleles, i.e., they did not share comD alleles between 
them. 
The profiles with comC-1.1, comD-1.1 and four diverse comE alleles (comE-1, 
comE-2, comE-3 and comE-6) were the most frequently identified. Although various 
comE alleles were associated with the canonical comD1 alleles, they produced the 
same ComE protein variant. Thus, ComC-1.1 (CSP1), ComD-1.1 and ComE-1 were 
the most frequent protein variants produced in these isolates. 
Table 4.4 – Profiles of comCDE sequences and respective serotypes and STs. 
Pherotype n comC comD comE Serotype Sequence Type 
CSP1 15 comC-1.1 comD-1.1 comE-3 14 (n=9); 9V 
(n=5); 12B (n=1) 
156 (n=6); 557 (n=4); 
218, 644, 790, 838, 1225 
(n=1 each) 
CSP1 13 comC-1.1 comD-1.1 comE-1 11A, 33F (n=3 
each); 18C, 22F 
(n=2 each); 8, 13, 
20 (n=1 each)  
408, 1012, 1367 (n=2 
each); 53, 62, 100, 574, 
717, 1026, 1233 (n=1 
each) 
CSP1 11 comC-1.1 comD-1.1 comE-2 1 (n=6); 4 (n=3); 
14, 16F (n=1 
each) 
306, 1221 (n=3 each); 
15, 228, 304, 350, 414 
(n=1 each) 
CSP1 5 comC-1.1 comD-1.1 comE-6 23F (n=4); 15B 
(n=1) 
338 (n=3); 1371, 1706 
(n=1 each) 
CSP1 4 comC-1.1 comD-1.2 comE-2 7F (n=4) 191 (n=4) 
CSP1 3 comC-1.1 comD-1.1 comE-4 6B (n=2); 6A (n=1) 273, 1224, 1369 (n=1 
each) 
CSP1 3 comC-1.2 comD-1.3 comE-8 3 (n=3) 180 (n=2); 1230 (n=1) 
CSP1 2 comC-1.1 comD-1.1 comE-11 12B (n=2) 218, 1365 (n=1 each) 
CSP1 2 comC-1.2 comD-1.4 comE-9 19A (n=2) 199, 876 (n=1 each) 
CSP1 2 comC-1.2 comD-1.5 comE-4 5 (n=2) 1223 (n=2) 
CSP1 2 comC-1.2 comD-1.8 comE-12 3 (n=2) 458 (n=2) 
CSP1 1 comC-1.1 comD-1.6 comE-2 19F (n=1) 347 (n=1) 
CSP1 1 comC-1.1 comD-1.7 comE-1 8 (n=1) 53 (n=1) 
CSP1 1 comC-1.1 comD-1.1 Insertion of 1274 bp 35F (n=1) 1368 (n=1) 
CSP1 1 comC-1.3 comD-1.1 comE-15 22F (n=1) 1372 (n=1) 
       
CSP2 4 comC-2.1 comD-2.1 comE-5 3 (n=4) 260, 1220 (n=2 each) 
CSP2 3 comC-2.1 comD-2.3 comE-1 19F (n=2); 10F 
(n=1) 
177, 391, 1649 (n=1 
each) 
CSP2 3 comC-2.2 comD-2.2 comE-7 23F (n=2); 19A 
(n=1) 
81 (n=3) 
CSP2 2 comC-2.1 comD-2.10 comE-10 4 (n=2) 247 (n=2) 
CSP2 1 comC-2.1 comD-2.1 comE-4 4 (n=1) 1222 (n=1) 
CSP2 1 comC-2.1 comD-2.5 comE-1 6C (n=1) 395 (n=1) 
CSP2 1 comC-2.1 comD-2.6 comE-4 12B (n=1) 989 (n=1) 
CSP2 1 comC-2.1 comD-2.7 comE-10 6B (n=1) 273 (n=1) 
CSP2 1 comC-2.1 comD-2.8 Insertion of 1246 bp 10A (n=1) 1231 (n=1) 
CSP2 1 comC-2.1 comD-2.11 comE-5 3 (n=1) 260 (n=1) 
CSP2 1 comC-2.2 comD-2.2 comE-14 9N (n=1) 66 (n=1) 
CSP2 1 comC-2.2 comD-2.4 comE-9 8 (n=1) 404 (n=1) 
CSP2 1 comC-2.2 comD-2.9 comE-7 19A (n=1) 276 (n=1) 
       
CSP3 1 comC-3 comD-3.1 comE-13 19A (n=1) 1201 (n=1) 
CSP3 1 comC-3 comD-3.2 comE-13 35F (n=1) 1366 (n=1) 





In this chapter the genetic diversity of the comCDE locus was presented. 
Three CSP variants were identified corresponding to pherotypes CSP1, CSP2 and 
CSP3. The diversity of comD could be related with pherotype but that was not the 
case for comE. The majority of the genetic divergence was located in the region 
coding the mature CSP and the sensor domain of ComD. The gene comD was the 
most diverse while comE was more conserved presenting just 5 protein variants. 
Regarding pherotype, which is identified by the type of CSP produced, most 
isolates presented CSP1 (n=66, 74.2 %) while the remaining isolates were CSP2 
(n=21, 23.6 %) and CSP3 (n=2, 2.2 %). Proportion of CSP1 and CSP2 was similar to 
previous work in our lab (Carrolo et al., 2009) but the PCR used by this study was 
not able to detect CSP3 strains. Until now CSP3 abundance has not been properly 
evaluated because only a few isolates of this pherotype were identified (Evans and 
Rozen, 2013, Ramirez et al., 1997, Whatmore et al., 1999). The proportion of CSP3 
reported here is not trustworthy because only 2 CSP3 isolates were found in the 89 
isolates tested, making it necessary to screen a larger number of isolates. The CSPs 
found in this study were already known, thus new variants of CSP were not 
discovered.  
Regarding comC alleles, comC-1.3 was found in a single isolate and resulted 
from a point mutation in the region coding the signal-peptide. This allele was not 
identified in the published studies of the diversity of comC (Evans and Rozen, 2013, 
Pozzi et al., 1996, Ramirez et al., 1997, Vestrheim et al., 2011, Whatmore et al., 
1999) but comC-1.1, comC-1.2, comC-2.2, comC-2.2 and comC-3 alleles were 
described in those studies.  
The CSP3 identified here is the same as CSP-4 described by Whatmore et al. 
(Whatmore et al., 1999). Furthermore, Whatmore et al. and Ramirez et al. (Ramirez 
et al., 1997) also identified a similar CSP (CSP-3 and CSPγ, respectively) that 
presented an additional NFF repetition before the terminal triple arginine (Figure 
4.4). However, this variant was not found in this study. The primers designed for 
sequencing the comCDE locus made it possible to detect pherotype CSP3 among 
our isolates and it was the first time CSP3 strains were identified in Portugal.  
The gene presenting more genetic diversity was comD. However, this 
diversity was not distributed evenly across the encoded protein. Most of the genetic 
variation was seen in the N-terminus thought to correspond to the ComD sensor 
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domain, which interacts with CSP, while the kinase domain located at the C-
terminus, which interacts with ComE, was more conserved. Thus, because of the 
diversity in the sensor domain, comD also forms 3 groups that correlate with 
pherotypes. However, when analyzing just the kinase domain, the relation with 
pherotype is lost, as also happens with comE. This strongly suggests that 
pherotype specificity is due to the interaction between CSP and the ComD sensor 
domain located in the N-terminus by an unknown mechanism.  
Interestingly, ComD1 variants could be divided into two groups, canonical 
and non-canonical (Figure 4.7), with the former corresponding to ComD1 in 
Iannelli et al. (Iannelli et al., 2005) and the later to ComD3 and ComD4 in the same 
study. The results of Iannelli et al. suggest a low affinity binding of non-canonical 
ComD1 to CSP1, requiring a higher dose of CSP1 to reach the same transformation 
efficiency as canonical ComD1 (Figure 4.10). They also observed that a non-
canonical ComD1 (termed ComD3 in their study) was cross-induced by high doses 
of CSP2 and the same was also observed when high doses of CSP1 were given to 
ComD2-carrying strains. Their results also suggest that ComD2 has a lower 
affinity binding to CSP2 than canonical ComD1 to CSP1, because at a dose of 30 
ng/mL of synthetic CSP, ComD2 is not induced while canonical ComD1 is fully 
induced (Figure 4.10). However, Evans and Rozen (Evans and Rozen, 2013) did 
not see any difference in transformation efficiency between canonical and non-
canonical ComD1 variants, but they observed significantly more admixture in 
isolates carrying non-canonical ComD1. Their study included a pherotype CSP3 
strain which was not able to transform in the presence of CSP1 synthetic peptide. 
Ramirez et al. reported a low response of a CSP3 isolate to CSP1 and also observed 
cross-induction of CSP2 isolates by adding CSP1 (Ramirez et al., 1997). Taking 
together the results of these studies, isolates carrying non-canonical ComD1 
variants respond to CSP1 and, although to a lesser extent, could also respond to 
CSP2. This could be the reason why they present more admixture than isolates 
carrying canonical ComD1 variants because, hypothetically, they would be able to 
more easily exchange DNA with both pherotype CSP1 and CSP2 populations. 
Induction of non-canonical ComD1 by CSP2 cannot be explained by looking at the 
amino acid sequence because non-canonical ComD1 do not share unique amino 
acids with ComD2 protein variants. Thus, a study comparing the transformation 
efficiencies of isolates carrying diverse ComD variants (ComD2, ComD3 and 
canonical and non-canonical ComD1) in the presence of synthetic CSPs (CSP1, 
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CSP2 and CSP3) complemented by a population structure analysis could shed light 
on this hypothesis. ComD3 variants seem a hybrid between both ComD1 subgroups 
and ComD2, sharing many of the positions characteristic of each of these variants. 
Response of ComD3 to CSP2 or CSP3 has not been reported yet. 
 
 
Figure 4.10 - Competence pheromone specificity in S. pneumoniae. Figure from Iannelli et al. 
(Iannelli et al., 2005). Four isogenic strains, each expressing a ComD variant in the same competence-
negative genetic background, were induced to competence with synthetic CSP1 (a) and CSP2 (b) 
peptides. CSP doses range from 10 to 1000 ng/mL. Transformation efficiency is expressed as number 
of CFU transformed with a streptomycin resistance marker in a 106 CFU/mL culture. Strains 
expressing the ComD1/ComD3/ComD4 receptors were induced to competence by CSP1, whereas 
strain expressing the ComD2 receptor was induced by CSP2. Cross-induction of competence was also 
observed in strains expressing ComD2 or ComD3. In the absence of CSPs, no transformants were 
obtained. The ComD1-carrying strain is indicated as a diamond, the ComD2-carrying strain as a 
square, the ComD3-carrying strain as a triangle, and the ComD4-carrying strain as a circle.  
 
The protein ComE is highly conserved among the pneumococcal population 
with only 5 variants identified in this study. It seems to be a gene under strong 
purifying selection as the majority of the SNPs observed were silent mutations. 
ComE does not take part in the recognition of CSP, thus the relation between 
pherotype and alleles which was seen for comC and comD is lost. ComE is 
conserved probably because of its gene activator function and the requirement to 
both interact with ComD for phosphorylation and the target DNA sequences.    
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Two isolates presented the insertion sequence ISSpn8 (IS1239) belonging to 
the family IS30 (Siguier et al., 2006) (ISfinder database available at https://www-
is.biotoul.fr) at the C-terminal end of comE. The resulting ComE proteins of these 
isolates are 244 aa and 296 aa in length while the canonical ComE is 250 aa. These 
proteins could be functional if the C-terminal end of ComE does not have a 
functional role. However, the 296 aa protein could be too large to be functional. 
Moreover, an insertion sequence was also reported in the comC gene of the strain 
AP200 (Table 4.1) and an insertion (comD-2.10) and deletion (comD-2.11) was 
observed here in comD, indicating that there could be alterations in all the genes of 
the comCDE locus leading to a loss of function. It was seen that mutations in 
ComD severely attenuate virulence in mouse models of pneumonia and 
bacteraemia infections (Lau et al., 2001). Thus, although pneumococci can survive 
with alterations in their competence induction genes, these may be ultimately 
detrimental to them or at least to their virulence potential. 
This chapter analyzed a relatively small sample chosen to represent the 
diversity of the pneumococcal population before conjugate vaccine introduction. 
Even though, ComC-1.1 (CSP1), ComD-1.1 and ComE-1 proteins were much more 
frequent than any other protein variants. It is not clear if these are the most 
efficient protein combination in controlling competence. Our results are similar to 
what was previously described in the literature. The dominance of CSP1 pherotype 
is well known, although it is unclear why CSP1 dominates over other pherotypes. 
The most immediate explanation could be that CSP1 and canonical ComD1 
presents the most effective peptide-receptor interaction translating in a best 
response to CSP. Maybe Phe22 of canonical ComD1 plays an important role 
because it is specific of this group. However, this is a hypothesis that will require 
formal testing. A previous study by our laboratory with mutants lacking the comC 
gene showed that CSP1 strains had a higher capacity to form in vitro biofilms and 
yielded more transformants than CSP2 strains (Carrolo et al., 2014). It was 
suggested that both effects could help explain the higher prevalence of CSP1 
strains in the pneumococcal population by enabling them to be more transmissible 
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CHAPTER 5.                        PHEROTYPE ABUNDANCE 
 
In the last chapter, pherotype CSP3 was identified for the first time in 
Portugal. The abundance of pherotypes CSP1 and CSP2 is well described in 
literature (Carrolo et al., 2009, Evans and Rozen, 2013, Ramirez et al., 1997, 
Valente et al., 2012, Vestrheim et al., 2011, Whatmore et al., 1999). Regarding 
CSP3, it is assumed to be a rare pherotype because those studies identify no strain 
or very few strains of this pherotype. Our laboratory previously described the 
abundance of pherotypes CSP1 and CSP2 of an invasive pneumococcal collection 
recovered between 1999 and 2002 (Carrolo et al., 2009). However, the PCR scheme 
designed in that study was unable to distinguish pherotype CSP1 from CSP3. 
The discovery of CSP3 isolates in Portugal prompted us to explore the 
abundance of this pherotype in natural populations of pneumococci. We used an 
extensive pneumococcal invasive isolate collection recovered during a period of 14 
years to identify the abundance of each pherotype and evaluate their evolution, 
using a new PCR scheme which would be able to identify the three pherotype 
variants. Then, associations between pherotype and other clonal characteristics 
were evaluated. 
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5.1. Materials and methods 
5.1.1. Bacterial isolates  
 
To determine the abundance of each pherotype, all invasive pneumococcal 
isolates recovered from children (<18 years) during 1999 and 2012 in Portugal and 
sent to the Instituto de Microbiologia of Faculdade de Medicina of Universidade de 
Lisboa (n=903) were selected. They represent a geographically well-defined 
population and this period included the introduction of conjugate vaccines, when 
changes in serotype distribution were described previously (Aguiar et al., 2010a, 
Aguiar et al., 2014, Aguiar et al., 2008). Although this collection does not include 
isolates recovered from adults, it is larger than any other study where pherotype 
was determined.  A high number of isolates was needed in order to have a reliable 
estimation of the proportion of CSP3 isolates. The serotype, MLST characterization 
and antibiotic susceptibility of these isolates were previously described by our 
laboratory (Aguiar et al., 2010b, Aguiar et al., 2014, Aguiar et al., 2010d, Aguiar et 
al., 2008, Serrano et al., 2005, Serrano et al., 2004). 
 
5.1.2. Pherotype identification 
 
In the previous work performed by our laboratory (Carrolo et al., 2009), a 
PCR was developed to identify the pherotype of pneumococcal isolates. This PCR 
used three primers (Table 5.1): CSP-fw, able to recognize all isolates, and CSP1-rv 
and CSP2-rv, specific for CSP1 and CSP2 isolates, respectively (Figure 5.1). 
However, this PCR was unable to distinguish CSP1 from CSP3, since CSP1-rv was 
able to recognize both pherotypes. Therefore, a new primer was designed: CSP3-rv 
(Table 5.1, Figure 5.1). The identification of pherotypes was performed by 
evaluating the size and number of the products amplified (Figure 5.2). 
 
The PCR reaction for identification of pherotype was composed of: 
- 0.05 U/µl GoTaq® DNA polymerase (Promega, Wisconsin, USA); 
- 1x enzyme’s buffer provided by manufacturer; 
- 2 mM magnesium chloride; 
- 0.4 mM dNTPs; 
- 0.4 pmol/µl of each primer (CSP-fw, CSP1-rv, CSP2-rv and CSP3-rv); 
- 20 µl of boiled bacterial cells. 
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With the following PCR program: 
- 5 min at 95 ºC; 
- 30x (1 min at 95 ºC, 30 s at 55 ºC and 1 min at 72 ºC) 
- 10 min at 72 ºC. 
 
 
Table 5.1 – Sequence of the primers used for pherotype determination. 
Primer Sequence (5'→ 3') Size (bp)  
CSP-fw TGAAAAACACAGTTAAATTGGAAC 24  
CSP1-rv TCAAGAAAGGATAAAGGTAGTCCTC 25  
CSP2-rv TAAAAATCTTTCAATCCCTATTTT 24  




Figure 5.1 – Primers used for pherotype identification. Primer CSP1-rv also binds to comD3 in 
CSP3 strains, whereas comD2 in CSP2 strains only have a single difference in the site of CSP1-rv 
binding, so this primer can also bind to CSP2 strains but with less specificity. 
 




Figure 5.2 – Example gel of pherotype determination. Primer CSP1-rv also binds to comD3 in 
CSP3 strains, whereas comD2 in CSP2 strains only have a single difference in the site of CSP1-rv 
binding, so this primer can also bind to CSP2 strains but with less specificity. 
 
5.1.3. Statistical analysis 
 
The Cochran-Armitage test (CA) was used to evaluate the temporal trends of 
pherotype, serotype, ST, CC and antimicrobial resistance. Fisher’s exact test (FET) 
was used to test association of pherotype with serotype, ST, CC and antimicrobial 
resistance. The false discovery rate (FDR) correction for multiple testing 
(Benjamini and Hochberg, 1995) was used in both tests. A p<0.05 was considered 
significant for all tests. 
Genetic diversity was evaluated using Simpson’s index of diversity (SID) and 
respective 95 % confidence intervals (CI95 %) (Carriço et al., 2006). Adjusted Wallace 
(AW) was used to evaluate the congruence between the typing methods and to 
quantify the ability of each trait to predict pherotype (Carriço et al., 2006). SID and 
AW were calculated using the online tool available at 
www.comparingpartitions.info. 
  




5.2.1. Pherotype abundance and evolution 
 
A total of n=903 isolates were recovered from children (<18 years) during a 
period of 14 years (1999-2012) (Table 5.2). These isolates were recovered from 
blood (n=768), CSF (n=94), pleural (n=35), synovial (n=4) and ascitic (n=2) fluids. 
The total number of isolates recovered per year increased over time, stabilizing 
around 2007. After 2010, a decrease of children IPD incidence was observed (Table 
5.2, (Aguiar et al., 2014)). 
The most abundant pherotype was CSP1 (n=681, 75.4 %), followed by CSP2 
(n=192, 21.3 %) and then by CSP3 (n=20, 2.2 %) (Table 5.2). The pherotype of 10 
isolates was not determined because either a PCR product was not amplified 
(serotype 25A/38, n=9) or it had a higher size indicating the presence of an 
insertion sequence (serotype 6C, n=1). The case of the isolates expressing serotype 
25A/38, which were all identified as ST393 (see 5.2.4. Sequence type and pherotype), 
will be discussed in the next section (5.2.2. ST393 serotype 25A/38 isolates). 
Analyzing pherotype proportions over the years, a decrease from 85.4 % in 
the period 1999-2002 to 67.1 % in 2012 was observed for pherotype CSP1, although 
this was only supported before FDR correction (CA p=0.0314) (Figure 5.3). 
However, no significant changes were seen for pherotypes CSP2 and CSP3. 
Therefore, pherotype proportions remained relatively stable despite the changes 
that occurred in serotype distribution (see 5.2.3. Serotype and pherotype).  
In this study four age groups were defined: 0-11 months (n=261), 12-23 
months (n=178), 2-4 years (n=207) and 5-17 years (n=257). Between the period 
1999-2002 and 2012, a decrease from 82.8 % to 44.4 % of pherotype CSP1 
proportion and an increase from 13.8 % to 50.0 % of pherotype CSP2 proportion 
were observed in the age group 0-11 months, although, as before, these changes 
were only supported before FDR correction (CA p=0.0385 and CA p=0.0316, 
respectively) (Figure 5.4). In the other age groups the pherotype proportions 
remained constant. Comparing the pherotype proportion between age groups, 
CSP1 proportion increased from 67.8 % to 85.2 % in the younger to older age 
groups, while CSP2 proportion decreased from 27.6 % to 12.5 % between the same 
age groups (CA p<0.001 for both pherotypes, significant after FDR) (Figure 5.5). 
In the section 5.2.3. Serotype and pherotype is presented the contribution of 
serotypes 1 and 19A for this association between pherotype and age. 
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Table 5.2 – Pherotype distribution of pneumococcal invasive isolates recovered in children 
in Portugal during 1999-2012. 
Pherotype 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
CSP1 20 15 25 22 22 29 35 60 98 80 116 62 48 49 681 
CSP2 0 3 5 5 6 11 12 22 21 26 32 12 17 20 192 
CSP3 0 0 1 0 1 1 1 2 3 1 2 4 2 2 20 
NDa 0 0 0 0 0 0 0 2 3 0 0 0 3 2 10 
Total 20 18 31 27 29 41 48 86 125 107 150 78 70 73 903 





Figure 5.3 – Evolution of pherotype proportion in invasive isolates recovered from 
children between 1999 and 2012. PCV7 and PCV13 were available in children vaccination since 




































Figure 5.4 – Evolution of pherotype proportion in invasive isolates by age group. PCV7 and 
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5.2.2. ST393 serotype 25A/38 isolates 
 
All serotype 25A/38 isolates were identified as ST393 and a PCR product was 
not obtained in the pherotype determination PCR. This was intriguing because 
these isolates could present a new type of CSP undetected by the PCR setup used. 
Thus, we focused in sequencing the comCDE locus of these strains. However, 
despite trying several primer pairs aimed at amplification of this locus, a PCR 
product with the complete operon was not obtained.  
To clarify this, we obtained preliminary data of the high throughput 
sequencing of an ST393 isolate. The contigs obtained from the assembly of this 
genome were queried with the comC and comD alleles from strain R6. Both genes 
were found in the same contig but they had a sequence of ≈ 70 000 bp between 
them, resulting from an inversion rearrangement of the genome (Figure 5.6). The 
comC gene was complete and its sequence was equal to comC-2.1 allele (see 
Chapter 4, Figure 4.3). However, downstream of comC, the first 48 bp of comD 
were identified but then this gene was truncated, appearing the rest of it upstream 
of the insertion sequence ISSpn8 and the fcsR gene (Figure 5.6). ISSpn8 was 
identified in the last chapter in two comE alleles (see 4.2.4 Gene comE). The primer 
CSP2-rv (Figure 5.1) was located in the comD region that was separated from 
comC, explaining why pherotype determination by PCR was unsuccessful. The 
inverted region (≈ 70 000 bp) between comC and fcsR in this ST393 isolate was 
similar to other pneumococcal isolates, maintaining the gene synteny from comD to 
adcA. The observed differences that are worth mentioning were: i) the presence of a 
direct repeat (DR) sequence in both comD extremities in the truncated zones; ii) 
the presence of a sequence of 26 bp with just a single SNP regarding the inverted 
repeat left (IRL) of ISSpn8, corresponding to the start of this IS; and iii) the 
presence of ISSpn8 between comD and fcsR (Figure 5.6). This suggests that the 
first event was the insertion of ISSpn8 within comD forming the DR sequences and 
then a recombination event promoted by this IS originated the inversion 
rearrangement. However, these preliminary data need to be confirmed by 
sequencing additional serotype 25A/38-ST393 isolates, including long read 
technologies which could provide further support for the detected rearrangement. 
 




Figure 5.6 – Inversion of a 70 000 bp region between comC and comD genes in a serotype 
25A/38-ST393 isolate. DR – direct repeat; IRL – inverted repeat left; SNP – single nucleotide 
polymorphism. 
 
5.2.3. Serotype and pherotype 
 
A total of 46 serotypes were identified among the isolates. However, serotypes 
1, 19A, 7F, 14 and 23F accounted for 61.4 % (n=554) of the population (Figure 5.7). 
Serotypes 1, 7F, 14 and 23F were associated with pherotype CSP1 (FET p<0.0001: 
1, 7F and 14; p=0.0015: 23F; all significant after FDR), serotypes 6A, 9N, 10A, 19A, 
19F, 24A, and 24F with pherotype CSP2 (FET p<0.0001: 6A, 9N, 10A, 19A, 19F 
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and 24F; p=0.0020: 24A; all significant after FDR) and serotype 19A with 
pherotype CSP3 (FET p<0.0001, significant after FDR). Regarding vaccine 
serotypes, PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F, n=229) were 
associated with pherotype CSP1 [n=193 (84.3 %), FET p=0.0003, significant after 
FDR] and NVT (n=182) with CSP2 [n=57 (31.3 %), FET p=0.0004, significant after 
FDR]. However, an association with a pherotype was not found for PCV13 
exclusive serotypes (1, 3, 5, 6A, 7F and 19A, n=492) possibly because of the 
inclusion of 19A, associated to both CSP2 and CSP3.  
The pherotype proportion of each serotype remained stable over time, despite 
the changes that occurred in serotype distribution. PCV7 serotypes decreased from 
56.3 % to 19.2 %, while NVT increased from 10.4 % to 46.6 % between 1999-2002 
and 2012 (CA p<0.0001, significant after FDR for both cases) (Figure 5.8a). 
PCV13 exclusive serotypes increased from 33.3 % to 60.7 % between 1999-2002 and 
2009 (CA p<0.0001, significant after FDR) but then decreased to 34.2 % between 
2009 and 2012 (CA p=0.0001, significant after FDR). The PCV7 serotypes 9V, 14 
and 23F presented the most significant decreases between 1999 and 2012 (CA 
p<0.0001: 9V, 23F; p=0.0023: 14; all significant after FDR) (Figure 5.8b). The 
PCV13 serotypes 1, 7F and 19A increased between 1999 and 2009 (CA p=0.0410, 
p=0.0075 and p=0.0085, respectively, only supported before FDR correction) but 
between 2009 and 2012 serotypes 1 and 19A decreased (CA p=0.0027 and 
p=0.0313, only supported before FDR correction), while serotype 7F remained 
constant (Figure 5.8c). Regarding NVT, serotypes 23B and 24F increased between 
1999 and 2012 (CA p=0.0170 and p=0.0238, respectively, only supported before 
FDR correction) while the increase of serotype 10A was noted only between 2009 
and 2012 (CA p=0.0011, significant after FDR) (Figure 5.8d). 
In the section 5.2.1. Pherotype abundance and evolution it was seen that 
pherotype CSP1 proportion increased with age while pherotype CSP2 decreased. 
Analyzing the relation of serotype with age group, serotype 19A decreased from 
22.6 % to 6.6 % between 0-11 months and 5-17 years age groups (CA p<0.0001, 
significant after FDR) and serotype 23F decreased from 8.4 % to 2.7 % between the 
same age groups (CA p=0.0022, significant after FDR) (Figure 5.5, serotype 23F 
data not shown). However, serotype 1 increased from 4.6 % in 0-11 months to 42.0 
% in 5-17 years (CA p<0.0001, significant after FDR) (Figure 5.5). Previously it 
was seen that serotypes 1 and 23F were associated with pherotype CSP1 while 
serotype 19A was associated with pherotypes CSP2 and CSP3. When the data of 
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serotypes 1 and 19A was removed from the analysis, the proportions of pherotypes 
CSP1 and CSP2 remained constant between the age groups, suggesting that the 
association of serotypes 1 and 19A with older and younger age groups, respectively, 




Figure 5.7 –Pherotype proportion within serotype. ND – not determined. Other – serotypes 
with <10 isolates (CSP1, n=9: 15A; n=8: 33A; n=7: 11A, 15C; n=6: 20, 21, 33F; n=3: 4, 16F; n=2: 13, 
29, 35F, NT; n=1: 6C, 12B, 17F, 18B, 23A, 28A, 35C/42; CSP2, n=4: 24A; n=3: 35F; n=2: 6C, 12B, 20, 






























Figure 5.8 – Evolution of (A) vaccine serotypes, (B) selected PCV7 serotypes, (C) selected 
PCV13 serotypes and (D) selected non-vaccine serotypes (NVT) in invasive isolates 
recovered from children between 1999 and 2012. It is only shown the serotypes where 
significant changes were observed. PCV13 data included only serotypes 1, 3, 5, 6A, 7F and 19A. PCV7 
and PCV13 were available in children vaccination since 2001 and 2010, respectively. 
 
5.2.4. Sequence type and pherotype 
 
All isolates were characterized by MLST and PHYLOViZ was used to define 
CCs at the SLV level taking in account all STs deposited in the pneumococcal 
MLST database (downloaded on 17th October 2016). A total of 210 STs were 
identified and distributed in 59 CCs and 12 singletons (Table 5.3, Figure 5.9). 
However, five genetic lineages accounted for more than half of the isolates (n=529, 
58.6 %): CC306 (n=179, 19.8 %), CC156 (n=150, 16.6 %), CC191 (n=86, 9.5 %), 
CC230 (n=66, 7.3 %) and CC177 (n=48, 5.3 %). 
Analyzing the association of pherotype and CC, it was observed that CC306, 
CC156, CC191, CC199, CC180 and CC1151 were associated with pherotype CSP1 
(FET p<0.0001: CC306, CC156, CC191; p=0.0003: CC199; p=0.0009: CC180; 
p=0.0014: CC1151; all significant after FDR), while CC230, CC81, CC460, CC994, 
CC315, CC473, CC260 and CC395 were associated with pherotype CSP2 (FET 
p<0.0001: CC230, CC81, CC460, CC994, CC473, CC260, CC395; p=0.0016: CC315; 
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pherotype CSP3 (FET p<0.0001: CC15, CC994; p=0.0005: CC102; all significant 
after FDR). Most STs presented a single pherotype but there were eight exceptions: 
ST306 (n=150 CSP1, n=1 CSP2), ST994 (n=12 CSP2, n=6 CSP3), ST143 (n=9 
CSP1, n=1 CSP2), ST439 (n=7 CSP1, n=1 CSP2), ST273 (n=5 CSP1, n=1 CSP2), 
ST30 (n=4 CSP1, n=1 CSP2), ST4577 (n=1 CSP1, n=1 CSP2) and ST1012 (n=1 
CSP1, n=1 CSP2). However, it was common that a clonal complex presented two 
pherotypes, although a dominant pherotype could generally be identified, with the 
exception of CC177 (Table 5.3, Figure 5.9). 
Similarly to serotypes, changes in the distribution of clonal complexes 
occurred over time. Between 1999-2002 and 2012, CC156 decreased from 42.7 % to 
16.4 % (CA p<0.0001, significant after FDR), while CC191 increased from 4.2 % to 
11.0 % in the same period (CA p=0.0175, only supported before FDR) (Figure 
5.10). The CC306 and CC230 increased from 14.6 % and 1.0 % in 1999-2002 to 21.3 
% and 7.3 % in 2009, respectively (CA p=0.0410 and p=0.0067, respectively, only 
supported before FDR) but then CC306 decreased from 21.3 % to 5.5 % between 
2009 and 2012 (CA p=0.0012, only supported before FDR), while CC230 remained 
stable after 2009. A decrease of the CC15 from 5.3 % to 0.0 % was noted only in the 
period between 2009 and 2012 (CA p=0.0360, only supported before FDR). 
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Table 5.3 – Clonal complexes and sequence types identified in the invasive isolates 
recovered from children between 1999 and 2012. 
CC ST Pherotype Serotype PMEN clone 
CC306 (n=179) 306 (n=151); 304 (n=14); 350 (n=5); 228, 
4578, 4579, 8127, 8292, 8293, 829, 9984 
(n=1 each)  
CSP1 (n=178) 
CSP2 (n=1) 
1 (n=179) Sweden1-ST304 
Sweden1-ST306 
CC156 (n=150) 156, 338 (n=39 each); 143 (n=10); 176 
(n=7); 273 (n=6); 162 (n=5); 557, 4573 
(n=4 each); 2016 (n=3); 138, 280, 469, 
4573 (n=2 each); 90, 124, 166, 172, 277, 
361, 392, 732, 790, 838, 1150, 1224, 1225, 
1227, 2356, 2372, 2616, 4576, 6265, 8126, 
8128, 8129, 8135, 8136, 8138 (n=1 each) 
CSP1 (n=148) 
CSP2 (n=2) 
14 (n=62); 23F (n=41); 
6B (n=23); 9V (n=12); 
19A, 19F, 23B, 24F (n=2 
each); 6C, 15B, 17F, 












CC191 (n=86) 191 (n=82); 1062, 4771, 8125, 9978 (n=1 
each) 
CSP1 (n=86) 7F (n=84); 8, NT (n=1 
each) 
Netherlands7F-ST191 
CC230 (n=66) 276 (n=40); 230 (n=10); 4253 (n=5); 2307 
(n=3); 4577, 6174 (n=2 each); 2674, 
8133, 9959, 9962 (n=1 each) 
CSP1 (n=1) 
CSP2 (n=65) 
19A (n=51); 24F (n=8); 
24A (n=4); 19F (n=3) 
Denmark14-ST230 
CC177 (n=48) 193 (n=23); 177 (n=4); 179, 1877 (n=3 
each); 391, 3863, 8123 (n=2 each); 390, 
1228, 4245, 4992, 8131, 8297, 9972, 9973, 
10034 (n=1 each) 
CSP1 (n=34) 
CSP2 (n=14) 
19A (n=26); 19F 
(n=16); 21 (n=3); 15A, 
15B, 15C (n=1 each) 
Portugal19F-ST177 
Greece21-ST193 
CC15 (n=30) 9 (n=17); 409, 1201 (n=6 each); 15 (n=1) CSP1 (n=24) 
CSP3 (n=6) 





CC199 (n=29) 411 (n=13); 416 (n=5); 199 (n=4); 667, 
1673, 2109, 4189, 4480, 8134, 9980 (n=1 
each) 
CSP1 (n=29) 19A (n=16); 15B (n=8); 
15C (n=4); 18C (n=1) 
Netherlands15B-ST199 
CC81 (n=27) 66 (n=10); 81 (n=8); 72 (n=6); 1654, 3403, 
4574 (n=1 each) 
CSP1 (n=2) 
CSP2 (n=25) 
9N (n=11); 19A (n=5); 
24F (n=4); 23F (n=3); 




CC180 (n=27)  180 (n=21); 1230 (n=3); 505, 2407, 10040 
(n=1 each) 
CSP1 (n=27) 3 (n=26); 14 (n=1) Netherlands3-ST180 
CC460 (n=27) 97 (n=7); 460 (n=6); 65 (n=5); 9893 (n=2); 
446, 460, 461, 585, 1551, 1635, 8296, 
9893, 10046 (n=1 each) 
CSP2 (n=27) 10A (n=13); 6A (n=10); 
35F (n=3); 6B (n=1) 
 
CC1151 (n=25) 1151 (n=13); 2732 (n=10); 8130, 8132 
(n=1 each) 
CSP1 (n=25) 19A (n=23); 19F (n=2)  
CC62 (n=20) 53 (n=10); 408 (n=5); 1012 (n=2); 62, 445, 
673 (n=1 each) 
CSP1 (n=19) 
CSP2 (n=1) 
8 (n=10); 11A (n=6); 
22F (n=2); 33F, NT (n=1 
each) 
Netherlands8-ST53 
CC994 (n=19) 994 (n=18); 4197 (n=1) CSP2 (n=12) 
CSP3 (n=7) 
19A (n=19)  
CC433 (n=12) 433 (n=10); 819, 1955 (n=1 each) CSP1 (n=12) 22F (n=11); 35C/42 
(n=1) 
 
CC717 (n=12) 717 (n=12) CSP1 (n=12) 33A (n=8); 33F (n=4)  
CC439 (n=11) 439 (n=8); 33 (n=2); 190 (n=1) CSP1 (n=10) 
CSP2 (n=1) 
23B (n=8); 23F (n=2); 
23A (n=1) 
Tennessee23F-ST37 
CC289 (n=10) 289 (n=6); 1223 (n=4) CSP1 (n=10) 5 (n=10) Columbia5-ST289 
CC393 (n=9) 393 (n=9) ND (n=9) 25A/38 (n=9)  
CC63 (n=8) 63 (n=6); 1621, 4268 (n=1 each) CSP1 (n=8) 15A (n=6); 15C, 19A 
(n=1 each) 
Sweden15A-ST63 





6B (n=6); 6C (n=2) Poland6B-ST315 




18C (n=4); 19A, 20, 31 
(n=1 each) 
Netherlands18C-ST113 
CC473 (n=7) 1876 (n=4); 473, 5679, 9988 (n=1 each) CSP2 (n=7) 6A (n=7)  
CC1381 (n=7) 1233 (n=6); 1381 (n=1) CSP1 (n=7) 18C (n=6); 18B (n=1)  
CC260 (n=6) 260 (n=4); 1220, 8124 (n=1 each) CSP2 (n=6) 3 (n=6)  
CC395 (n=6) 327 (n=4); 395 (n=2) CSP2 (n=6) 6A (n=5); 6C (n=1) Portugal6A-ST327 
CC30 (n=5) 30 (n=5) CSP1 (n=4) 
CSP2 (n=1) 
16F (n=3); 5, 21 (n=1 
each) 
 
CC320 (n=5) 320 (n=3); 4251, 8139 (n=1 each) CSP1 (n=5) 19A (n=3); 19F (n=2) Taiwan19F-ST236 
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Table 5.3 – (Continued). 
CC ST Pherotype Serotype PMEN clone 
CC235 (n=3) 235 (n=2); 10047 (n=1) CSP1 (n=3) 20 (n=3)  
CC1026 (n=3) 1026 (n=3) CSP1 (n=3) 20 (n=3)  
CC1221 (n=3) 1221 (n=3) CSP1 (n=3) 4 (n=3)  
CC102 (n=2) 102 (n=2) CSP3 (n=2) 18C (n=2)  
CC198 (n=2) 198 (n=2) CSP1 (n=2) 29 (n=2)  
CC378 (n=2) 232 (n=2) CSP2 (n=2) 3 (n=2)  
CC458 (n=2) 458, 2633 (n=1 each) CSP1 (n=2) 3, 33F (n=1 each)  
CC1368 (n=2) 1368 (n=2) CSP1 (n=2) 35F (n=2)  
CC1650 (n=2) 1650 (n=2) CSP1 (n=2) 18C (n=2)  
CC2669 (n=2) 2669 (n=2) CSP1 (n=2) 19A (n=2)  
CC99 (n=1) 99 (n=1) CSP1 (n=1) 11A (n=1)  
CC217 (n=1) 3081 (n=1) CSP1 (n=1) 1 (n=1) Sweden1-ST217 
CC218 (n=1)  218 (n=1) CSP1 (n=1) 12B (n=1) Denmark12F-ST218 
CC251 (n=1) 251 (n=1) CSP3 (n=1) 19F (n=1)  
CC342 (n=1) 1371 (n=1) CSP1 (n=1) 23F (n=1)  
CC346 (n=1) 1706 (n=1) CSP1 (n=1) 15B (n=1)  
CC347 (n=1) 347 (n=1) CSP1 (n=1) 19F (n=1)  
CC432 (n=1) 432 (n=1) CSP1 (n=1) 21 (n=1)  
CC447 (n=1) 447 (n=1) CSP2 (n=1) 37 (n=1)  
CC476 (n=1) 476 (n=1) CSP3 (n=1) 19F (n=1)  
CC546 (n=1) 494 (n=1) CSP1 (n=1) 28A (n=1)  
CC558 (n=1) 558 (n=1) CSP2 (n=1) 29 (n=1) Utah35B-ST377 
CC912 (n=1) 4248 (n=1) CSP2 (n=1) 6A (n=1)  
CC989 (n=1) 989 (n=1) CSP2 (n=1) 12B (n=1)  
CC1046 (n=1) 1046 (n=1) CSP2 (n=1) 34 (n=1)  
CC1262 (n=1) 9975 (n=1) CSP1 (n=1) 15C (n=1)  
CC1778 (n=1) 1778 (n=1) CSP2 (n=1) 34 (n=1)  
CC2186 (n=1) 8322 (n=1) CSP1 (n=1) 15A (n=1)  
CC2402 (n=1) 2402 (n=1) CSP3 (n=1) 16F (n=1)  
CC2831 (n=1) 2831 (n=1) CSP2 (n=1) 45 (n=1)  
CC3324 (n=1) 3324 (n=1) CSP2 (n=1) 6A (n=1)  
CC5067 (n=1) 28 (n=1) CSP1 (n=1) 18C (n=1)  
Singleton 923 (n=1) CSP1 (n=1) 13 (n=1)  
Singleton 1646 (n=1) CSP2 (n=1) 3 (n=1)  
Singleton 1648 (n=1) CSP2 (n=1) 6A (n=1)  
Singleton 1662 (n=1) CSP2 (n=1) 6B (n=1)  
Singleton 2228 (n=1) CSP3 (n=1) 19F (n=1)  
Singleton 8060 (n=1) CSP2 (n=1) 12B (n=1)  
Singleton 8122 (n=1) CSP1 (n=1) 23F (n=1)  
Singleton 8137 (n=1) CSP2 (n=1) 6B (n=1)  
Singleton 8294 (n=1) CSP1 (n=1) 19F (n=1)  
Singleton 9964 (n=1) CSP1 (n=1) 15A (n=1)  
Singleton 9976 (n=1) CSP3 (n=1) 16F (n=1)  
Singleton 10045 (n=1) CSP2 (n=1) 19A (n=1)  
 
 




Red: CSP1, Blue: CSP2 and Green: CSP3. 
Figure 5.9 – Distribution of pherotype among the main clonal complexes (≥10 isolates) of 
the pneumococcal isolates recovered from children between 1999 and 2012. Each circle 
represents an ST and the diameter represents its frequency in a logarithmic scale. Grey lines connect 
STs that are double locus variants (DLVs), while lines of other colors connect STs that are single locus 
variants (SLVs) according to the PHYLOViZ tie-break rule reached. Unconnected STs using only our 
isolates that belong to the same CC when using all STs deposited in the public database are 




Figure 5.10 – Evolution of clonal complexes in invasive isolates recovered from children 
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5.2.5. Antibiotic resistance and pherotype  
 
The antibiotic susceptibility profile was determined for all isolates. 
Tetracycline presented the highest number of non-susceptible isolates (n=317, 35.1 
%), followed by penicillin (n=237, 26.2 %), erythromycin (n=208, 23.0 %), co-
trimoxazole (n=196, 21.7 %), clindamycin (n=171, 18.9 %), chloramphenicol (n=39, 
4.3 %) and cefotaxime (n=29, 3.2 %) (Figure 5.11). All isolates were susceptible to 
levofloxacin, linezolid and vancomycin. Although the number of non-susceptible 
isolates of pherotype CSP1 was higher than other pherotypes, as expected given its 
higher abundance, it was observed that pherotype CSP2 was associated with non-
susceptibility to most antibiotics (FET p<0.0001: penicillin, erythromycin, 
clindamycin, tetracycline and co-trimoxazole; p=0.0002: cefotaxime, all significant 
after FDR) with the exception of chloramphenicol (FET p=0.1598). 
Resistance to antibiotics remained stable over time with the exception of the 
decrease in non-susceptibility to penicillin (from 41.7 % in 1999-2002 to 20.5 % in 
2012, CA p=0.0056, significant after FDR), co-trimoxazole and chloramphenicol 
(from 33.3 % to 26.0 % and from 6.3 % to 0.0 %, CA p=0.0290 and p=0.0363, 
respectively, only supported before FDR) (Figure 5.12). The decrease in non-
susceptibility to penicillin and co-trimoxazole was due to a decrease of CSP1 non-
susceptible isolates to these antibiotics (CA, p=0.0002 and p=0.0010, respectively, 
both significant after FDR), while the decrease in resistance to chloramphenicol 









Figure 5.11 – Number of isolates of each pherotype among non-susceptible isolates. PEN: 
penicillin, CEF: cefotaxime, ERY: erythromycin, CLI: clindamycin, TET: tetracycline, SXT: co-




Figure 5.12 – Evolution of non-susceptibility to penicillin (PEN), co-trimoxazole (SXT) and 
chloramphenicol (CHL) in invasive isolates recovered from children between 1999 and 
2012. PCV7 and PCV13 were available in children vaccination since 2001 and 2010, respectively. 
 
5.2.6. Comparing partitions 
 
The Simpson’s index of diversity (SID) was calculated with the typing data of 
serotype, ST and CC for all the isolates and then for CSP1, CSP2 and CSP3 
subpopulations (Table 5.4). ST presented the highest discriminatory power while 
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Comparing CSP1 with CSP2 isolates, their SID of serotype, CC and ST were 
similar, however, the difference between serotype diversity of each pherotype was 
close to be statistically supported (p=0.0504). CSP3 isolates presented lower SID 
values but very large confidence intervals due to their small number. 
Adjusted Wallace (AW) was used to evaluate the congruence between the 
typing methods and to assess the ability of each trait to predict pherotype (Table 
5.5). ST and CC were the best typing methods to predict the type of CSP produced, 
reflecting the clonal property of pherotype. ST was also a good predictor of serotype 
and antibiotic susceptibility, with the exception of non-susceptibility to tetracycline 
and cefotaxime. The case of tetracycline could be because the transmission of 
resistance to this antibiotic is through transposons which can more easily transfer 
between isolates. Serotype presented lower AW values than ST, revealing the 




Table 5.4 – Simpson’s index diversity (SID) regarding serotype, ST and CC of the overall 
pneumococcal invasive isolates and of the CSP1, CSP2 and CSP3 isolates.  
 Serotype SID (95 % CI)a ST SID (95 % CI)a CC SID (95 % CI)a 
Overall (n=903) 46 0.904 (0.894-0.914) 210 0.954 (0.946-0.962) 71 0.909 (0.899-0.919) 
CSP1 (n=681) 37 0.879 (0.864-0.893) 140 0.925 (0.912-0.938) 44 0.859 (0.843-0.875) 
CSP2 (n=192) 24 0.835 (0.794-0.877) 68 0.941 (0.919-0.964) 30 0.839 (0.800-0.877) 
CSP3 (n=20) 5 0.626 (0.382-0.871) 9 0.837 (0.717-0.956) 8 0.805 (0.675-0.935) 
aJackknife pseudo-values 95 % confidence intervals.  
 
 
Table 5.5 – Adjusted Wallace values to assess congruence between pherotype, serotype, 
sequence type (ST), clonal complex (CC) and susceptibility to antimicrobials. Values >0.70 
are presented in bold. 
 
CSP Serotype ST CC 
























   
 





















































Pherotype abundance was determined in this chapter and three pherotypes 
were identified: CSP1 (n=681, 75.4 %), CSP2 (n=192, 21.3 %) and CSP3 (n=20, 2.2 
%) (Table 5.2). Pherotype association with serotype, ST and antibiotic resistance 
was evaluated. PCV7 serotypes were associated with CSP1 while NVTs were 
associated with CSP2. However, despite the decrease of PCV7 serotypes and the 
increase of NVTs, pherotype abundance remained stable over 14 years. Most STs 
presented a single pherotype but it was common that a CC presented two 
pherotypes. Pherotype CSP2 was associated with non-susceptibility to most 
antibiotics and, together with the fact that NVTs were also associated with this 
pherotype, CSP2 abundance could potentially increase in the pneumococcal 
population. Pherotypes CSP1 and CSP2 are equally diverse and distributed 
through several genetic lineages. Pherotype CSP3 is rare but it was definitively 
identified as a third pneumococcal pherotype and it was present in a variety of 
serotypes and genetic backgrounds. 
 
Over the 14 years covered by this study, when pneumococcal conjugate 
vaccines were introduced and serotype distribution was widely changed, pherotype 
proportions remained stable, although a small decrease was seen for pherotype 
CSP1 which was not statistically supported. The pherotype proportion within each 
serotype also remained stable over time. In all the studies that identified the 
pherotype of pneumococcal isolates, CSP1 was always the dominant pherotype over 
CSP2 and pherotype CSP3 was rarely seen, if at all (Table 5.6). More importantly, 
the abundance of pherotypes determined in all those collections was similar, with 
the exception of three of them (Evans and Rozen, 2013, Ramirez et al., 1997, 
Whatmore et al., 1999). It is possible that the process of selection of the isolates of 
those studies introduced some bias which resulted in different pherotype 
abundance. The studies included in Table 5.6 represented temporal and 
geographically diverse isolates. Excluding the three studies mentioned above, 
CSP1 abundance ranged from 62.7 % to 76.3 %. The fact that pherotype abundance 
remained stable during the study period and that it was similar to other collections 
from other geographical sites and isolation dates, suggests that there may be a 
selective force which was responsible for maintaining CSP1 as the dominant 
pherotype. However, it could also be expected that CSP2 abundance would increase 
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with the pressure of vaccination and antimicrobial use because PCV7 serotypes 
were associated with pherotype CSP1, whereas NVT serotypes were associated 
with CSP2, and because CSP2 strains were associated with resistance to most 
antibiotics. The association of CSP2 strains with antimicrobial resistance was also 
observed in another Portuguese study with pneumococci isolated from 
nasopharyngeal samples of children attending day-care centers (Valente et al., 
2012). Nevertheless, it was seen that CSP1 strains formed biofilms that were 
thicker and denser than those formed by CSP2 strains and also that they yielded 
more transformants than CSP2 strains in both planktonic and biofilm growth 
(Carrolo et al., 2014). Maybe the more robust biofilm formation and higher 
transformation efficiency of pherotype CSP1 strains in relation to CSP2 strains 
were the forces ensuring the dominance of CSP1 over CSP2, despite the potential 
contrary forces of antimicrobial consumption and vaccine use. The nature of the 
selective forces maintaining the 7:3 ratio of CSP1:CSP2 remain elusive but it is 
possible that some form of balancing selection is involved (Fijarczyk and Babik, 
2015). It would be important to continue monitoring pherotype abundance now that 
PCV13 was included in the National Vaccination Plan to evaluate if pherotype 
abundance remains stable or there is an increase of CSP2 strains. 
The association of CSP1 with older age groups was concluded to be mainly 
due to the association of serotypes 1 and 19A with IPD in older and younger 
children, respectively. However, the possibility that pherotype CSP1 strains have a 
higher capacity than other pherotypes to cause invasive infections in individuals 
with a robust immunologic system cannot be completely discarded. In fact, CSP1 
strain abundance was observed to be slightly higher in IPD than in carriage (Table 
5.6), supporting the hypothesis that CSP1 strains could have a higher invading 
capacity than CSP2. 
 
Table 5.6 – Comparison of pherotype abundance between several studies.   
Study Collection Age n CSP1 (%) CSP2 (%) CSP3 (%) 
This studya Invasive Children 893a 681 (76.3) 192 (21.5) 20 (2.2) 
(Carrolo et al., 2009) Invasive All 483 341 (70.6) 142 (29.4) Not found 
(Valente et al., 2012)  Colonization Children 366 233 (63.7) 133 (36.3) Not found 
(Vestrheim et al., 2011)b Colonization Children 150 94 (62.7) 56 (37.3) Not foundb 
(Cornejo et al., 2010) Clinical Adults 88 65 (73.9) 23 (26.1) Not found 
(Whatmore et al., 1999) Not described Not described 58 29 (50.0)  27 (46.6) 2 (3.4) 
(Evans and Rozen, 2013) Colonization 3-36 months 54 53 (98.1) Not found 1 (1.9) 
(Ramirez et al., 1997) Clinical/colonization Not described 50 24 (48.0) 25 (50.0) 1 (2.0) 
(Pozzi et al., 1996) Clinical All 43 30 (69.8) 13 (30.2) Not found 
(Iannelli et al., 2005) Clinical All 17 11 (64.7) 6 (35.3) Not found 
aThe 10 isolates with unidentified pherotype were excluded for this comparison. 
bTwo strains of this study did not amplify a PCR product and their pherotype was not determined. However, one of 
them was 19F-ST476 and in our collection we found a CSP3 isolate presenting the same serotype and ST, so 
maybe at least this isolate could be CSP3. 
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The genetic diversity of each pherotype was similar, as suggested by their 
SID values regarding ST, CC and serotype (Table 5.4). This means pherotypes 
were not only distributed through several genetic backgrounds, but they also 
presented the same diversity of serotypes, consistent with an ancient origin of each 
of the pherotypes in the pneumococcal population. Another characteristic of 
pherotype was that it corresponded to a clonal property which reflects the 
observation that ST and CC were the best typing methods to predict the type of 
CSP produced. Most STs presented a single pherotype, with eight exceptions which 
could have been the result of horizontal gene transfer including the comCDE locus. 
Regarding CC, a dominant pherotype could frequently be identified, with the 
exception of CC177, but it was quite common to find some isolates of a different 
pherotype grouped in the same CC suggesting that occasional horizontal gene 
transfer of the comCDE locus can generate stable lineages. In the previous chapter 
it was seen that indels and insertion sequences were present at the comCDE locus 
of some strains, so recombination involving this region could be an effective way to 
repair the competence regulating genes when these lose their functionality. 
 
Pherotype CSP3 strains presented a total of 9 STs (ST102, ST251, ST476, 
ST994, ST1201, ST2228, ST2402, ST4197 and ST9976) distributed through 6 CCs 
(CC15, CC102, CC251, CC476, CC994 and CC2402) and 2 singletons (ST2228 and 
ST9976) and expressed a total of 5 serotypes (7C, 16F, 18C, 19A and 19F) (Table 
5.3). This indicates that this pherotype was genetically diverse, despite its rarity in 
the pneumococcal population, suggesting it has not emerged recently in this 
population. As far as we know, this study provided the most accurate data 
concerning the abundance of pherotype CSP3 among pneumococci by identifying a 
total of n=20 isolates (2.2 %) of this pherotype in a collection of n=903 invasive 
pneumococcal isolates recovered from a defined geographic region. Thus, CSP3 was 
confirmed to be an established third pneumococcal pherotype in the population but 
found in a very low proportion, as was suggested by other studies that identified 
CSP3 strains (Evans and Rozen, 2013, Ramirez et al., 1997, Whatmore et al., 1999). 
The rarity of the CSP3 pherotype could be due to the fact that CSP3 competence 
regulating alleles are less efficient than the CSP1 and CSP2 alleles at triggering 
the competence response. Preliminary studies were performed to determine the 
sequence of the comCDE locus of most of the CSP3 strains identified here and also 
some of these strains were subject to transformation assays in the presence of 
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synthetic CSP3 peptide. These preliminary data identified at least 3 variants of the 
CSP3 peptide differing in the number of NFF amino acid repeats before the 
terminal triple arginine (1, 2 or 3 repeats, see Figure 4.4). The variants with 2 and 
3 repeats were already identified in the previous chapter and in other studies 
(Ramirez et al., 1997, Whatmore et al., 1999) but these preliminary data could be 
the first report of a CSP3 peptide variant with just 1 repeat of the NFF amino 
acids. The transformation ability of some CSP3 strains tested in the presence of 
synthetic CSP3 showed the specific response of at least two strains to this peptide, 
with most of the strains tested being unable to yield transformants. Although not 
strong, this suggests that CSP3 is a bona fide competence inducer. However, it is 
possible that the CSP3 mature peptide varies in length, as opposed to CSP1 and 
CSP2 peptides that were restricted to exactly 17 amino acids. The variation of NFF 
amino acid repeats in CSP3 peptide variants could be a factor affecting the 
transformation efficiency of CSP3 strains and could explain in part the absence of 
response of many of the strains tested. However, formal testing of this hypothesis 
is required with the synthesis of peptides with variable numbers of the NFF 
repeat. 
 
Regarding the case of serotype 25A/38-ST393 isolates, preliminary data 
suggests that an inversion rearrangement occurred in the genome of these isolates, 
resulting in the separation of comC from the comDE genes by an intervening 
sequence of approximately 70 000 bp. Genetic recombination events involve 
typically shorter sequences but recombination of sequences in the order of 70 000 
bp in length had been also reported in the literature in S. pneumoniae (Croucher et 
al., 2011, Vijayakumar et al., 1986). This inversion could have been caused by the 
insertion sequence ISSpn8 but a comprehensive analysis including more isolates 
should be done to confirm this hypothesis. It is unknown if these strains can enter 
the competence state and therefore yield transformants. Preliminary studies of 
transformation, including the addition of excess synthetic CSP peptide, with these 
strains were performed and no transformants were obtained, suggesting that a loss 
of function of the competence-regulating genes could have occurred concomitantly 
with the inversion event. One possibility is that the expression of the ComD and 
ComE proteins, essential for sensing extracellular CSP, was abrogated. 
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Finally, comparing the results of this and the last chapters, the pherotype 
abundance identified in this work was very similar to the abundance observed in 
the pneumococcal sample studied in Chapter 4: CSP1 n=681, 75.4 %; CSP2 n=192, 
21.3 %; and CSP3 n=20, 2.2 % vs. CSP1 n=66, 74.2 %; CSP2 n=21, 23.6 %; and 
CSP3 n=2, 2.2 %, respectively. This clearly showed that the sample used was 
representative of the Portuguese pneumococcal invasive population circulating in 
Portugal and it was another evidence that pherotype abundance remained stable 
because that sample was selected from a period when conjugate vaccines were still 
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III. PHEROTYPE SPECIFICITY AND INFLUENCE ON THE GENETIC 
STRUCTURE 
 
After studying the genetic diversity of the comCDE locus and determining the 
abundance of pherotypes, our next question was if pherotype has a role in the 
evolution of S. pneumoniae, particularly if it has an influence in shaping the 
genetic structure of this pathogen. To answer this question, we attempted to use X-
ray crystallography to study the interaction between CSP and ComD by 
determining the 3D structure of this receptor and also of the receptor in complex 
with its ligand. Afterwards, we studied the clonal and serotype dynamics of 
serogroup 6 isolates causing IPD in Portugal during 1999-2012 and we used this 
work to also evaluate the influence of pherotype on the genetic recombination 
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CHAPTER 6. STRUCTURAL STUDY OF PHEROTYPE 
SPECIFICITY BY X-RAY CRYSTALLOGRAPHY 
 
This chapter presents the work performed during my visit to Dr. Juan 
Hermoso lab (Instituto de Química-Física “Rocasolano”, CSIC, Madrid), a 
laboratory expert in X-ray crystallography. 
 
The pneumococcal pherotypes exhibit different phenotypes. A previous study 
by our laboratory with mutants lacking the comC gene indicated that CSP1 strains 
were able to respond much better to their cognate peptide than CSP2 strains, 
resulting in a better capacity to form biofilms and a higher transformation 
efficiency of CSP1 in relation to CSP2 strains (Carrolo et al., 2014). These results 
suggested either a stronger binding of CSP1 to its receptor or an amplification of 
the response in the CSP1 genetic background and could explain the higher 
prevalence of comC1 allele in the pneumococcal population. 
To determine the reasons for these differences, we wanted to study the 
pherotype specificity by X-ray crystallography. The goal was to solve the 3D 
structure of ComD variants in the absence of CSP and in complex with their 
cognate CSP. This approach would allow us to identify with atomic resolution 
which regions of the receptor interact with the pheromone peptide and are 
responsible for its specificity.  
Determination of the 3D structure of a protein by X-ray crystallography 
requires several steps (Figure 6.1). The first bottle-neck in the process is the 
production of pure protein in sufficient quantity to perform protein crystallization. 
The strategies attempted to produce ComD protein will be described in this 
chapter, although due to its complexity, this goal was not achieved. 
III. Pherotype specificity and influence on the genetic 
structure 





Figure 6.1 – Crystallography pipeline work depicted as a ladder. Each step represents a 
possible bottleneck in the process to solve a protein structure by X-ray crystallography. 
 
6.1. Designing of ComD constructs 
 
ComD is an integral membrane histidine kinase protein composed of two 
domains: an extracellular sensor and an intracellular kinase. Our aim was the 
crystallization of the soluble extracellular sensor domain instead of the full-length 
protein due to the high complexity of an integral membrane protein production. 
The reference strain R6 ComD sensor domain, which presents pherotype CSP1 and 
its sequence is equal to the ComD-1.1 variant (see Chapter 4, Table 4.1, Figures 
4.5 and 4.6), was chosen to be produced. Although the sensor domain is reported to 
be placed in the N-terminus of ComD, very little is known about its extension and 
topology. Therefore, we ran an in silico simulation to predict the topology of ComD 
using the algorithm TopPred (Claros and von Heijne 1994; von Heijne 1992). Seven 
membrane helices were identified but only four were classified as certain (Table 
6.1, Figure 6.2). Primers were designed (Table 6.2), considering these predictions, 
to generate several constructs summarized in Table 6.3. We decided to attempt the 
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production of constructs with and without the first predicted helix (from Met1 or 
His21, respectively) and until the third putative helix (Arg84). After the initial set 
of expression experiments, constructs until the fourth helix (Asn114) were also 
produced. The four constructs were named 1-84, 21-84, 1-114 and 21-114 (Table 
6.3). 
 
Table 6.1 – Amino acid residues and classification of membrane helices identified for 
ComD by the algorithm TopPred (Claros and von Heijne 1994; von Heijne 1992). 
Helix Begin-End Score Certaintya 
1 1-21 1.510 Certain 
2 32-52 0.803 Putative 
3 85-105 0.645 Putative 
4 119-139 1.856 Certain 
5 160-180 1.422 Certain 
6 186-206 2.296 Certain 
7 379-399 0.603 Putative 






Figure 6.2 – Possible topologies identified with the algorithm TopPred (Claros and von 
Heijne 1994; von Heijne 1992). The topologies with the putative helix 7 are not shown because they 
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Table 6.2 – Primers used to produce constructs of the ComD sensor domain. 
Primer Sequence (5'→ 3')a Size (bp)  
ComD FM1 GGTGAAAACCTGTATTTCCAGGGCATGGATTTATTTGGATTTGGGACG 48  
ComD FM21 GGTGAAAACCTGTATTTCCAGGGCATGCATTTTATTTGTAAAGGTCAA 48  
ComD RM84 AAGCTTAGTTAGCTATTATGCGTATCATCTATCCCTCTCATACTGTTTCATC 52  
EcoRI Fw1 CCGAATTCATGGATTTATTTGGATTTGGGACG 32  
EcoRI Fw21 CCGAATTCCATTTTATTTGTAAAGGTCAA 29  
HindIII Rv84 GGCCAAGCTTTTATCTATCCCTCTCATACTGTTTCATC 38  
HindIII Rv114 GGCCAAGCTTTTAATTATCTCCTGTTATAGAGGA 34  
aUnderlined: sequence pairing the vector pURI3-TEV (ComD FM1, FM21 and RM84) and restriction site (EcoRI 
Fw1 and Fw21 and HindIII Rv84 and Rv114. Bold: start/stop codon. 
 
Table 6.3 – Constructs of the ComD sensor domain produced during this work. 
Construct Begin-End Vector Primer Forwarda Primer Reversea M.W. (Da)b 
1-84 Met1-Arg84 pURI3-TEV ComD FM1 ComD RM84 12208.12c 
21-84 His21-Arg84 pURI3-TEV ComD FM21 ComD RM84 10060.62c 
1-114 Met1-Asn114 pKLSLt EcoRI Fw1 HindIII Rv114 32021.43d 
21-114 His21-Asn114 pKLSLt EcoRI Fw21 HindIII Rv114 29742.73d 
aThe sequence of the primers is presented in the Table 6.2. 
bMolecular weight calculated with ProtParam (Gasteiger et al., 2005) (accessed in 
http://web.expasy.org/protparam/protpar-ref.html) 
cCalculated with His-tag and TEV recognition site. ComD 1-84 and ComD 21-84 predicted molecular weights were 
10143.94 Da and 7865.24 Da, respectively. 
dCalculated with LSL150 and TEV recognition site. ComD 1-114, ComD 21-114 and LSL150 predicted molecular 
weights were 13415.65 Da, 11136.95 Da and 17163.27, respectively. 
 
6.2. Cloning of ComD sensor in vector pURI3-TEV 
 
The plasmid pURI3-TEV (Curiel et al., 2011) was chosen as the vector for the 
cloning of ComD sensor. This plasmid, harbouring the ampicillin resistance gene as 
a selective marker, can produce a recombinant protein with a His-tag in the N-
terminus which can be later removed by using tobacco etch virus (TEV) protease. 
We decided to clone the constructs 1-84 and 21-84 (Table 6.3) in this vector using 
the primers ComD FM1, ComD FM21 and ComD RM84 (Table 6.2).  
Due to its ease of use and high efficiency, the ligation independent cloning 
(LIC) methodology was chosen to introduce all targets into the vector. The LIC 
approach consisted in two consecutive PCRs: the first one amplifies the gene of 
interest introducing specific complementary overhangs adaptors for the desired 
plasmid.  The second PCR takes advantage of the adaptors to perform the 
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The conditions of the first PCR to amplify the insert were: 
- 0.02 U/µL KOD Hot Start DNA polymerase (Toyobo, Osaka, Japan) 
- 1x KOD buffer  
- 0.2 mM dNTPs 
- 1.5 mM MgSO4 
- 1 M Betaine 
- 0.4 pmol/µL of each primer (Table 6.2) 
- 4 ng/µL of R6 genomic DNA extracted through CTAB method (Wilson, 
2001) 
 
With the following PCR program: 
- 5 min at 94 ºC  
- 30x (1 min at 94 ºC, 45 s at 55 ºC and 2 min at 68 ºC) 
- 5 min at 68 ºC  
 
Agarose gel electrophoresis was used to confirm the amplification of the 
fragment of interest. The DNA fragment was purified by using the QuickClean II 
PCR Extraction Kit® (GenScript, Piscataway, USA) following the manufacturer’s 
instructions. Cleaned DNA was used in the second PCR to generate vectors with 
the inserted gene using the following conditions: 
- 0.02 U/µL KOD Hot Start DNA polymerase (Toyobo, Osaka, Japan) 
- 1x KOD buffer,  
- 0.2 mM dNTPs 
- 1.5 mM MgSO4 
- 0.3 M Betaine  
- 4 ng/µL vector pURI3-TEV 
- 19 µL of the purified gene fragment from first PCR 
 
With the following PCR program: 
- 4 min at 95 ºC  
- 25x (20 s at 98 ºC, 30 s at 55 ºC, 4 min at 68 ºC) 
 
After the second PCR an additional digestion with 20 U of the enzyme DpnI 
(New England Biolabs, Ipswich, USA) was performed in the buffer provided by the 
manufacter at 37 ºC overnight. This digestion eliminates the parent pURI3-TEV 
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plasmids because DpnI recognizes and digests only methylated DNA. This was 
followed by a second digestion using 10 U of the enzyme NotI (New England 
Biolabs, Ipswich, USA) in the buffer provided by the manufacturer at 37 ºC during 
6 h because the pURI3-TEV plasmid was engineered to be digested by NotI in the 
absence of an inserted fragment. 
The product obtained after these two digestions was used to transform 
Escherichia coli DH5α competent cells created by the heat-shock method (Froger 
and Hall, 2007). PCR was used to identify the presence of the insert in the several 
colonies obtained after transformation. Briefly, transformed E. coli DH5α cells 
were boiled for 20 min at 98 ºC before addition to a PCR reaction which was 
performed under the following conditions: 
-  0.1 U/µL Taq DNA polymerase (New England BioLabs, Ipswich, USA)  
- 1x Taq buffer with MgSO4 
- 0.2 mM dNTPs 
- 0.4 pmol/µL of each primer (Table 6.2) 
- 5 µL of boiled cells 
 
With the following PCR program: 
- 4 min at 95 ºC  
- 30x (30 s at 95 ºC, 1 min at 55 ºC and 3 min at 72 ºC) 
- 10 min at 72 ºC  
 
The plasmids from the positive colonies were extracted using QuickClean II 
Plasmid Miniprep Kit® (GenScript, Piscataway, USA) following the manufacturer’s 
instructions and were sent for sequencing in Secugen (Madrid, Spain) to verify if 
the fragment sequence was correct and in frame. 
In the end, we obtained the constructs 1-84 and 21-84 inserted into the vector 
pURI3-TEV (Table 6.3). 
 
6.3. Expression tests of ComD sensor with a His-tag 
 
The pURI3-TEV constructs 1-84 and 21-84 were inserted into the bacterial 
expression hosts E. coli BL21(DE3) and E. coli JM109(DE3), made competent by 
the heat shock method, for recombinant protein expression. However, only four 
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colonies were obtained for each of these expression hosts. This section describes the 
expression tests performed with these strains, which are summarized in Table 6.4. 
 
Table 6.4 – Summary of the expression tests performed using the vector pURI3-TEV.  
Construct Expression host Medium  Volume Purification 
1-84 E. coli BL21(DE3) LB  200 mL HisTrap HP® Ni-NTA/Superdex 75 
1-84 E. coli BL21(DE3) LB  2 L HisTrap HP® Ni-NTA 
1-84 E. coli JM109(DE3) 2xTY  1 L HisTrap HP® Ni-NTA 
21-84 E. coli JM109(DE3) 2xTY  1 L HisTrap HP® Ni-NTA 
 
6.3.1. Expression in E. coli BL21(DE3) 
 
The construct 1-84 was used for the first small-scale expression test in E. coli 
BL21(DE3).  The cells were inoculated in 20 mL of LB medium supplemented with 
ampicillin (100 µg/mL) followed by incubation at 37 ºC overnight with agitation. 
This pre-inoculum was diluted 1:100 in 200 mL of LB medium supplemented with 
ampicillin (100 µg/mL) and grown at 37 ºC with agitation until an OD600nm=0.6. 
Protein production was induced at this point by the addition of 1 mM isopropyl-β-
D-thiogalactopyranoside (IPTG) to the culture followed by overnight incubation at 
16 ºC with agitation. Cells were harvested by centrifugation and suspended in 10 
mM Tris pH 7.5, 100 mM NaCl. 
The step of protein purification started with the lysis of the cells by sonication 
(10 cycles of 30 s at maximum intensity with 10 s of interval, model SONOPULS 
HD 2200, Bandelin, Berlin, Germany). The soluble and insoluble fractions of the 
lysate were separated by centrifugation at 38000 RCF during 40 min at 4 ºC. Since 
the protein was engineered to include a six-histidine purification tag (His-tag), 
enrichment of the soluble fraction was performed by immobilized metal ion affinity 
chromatography (IMAC) using a 1 mL HisTrap HP® Ni-NTA column (GE 
HealthCare, Chicago, USA) and following the manufacturer’s instructions. Elution 
was performed in 10 mM Tris pH 7.5, 100 mM NaCl with an isocratic gradient 
ranging from 0 to 1 M imidazole on a low pressure liquid chromatography system 
(BioLogic LP System®, Bio-Rad, Hercules, USA). The chromatogram of this 
purification presented a peak of 0.51 AU in the elution phase (Figure 6.3a). The 
result of this purification was analyzed by SDS-PAGE. Two weak protein bands 
with molecular weights of approximately 31 kDa and between 6.5 and 14.4 kDa 
were seen in the eluted fractions, although no overexpressed protein was observed 
in the lysate nor in the insoluble fraction (data not shown).  
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The predicted molecular weight of the construct 1-84 was 12.2 kDa (Table 
6.3), so we thought the protein band with a molecular weight between 6.5 and 14.4 
kDa could be the ComD sensor protein. For this reason, a gel-filtration 
chromatography was performed to further purify the putative protein. Sample 
volume was reduced to 5ml by using 10 kDa cutoff centrifugal concentration 
devices (Millipore) and injected into a superdex 75 column (GE HealthCare, 
Chicago, USA) attached to a fast protein liquid chromatography system (BioLogic 
DuoFlow®, Bio-Rad, Hercules, USA). Afterwards, a sample of molecular weight 
markers (Gel Filtration Standard®, Bio-Rad, Hercules, USA) was also passed 
through the column with the same conditions to allow the estimation of the 
molecular weights of the purified proteins. The chromatogram showed three 
protein species, two with more than 44 kDa and the third with less than 17 kDa 
but the quantity of this protein was much smaller than the other two (Figure 6.4). 
A scale-up of the previous experiment was performed by repeating the same 
procedures. In this experiment, 2 L of cell culture were induced for protein 
overexpression. After centrifugation separation, Lysate supernatants were 
enriched by using a 5 mL HisTrap HP® Ni-NTA column (GE HealthCare, Chicago, 
USA). The resulting chromatogram was similar to that of the previous experiment 
but showed a peak of 1.1 AU in the elution phase. The result of this purification 
step was analyzed by SDS-PAGE but this time a band between 6.5 and 14.4 kDa 
was not seen in the fractions of the elution phase. As in the previous experiment, 
an overexpressed protein band was also not seen in the lysate or in the insoluble 
fraction. Therefore, the purification was terminated and the gel-filtration step was 
not performed. 
 
6.3.2. Expression in E. coli JM109(DE3) 
 
After performing the expression tests of construct 1-84 in E. coli BL21(DE3), 
the production of the ComD sensor was attempted in E. coli JM109(DE3) following 
the same general procedures. One liter of culture was used with both constructs, 1-
84 and 21-84 for protein overexpression tests. The purification through the Ni-NTA 
column of constructs 1-84 and 21-84 yielded peaks of 0.94 and 0.54 AU (Figure 
6.3b), respectively. The result of this purification step was evaluated by SDS-
PAGE but it was similar to the result obtained with E. coli BL21(DE3). A protein 
band between 6.5 and 14.4 kDa molecular weight was not observed in the eluted 
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sample of both constructs and an overexpressed protein band was not detected in 
any fraction (Figure 6.5). 
 
Production of ComD sensor with an N-terminus His-tag was not achieved and 
a new strategy needed to be devised. 
 
 
Figure 6.3 – Chromatograms of the purifications through a Ni-NTA column of (A) the 
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Figure 6.4 – Chromatogram of the gel-filtration of the protein sample (blue line) purified 
through a Ni-NTA column from the construct 1-84 expressed in E. coli BL21(DE3). The 




Figure 6.5 - SDS-PAGE 17.5 % of the purification through a Ni-NTA column of (A) the 
construct 1-84 and (B) the construct 21-84, both expressed in E. coli JM109(DE3). L – lysate, 
I – insoluble fraction, P – precipitate of DNA, S – soluble fraction, FT – flow-through after passing the 
protein sample through a Ni-NTA column, E1 to E4 – elution fractions of the peak, MW – molecular 
weight markers (Molecular Weight Standards Broad Range, Bio-Rad, Hercules, USA). 
 
6.4. Cloning of the fusion protein LSL150-ComD in vector pKLSLt 
 
After the experiments to produce his-tagged recombinant ComD sensor, 
which were not satisfactory, another strategy was followed. We decided to try the 
production of ComD sensor fused to an affinity tag protein. Tag proteins often 
promote greater expression and solubility of recombinant proteins because they 
fold into a stable and highly soluble protein upon translation.  
LSLa is a hemolytic lectin produced by the mushroom Laetiporus sulphureus 
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protein and a solubility enhancer of other proteins (Angulo et al., 2011). It was seen 
that LSL150 is an autonomous folding unit highly translated in E. coli BL21(DE3) 
that increase the solubility and the ratio of the target fused protein. Moreover, 
LSL150 behaved as an excellent affinity tag because of its binding specificity to 
lactose which enabled purification in a single-step using Sepharose 4B® columns 
(Angulo et al., 2011). 
The vector pKLSLt, which was kindly provided by Dr. José Miguel Mancheño 
and Dr. Iván Acebrón, produces the LSL150 domain followed by a linker sequence 
and a TEV cleavage site for tag removal (Figure 6.6). Constructs were inserted 
after the TEV cleavage site by using the restriction enzymes EcoRI and HindIII, 
whose recognition sequences were not present in the target proteins. At this point, 
the construct design was revisited and two more constructs terminating in the 
predicted fourth helix, 1-114 and 21-114, were decided to be produced in addition to 
constructs 1-84 and 21-84 (Tables 6.1 and 6.3 and Figure 6.2).  
The four target proteins were amplified by PCR, following the same 
conditions used for the amplification of the inserts for the vector pURI3-TEV, with 
the exception that the primers used had the EcoRI and HindIII recognition 
sequences (Table 6.2), inserting these sequences in the N- and C-terminus of the 
fragments, respectively.  The inserts and the vector pKLSLt were digested with 
EcoRI and HindIII (New England BioLabs, Ipswich, USA) at 37 ºC during 6 h. 
Digested DNA was further purified by using 0.75 % agarose gel and recovered by 
using QIAquick Gel Extraction Kit® (Qiagen, Venlo, Netherlands) following the 
manufacturer’s instructions. Ligation of the digested products was performed using 
T4 ligase (New England BioLabs, Ipswich, USA) during 10 h at 16 ºC. The product 
of ligation was used to transform heat-shock competent E. coli DH5α cells.  After 
various attempts, only 3 and 5 transformant colonies of constructs 1-114 and 21-
114 were obtained, respectively. The presence of the inserts was confirmed by PCR 
following the same conditions used in the cloning of pURI3-TEV. The plasmids of a 
single positive colony of each construct were extracted using QuickClean II 
Plasmid Miniprep Kit® (GenScript, Piscataway, USA) following the manufacturer’s 
instructions and sent to sequencing in Secugen (Madrid, Spain) to verify if the 
insert sequence was correct and in frame. Although the sequencing results of the 
construct 1-114 showed bad quality in the beginning of ComD, we performed the 
initial expression tests experiments using the plasmids from this colony. 
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In summary, we successfully inserted the constructs 1-114 and 21-114 into 
the vector pKLSLt (Table 6.3). However, the constructs 1-84 and 21-84 were not 
obtained in this vector. 
 
 
Figure 6.6 – (A) Schematic representation of the vector pKLSLt and (B) sequence of this 
vector containing the end of LSL150, the linker, the TEV and restriction enzymes 
recognition sites. Figure kindly provided by Dr. Iván Acebrón and adapted to this work. 
 
6.5. Expression tests of the fusion protein LSL150-ComD 
 
The production of a fusion protein with the LSL150 domain in the N-terminus 
and the ComD sensor domain in the C-terminus was attempted by inserting the 
vector pKLSLt with constructs 1-114 and 21-114 in the strains E. coli BL21(DE3) 
and E. coli JM109(DE3). All the expression tests described in this section are 
summarized in Table 6.5. 
 
 
Table 6.5 – Summary of the expression tests performed using the vector pKLSLt.  
Construct Expression host Medium  Volume Purification 
1-114a E. coli BL21(DE3) LB  500 mL Sepharose 4B® 
1-114a E. coli JM109(DE3) LB  500 mL Sepharose 4B® 
1-114a E. coli JM109(DE3) LB  2 L Sepharose 4B® 
21-114 E. coli JM109(DE3) LB  2 L Sepharose 4B® 
21-114 E. coli BL21(DE3) LB  500 mL Sepharose 4B® 
1-114 E. coli BL21(DE3) LB  500 mL Sepharose 4B® 
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Four independent 500 mL cultures were prepared to test expression of 
constructs 1-114 and 21-114 in both E. coli BL21(DE3) and E. coli JM109(DE3) 
strains. Protein overexpression of these cultures was induced at OD600nm=0.6 with 1 
mM IPTG followed by incubation at 16 ºC overnight with agitation. Interestingly, 
despite all our efforts, the construct 21-114 in E. coli JM109(DE3) did not grow for 
reasons that we could not identify. After induction, the cells were harvested in 20 
mM Tris pH 8.0, 100 mM NaCl and kept at -20 ºC until use. From the three pellets 
obtained, the construct 1-114 expressed in E. coli BL21(DE3) and in E. coli 
JM109(DE3) was chosen to be purified first to allow the comparison of the 
expression between both E. coli strains. Cells were lysed by sonication (10 cycles of 
30 s at maximum intensity with 10 s of interval, model SONOPULS HD 2200, 
Bandelin, Berlin, Germany) and soluble and insoluble fractions were separated by 
centrifugation at 38000 RCF during 50 min. The soluble fraction was applied to a 
column with 3 mL of Sepharose 4B® resin (GE HealthCare, Chicago, USA) which 
was previously equilibrated with the buffer 20 mM Tris pH 8.0, 100 mM NaCl. 
Elution was performed in 3 mL of 20 mM Tris pH 8.0, 100 mM NaCl, 200 mM 
lactose. The result of both purifications was assessed by SDS-PAGE. Both E. coli 
BL21(DE3) and E. coli JM109(DE3) strains presented a protein in the elution 
fractions with a molecular weight close to 21.5 kDa, although in E. coli BL21(DE3) 
the SDS denaturing gels showed that this protein was heavily contaminated with 
other unspecific bands (data not shown). The predicted molecular weight of the 
fusion protein of LSL with construct 1-114 was 32.0 kDa (Table 6.3), so we 
concluded that the protein was not being properly expressed under this condition. 
Another expression test was performed preparing 2 L of cultures of both 
constructs in E. coli JM109(DE3) because this strain produced purer protein than 
E. coli BL21(DE3) in the previous experiment. The protocol of the previous 
expression experiment was followed, although, to improve cell lysis, a French Press 
(Thermo Fisher Scientific, Waltham, USA) was used instead of the ultra-wave 
sonicator and the volume of the Sepharose 4B® resin was increased to 5 mL to cope 
with the increased cell lysate volume. The column was connected to a low pressure 
liquid chromatography system (BioLogic LP System®, Bio-Rad, Hercules, USA) and 
elution of the protein was performed in the same buffer but with a 30ml gradient of 
0-200 mM lactose. The result of the purification was observed by SDS-PAGE. The 
21.5 kDa protein observed in the previous experiment was also present in the 
elution fractions of construct 1-114 (Figure 6.7a) but was absent in construct 21-
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114 purification. In fact, the lack of expression of the fusion protein by construct 
21-114 was further confirmed by purification of the same construct expressed in E. 
coli BL21(DE3) using a similar protocol (Figure 6.7b).  
 
After confirming that the construct 21-114/LSL fusion protein was not being 
produced, the focus was turned to the construct 1-114. The protein purified from 
this construct was shorter than what was expected and since the sequence of the 
plasmid of this construct showed a zone with bad quality in the beginning of ComD, 
sequencing was repeated for the 3 transformant colonies obtained (see 6.4. Cloning 
of the fusion protein LSL150-ComD in vector pKLSLt). The plasmid that was 
originally used in the previous experiments showed a deletion in the zone that 
presented bad quality in the first sequencing. The deleted nucleotide was T18 
affecting the coding of the amino acid residue Phe6 and onwards of ComD. This 
mutation led to the production of LSL fused with a 13 amino acid peptide with a 
predicted molecular weight of 20.1 kDa, which correspond to the weight observed 
by SDS-PAGE for the protein purified from the construct 1-114, explaining the 
results described above. The other two colonies presented the expected sequence 
and the plasmid of one of them was transformed into E. coli BL21(DE3) and E. coli 
JM109(DE3) strains. 
A new expression test was performed with the new construct using E. coli 
BL21(DE3) and E. coli JM109(DE3) hosts following the protocol of previous 
experiments. However, the culture of E. coli JM109(DE3) did not grow, similarly to 
what had happened with construct 21-114, and induction of expression was not 
performed. Thus, only the expression of the culture of 500 mL of LB of E. coli 
BL21(DE3) was tested. After purification and observing the result by SDS-PAGE, 
expression of the fusion protein was not observed, confirming that construct 1-114 
was not produced as a fusion protein in any of the host strains used with the 
affinity tag LSL150, as was the case of construct 21-114. 
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Figure 6.7 - SDS-PAGE 12 % of the purification through a Sepharose 4B® resin of (A) the 
construct 1-114 expressed in E. coli JM109(DE3) and (B) the construct 21-114 expressed in 
E. coli BL21(DE3). MW – molecular weight markers (Molecular Weight Standards Broad Range, 
Bio-Rad, Hercules, USA), L – lysate, I – insoluble fraction, S – soluble fraction, FT – flow-through 
after passing protein sample through a Sepharose 4B® column, E1 to E4 – elution fractions, R1 and R2 
– references: purified protein of construct 1-114 expressed in E. coli BL21(DE3) and E. coli 
JM109(DE3) respectively, LSL – purified LSL150.  
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The goal of this work was to study the specificity of ComD sensor domain 
towards CSP through the structural characterization by X-ray crystallography. 
Four constructs of parts of the ComD sensor were designed and produced with His 
and LSL150 affinity tags and inserted into the E. coli strains BL21(DE3) and 
JM109(DE3). Production of the ComD sensor was not achieved in any of the 
conditions tested and further experiments were not performed with this protein. 
 
The construct design was based on the results of the prediction of ComD 
topology performed with the algorithm TopPred, but the online tool that was used 
is no longer available. A review of currently available tools identified CCTOP 
(Dobson et al., 2015) as a robust method since it combines the results of ten 
algorithms of protein topology prediction. Prediction of ComD topology by CCTOP 
identified a total of 7 membrane helices in ComD between the positions 4-23, 34-53, 
58-74, 85-104, 121-140, 161-180 and 187-206. These positions are very similar to 
the positions of the helices predicted by TopPred with the exceptions of 58-74, helix 
not identified by TopPred, and helix 7 (379-399), not identified by CCTOP (Table 
6.1). Regarding the pneumococcal strain TIGR4, which presents pherotype CSP2, 
the sequence of its comD is equal to allele comD-2.8 (see Chapter 4, Figure 4.5). 
Performing the topology prediction of TIGR4 ComD with CCTOP tool, a total of 5 
helices were identified: 4-22, 34-53, 121-139, 161-179 and 187-206. Comparing with 
the prediction of R6 ComD, two helices were not detected (58-74 and 85-104), 
indicating that ComD could present a topology with 5 or 7 transmembrane 
segments. 
 
AgrC is a histidine kinase membrane receptor from S. aureus that was 
classified in the same family as ComD, the HPK10 family (Grebe and Stock, 1999). 
AgrC topology was shown to present 7 transmembrane segments, a periplasmatic 
N-terminus and a cytoplasmatic C-terminus and it was suggested that this protein 
has a membrane-embedded sensor (Wang et al. 2014). ComD could present a 
similar topology presenting a membrane-embedded sensor with 7 transmembrane 
segments connected by small extracellular regions, where many of the amino 
substitutions between ComD1, ComD2 and ComD3 could be located in 
transmembrane domains as predicted by CCTOP (Figure 6.8). The presence of so 
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many membrane helices could be the reason why the production of ComD sensor 
was a failure. We chose to limit the number of putative transmembrane domains in 
the hope of facilitating expression but including all membrane segments could also 
diminish toxicity and improve expression or recovery of the protein. Cloning of 
constructs containing all the predicted transmembrane domains (residues 1-207) 
was started but due to the end of the visit period this was not finished.  
 
Little is known about the mechanism of recognition of ligands by membrane-
embedded sensors. The lack of structural studies of this type of sensors is due to 
the difficulty of producing and analyzing proteins with so many transmembrane 
segments, as was probably the case of ComD. Although the interaction of ComD 
kinase domain with ComE was already structurally characterized (Sanchez et al., 
2015), the atomic structural characterization of ComD sensors and their 
interaction with CSPs would not only elucidate the mechanism of recognition and 
specificity of these peptides but would also be helpful to design possible inhibitors 
with a therapeutic function. Abolishment of competence activation was shown to 
result in an attenuated virulence in in vivo models (Lau et al. 2001; Oggioni et al. 
2004; Zhu and Lau 2011). Several studies about the structure and specificity of 
CSPs and also of their analogues were performed to evaluate their ability to 
activate or inhibit competence (Duan et al. 2012; Johnsborg et al. 2006; Yang et al. 
2017; Zhu and Lau 2011). These studies showed that the first three amino acids of 
CSP were crucial for receptor binding and activation, while the central region of 
CSP was responsible for specificity towards the type of ComD, possibly through 
hydrophobic interactions. The degree of α-helix conformation of the central region 
was correlated with the biological activity of the CSP analogues (Yang et al., 2017). 
The analogue CSP1-E1A was found to competitively inhibit CSP1-mediated 
competence development in a concentration dependent-manner (Zhu and Lau, 
2011), while the analogue CSP1-K6A was found to be a pan-group activator of 
competence development independent of ComD type (Yang et al., 2017). However, 
the actual interaction between ComD and the CSPs was not elucidated. 
 
Regarding the expression experiments to produce the ComD sensor with a 
His-tag, some proteins were being eluted from the Ni-NTA column (Figures 6.3 
and 6.5). However, these proteins were probably host proteins with a small affinity 
to the Ni-NTA matrix. A small concentration of imidazole could have been used in 
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the equilibration buffer to prevent these unspecific interactions, although the 
success of such an approach would also not be guaranteed and could result on a 
lower yield of the protein of interest. 
 
The construct 1-114 presenting a premature stop codon originated an 
overexpressed protein with the affinity tag LSL150. However, when this was 
recognized and expression was tried with the correct ComD sequence, a fusion 
protein was not obtained. This suggested that the experimental setup used was 
working and that it was the production of the ComD sensor that prevented the 
overexpression of the fusion protein LSL150-ComD. However, observing Figure 
6.7b, a protein band around 31 kDa was seen in the insoluble fraction. This 
molecular weight was compatible with the molecular weight expected for the fusion 
protein of LSL150 with construct 21-114 (Table 6.3). Although it is probably 
improperly folded protein, ComD could be a sensor inserted into the membrane, so 
taking into account the literature published in the meantime, it cannot be excluded 
the possibility that the recombinant ComD was located in the membrane and was 
therefore in the insoluble fraction. Indeed, during the experimental work, we did 
not consider this possibility because we were assuming that the sensor domain 
would be exposed in the outer face of the membrane and so we were trying to 
produce a predicted soluble sensor domain. We did not perform any further 
manipulations to try to extract any possibly expressed protein located in the E. coli 
membrane. 
 
In the future, structural studies of ComD should focus not only in the ComD 
sensor containing the 7 predicted transmembrane segments but also on the full-
length protein because nowadays increasingly efficient protocols for purification 
and solubilization of membrane proteins for crystallization are being established 
(Newby et al. 2009). In fact, several structures of membrane proteins are being 
solved (Moraes et al., 2014), although only a few families of membrane proteins 
have been successfully crystallized and the crystallographic structure of a full-
length histidine kinase has not been described yet. In addition to ComD1, 
production of ComD2 should also be attempted because its sensor seems to be less 
hydrophobic with just 5 membrane helices identified by CCTOP, raising the 
possibility that the two sensors do not share the same structure. 
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Figure 6.8 – Possible topology of ComD1 based in the prediction by CCTOP. The 
cytoplasmatic kinase domain was omitted. Colored amino acid residues are positions presenting 
substitutions in ComD2.8 and/or ComD3.1: red – substitution in ComD2.8; blue – substitution in 
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CHAPTER 7. SEROGROUP 6 AND INFLUENCE OF PHEROTYPE 
IN GENETIC RECOMBINATION 
 
The polysaccharide capsule of S. pneumoniae is a major virulence factor and 
is the target of the current available pneumococcal conjugate vaccines. The type of 
capsule produced (serotype) is defined by the cps region which contains several 
capsular genes. Currently, almost one hundred serotypes are identified and many 
of them are grouped into serogroups due to their similar capsular composition. 
However, new serotypes are constantly being identified. Although historically only 
two serotypes were recognized within serogroup 6 (6A, 6B), five more were recently 
discovered (6C, 6D, 6F, 6G and 6H) and shown to be the result of alterations in the 
wciN and wciP genes (Bratcher et al., 2011, Burton et al., 2016). The distinction 
between serotype 6A and 6B was seen to correspond to a single amino acid in the 
gene wciP (Mavroidi et al., 2004). Serotype 6A pneumococci have a serine in the 
amino acid position 195 of this gene, while serotype 6B pneumococci have an 
asparagine, resulting in a 1→3 or 1→4 linkage, respectively, between the 
rhamnose and the ribitol of their capsule repeating unit. However, in 2007 two 
alleles of the gene wciN (wciNα and wciNβ) were identified leading to the 
identification of serotypes 6C and 6D, which have the wciNβ allele, among 
serotypes 6A and 6B pneumococci, respectively (Bratcher et al., 2009, Jin et al., 
2009, Park et al., 2007a, Park et al., 2007b). The capsule repeating unit of isolates 
with wciNα (6A and 6B) is composed of galactose-(1→3)-glucose before rhamnose 
and ribitol, while isolates with wciNβ have another glucose instead of the galactose 
(Park et al., 2007b).  
An additional serotype “6E” was proposed (Elberse et al., 2011) and its 
prevalence has been investigated (Baek et al., 2014a, Baek et al., 2014b, 
Kawaguchiya et al., 2015, Marimon et al., 2016, Shi et al., 2014, van Tonder et al., 
2015). The proposal of this new serotype was based on the divergent capsular 
genetic sequence regarding typical serogroup 6 capsular loci (≈5 % on average, 
including SNPs and indels), and the differences observed among, most frequently, 
some phenotypically serotype 6B isolates. The capsular sequences of these isolates 
were defined as class 2 sequences (Mavroidi et al., 2004) and it was proposed that 
they could produce a different capsule (Elberse et al., 2011). However, the capsule 
of an isolate containing class 2 capsular sequences was recently confirmed to have 
the same biochemical composition as the capsule of a serotype 6B isolate with class 
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1 capsular sequences (Burton et al., 2016). Thus, isolates with class 2 capsular 
sequences are henceforth designated serotype 6B-2 isolates, whereas isolates with 
canonical serotype 6B loci are designated serotype 6B-1 isolates in this work.  
PCV7, which includes serotype 6B, was introduced in Portugal in 2001. 
However, PCV7 was not included in the National Immunization Plan so its uptake 
increased slowly. Previous work from our laboratory identified a period when no 
PCV7 attributable changes in serotypes causing IPD occurred (Pre-PCV7, 1999-
2002), distinguishable from early-PCV7 (2003-2006) and late-PCV7 (2007-2009) 
periods (Aguiar et al., 2010b, Aguiar et al., 2014, Aguiar et al., 2008, Horácio et al., 
2012, Horácio et al., 2013, Serrano et al., 2004) when significant serotype changes 
were seen. By mid-2009 and start of 2010, PCV10 and PCV13 were introduced 
replacing PCV7. While PCV10 was used only briefly and does not include 
additional serogroup 6 serotypes, PCV13 includes serotype 6A. 
A previous study by our lab showed that two genetically distinct 
subpopulations could be identified associated with CSP1 and CSP2 pherotypes 
(Carrolo et al., 2009). It was suggested that “assortative mating” mediated by 
different pherotypes and ongoing genetic drift could be driving an incipient 
speciation process within pneumococci, supporting theoretical predictions that the 
existence of barriers to recombination allow the accumulation of significant genetic 
drift, even within highly recombinogenic bacterial species. However, another study 
about this topic was unable to find a restriction in recombination imposed by 
pherotype (Cornejo et al., 2010). We chose to use serogroup 6 as a case-study to 
evaluate pherotype influence on genetic recombination because serogroup 6 
serotypes presented diverse pherotypes. Serotype 6A was associated with 
pherotype CSP2 (see section 5.2.3. Serotype and pherotype) and serotype 6B 
presented mostly CSP1 (Figure 5.7 in Chapter 5). Capsular switching between 6A 
and 6B can be just a point mutation, but between 6A and 6C the recombination of 
the wciN gene is necessary and between 6B and 6C the recombination must include 
the wciN and wciP genes. Thus, capsular switching events were analyzed among 
serogroup 6 isolates to evaluate if pherotype could be influencing recombination 
between serogroup 6 isolates. 
In summary, on the one hand this study aimed to evaluate which serogroup 6 
serotypes were causing IPD in Portugal, the genetic lineages associated and their 
antimicrobial resistance as well as any changes occurring during a period when 
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PCVs were being introduced. While on the other hand, serogroup 6 was used to 
evaluate the pherotype influence on genetic recombination. 
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7.1. Materials and methods 
7.1.1. Bacterial isolates, serotyping, multilocus sequence typing (MLST) and 
pherotype identification 
 
In 1999-2012, n=4812 isolates causing IPD (n=985 in children <18 years and 
n=3847 in adults ≥18 years) were identified and characterized regarding serotype 
and antimicrobial susceptibility (Aguiar et al., 2010b, Aguiar et al., 2014, Aguiar et 
al., 2008, Horácio et al., 2012, Horácio et al., 2013, Serrano et al., 2004). Isolates 
were serotyped by the standard capsular reaction test (Statens Serum Institut, 
Copenhagen, Denmark). Only isolates expressing serogroup 6 (n=242, 5 %) were 
retained for further study.  
To confirm the phenotypically determined serotypes and to identify the most 
recent serotypes and locus class, three PCR reactions were used (Table 7.1, 
Figures 7.1 and 7.2), complemented by sequencing of wciN and wciP. 
Identification of the alleles of the wciP gene was done as described in other studies 
(Bratcher et al., 2011, Mavroidi et al., 2004, Yun et al., 2014) and a similar 
procedure was followed for the wciN gene. 
MLST was performed as described in Chapter 3 [see 3.4 - Multilocus Sequence 
Typing (MLST)] with the exception of the definition of CCs by PHYLOViZ. In this 
work, CCs were defined at the double-locus-variant (DLV) level using only the STs 
found in this study and not the entire MLST database. 
Pherotype identification was performed as described in Chapter 5 (see 5.1.2 – 
Pherotype identification). 
 
7.1.2. Statistical analysis 
 
Genetic diversity was evaluated using Simpson’s index of diversity (SID) and 
respective 95 % confidence intervals (CI95 %) (Carriço et al., 2006). The Cochran-
Armitage test (CA) was used to evaluate the temporal trends of serotypes, STs and 
CCs. Only STs and CCs with ≥5 isolates were considered for the CA analysis. 
Fisher’s exact test (FET) was used to test association of serotypes, STs and CCs 
with age group. The false discovery rate (FDR) correction for multiple testing 
(Benjamini and Hochberg, 1995) was used in both tests. A p<0.05 was considered 
significant for all tests. 
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Table 7.1 – PCRs used for serotype and class identification. 




Primer Sequence (5’-3’) Target 
serotype 
Product size Reference 
Multiplex PCR 
for identification 













6A, 6C and 
6F 














578 bp (Kawaguchiya 







217 bp (Kawaguchiya 







Serogroup 6 1.4 kb  
(6A/6B-1/6F/6G) 
1.2 kb (6C/6D) 








Serogroup 6 1.0 kb This study 
 
 
Figure 7.1 – Multiplex PCR for identification of 6A, 6B, 6C and 6D serotypes. M – size 
marker. aCould also be 6G or 6H and it cannot distinguish the class (6B-1 or 6B-2). bCan also be 6F. 
 
 
Figure 7.2 – PCR for class identification. M – size marker; C1 – class 1 sequence; C2 – class 2 
sequence. 
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7.1.3. Gene flow and genetic differentiation analyses 
 
To estimate the level of gene flow and the genetic differentiation between 
subpopulations the classical FST parameter (Hudson et al., 1992b) and the statistics 
K*ST (Hudson et al., 1992a) and Snn (Hudson, 2000) were used. These analyses were 
performed with the sequence of the MLST genes (aroE, ddl, gdh, gki, recP, spi and 
xpt) and also with the sequence obtained from the concatenation of these MLST 
genes, with the exception of ddl since it was previously shown that this gene 
showed a hitchhiking effect with pbp2b involved in penicillin resistance (Enright 
and Spratt, 1999). The DnaSP v5.10.01 program was used to perform the 
distribution of the sequences in populations regarding their pherotype and to 
perform the analyses of gene flow and genetic differentiation. K*ST and Snn 
statistics were used in combination with permutation tests performing a total of 
1000 permutations, considering p<0.05 statistically significant. 
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7.2.2. Evolution of serogroup 6 serotypes in children and in adults 
 
The serotypes identified were 6A (n=80), 6B (n=79) and 6C (n=83). All class 2 
loci were identified among serotype 6B isolates (6B-2, n=52; 6B-1, n=27). No 
representatives of serotypes 6D, 6F, 6G and 6H were found, confirming their rarity 
in Europe (Marimón et al., 2016, van der Linden et al., 2013b). The proportion of 
serogroup 6 isolates was higher in children than in adults (6.4 % and 4.7 %, 
respectively, FET p=0.032) and differences in serotype distribution were also 
observed (Figure 7.3a and 7.3b and Tables 7.2 and 7.3). Most 6C pneumococci 
were recovered from adults (n=79/83) resulting in an association with this age 
group (FET p<0.001, significant after FDR correction). There was no association 
between serotype and isolate source. Despite no overall change in frequency of 
serogroup 6 pneumococci following the introduction of PCVs, there were changes in 
proportion of serotypes (Figure 7.3a and 7.3b). In the pre-PCV7 period, serotype 
6B (6B-2) was the most frequent in contrast to neighboring Spain where 6B-1 
predominated (Marimón et al., 2016), but it subsequently decreased in both adults 
and children, similarly to Spain (supported only in children: CA p<0.001, 
significant after FDR; CA p=0.160, in adults). Class 6B-1 accounted for a small 
proportion of IPD in both age groups before vaccine introduction and, although 
there was an increase in the proportion of 6B-1 isolates in both age groups, this 
was supported only in adults and before FDR correction (CA p=0.041). So although 
both 6B-1 and 6B-2 express the same polysaccharide, they showed different 
dynamics following vaccination. It was hypothesized that the two classes could 
present differences in capsule expression (Burton et al., 2016) potentially 
explaining their contrasting variations seen here. Serotype 6A increased to become 
the most frequent serotype in children in late-PCV7 and PCV13 periods. In adults, 
although 6A was an important serotype up to 2009, a decrease was seen afterwards 
(CA p=0.006, significant after FDR), coinciding with PCV13 introduction in 
children (Figure 7.3b). While the proportion of isolates expressing serotype 6C 
remained low and stable in children, in adults an increase in serotype 6C was 
noted after 2008, although not statistically supported (CA p=0.392), establishing it 
as the most frequent serotype of serogroup 6 in adults. 
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Table 7.2 – No. of isolates of serogroup 6 responsible for invasive infections in children 
(<18 years) in Portugal between 1999 and 2012. 
 
Pre-vaccine PCV7  PCV13 
 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
Serogroup 6 2 3 3 2 3 1 2 5 7 7 10 5 7 5 62 
6A 0 1 0 1 2 0 1 0 4 4 6 2 4 2 27 
6B-1 0 0 0 1 0 1 0 1 0 2 2 1 2 2 12 
6B-2 2 2 3 0 1 0 1 2 3 1 2 1 1 0 19 
6C 0 0 0 0 0 0 0 2 0 0 0 1 0 1 4 
All invasive 
pneumococci 
20 19 31 27 29 42 51 93 145 115 160 87 72 74 965 
 
 
Table 7.3 – No. of isolates of serogroup 6 responsible for invasive infections in adults (≥18 
years) in Portugal between 1999 and 2012. 
 
Pre-vaccine PCV7  PCV13 
 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
Serogroup 6 4 1 6 6 13 10 17 17 16 11 26 18 19 16 180 
6A 0 0 3 2 6 4 6 8 6 6 7 2 1 2 53 
6B-1 0 0 0 0 1 0 0 2 2 0 3 0 2 5 15 
6B-2 0 0 3 3 2 3 2 3 3 1 3 3 7 0 33 
6C 4 1 0 1 4 3 9 4 5 4 13 13 9 9 79 
All invasive 
pneumococci 
67 91 113 105 167 214 312 285 406 409 448 404 413 413 3847 
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Figure 7.3 - Clonal composition and changes in serogroup 6 serotypes among invasive 
pneumococci recovered in Portugal (1999-2012). (A) Shows the variations of the serotypes and 
serotype classes in children and (B) in adults. The years before PCV7 introduction (1999-2002) and 
subsequent periods were defined as described in the text. (C) Shows STs and CCs identified colored by 
serotype. Each circle represents an ST and the diameter represents its frequency in a logarithmic 
scale. Grey lines connect STs that are double-locus variants, while lines of other colors connect STs 
that are single-locus variants according to the PHYLOViZ tie-break rule reached. STs that are linked 
belong to the same CC. This data set can be explored online at http://bit.do/PHYLOViZ_sero6. 
 
7.2.2. Serogroup 6 genetic diversity 
 
All isolates were characterized by multilocus sequence typing (MLST) to 
complement the information already available (Horácio et al., 2016) and 
PHYLOViZ was used to define CCs (Figure 7.3c). Serotype 6A was the most 
diverse (27 STs and 13 CCs) followed by 6B-2 (21 STs and 12 CCs), 6C (17 STs and 
9 CCs) and 6B-1 (5 STs and 2 CCs). Still, the majority of serogroup 6 isolates 
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(n=210, 87 %) were distributed into only 7 genetic lineages, three of which included 
PMEN clones (McGee et al., 2001): CC315 (Poland6B315, n=47), CC395 
(Portugal6A327, n=37), CC65 (n=35), CC176 (n=26), CC273 (Greece6B273 and 
Spain6B90, n=26), CC1876 (n=22) and CC1150 (n=17) (Tables 7.4 and 7.5). Mostly, 
each ST presented only one serotype, with the exception of STs ST176, ST460, 
ST473, ST386 and ST395, possibly reflecting capsular switching events (Figure 
7.3c). The 6B-2 ST90 lineage dominant in Asia (Baek et al., 2014b, Kawaguchiya et 
al., 2015) was represented by a single isolate. 
The genetic diversity of serogroup 6 isolates recovered from both children and 
adults was similar when considering both STs and CCs, with all seven major 
lineages present in both age groups (Tables 7.4 and 7.5). Although CC176 was 
found more frequently in children (FET p=0.017, not supported after FDR), no 
association of particular STs or CCs with age group was observed. While in adults 
the majority of CC315 and CC395 isolates expressed serotype 6C (n=28/39 and 
n=27/31, respectively), in children these lineages expressed mostly other serotypes: 
CC315/6B-2 (n=6/8) and CC395/6A (n=5/6). Serotype 6C was found in 3.0 % of 
carriage isolates in children (Nunes et al., 2009) but in only 0.4 % of IPD (Table 
7.2). Taken together these observations suggest that children may be particularly 
protected against serotype 6C IPD, potentially through cross-protection due to the 
presence of polysaccharides 6A and 6B in PCV13. CC315 increased in adults (CA 
p=0.012, significant after FDR). This CC included both 6C and 6B-2 isolates but 
only the 6C drove the increase (CA p=0.001). In contrast, and in agreement with 
the decrease of 6B-2, there was a decrease in the major lineage expressing this 
class (CC273) in both children and adults (CA p<0.001 and p=0.002, respectively, 
both significant after FDR) (Figure 7.4 and Tables 7.4 and 7.5). Increase of the 
prevalence of serotype 6C pneumococci was reported in several regions (Loman et 
al., 2013, Rolo et al., 2011b, van der Linden et al., 2013b). However, the genetic 
lineage that increased was not always CC315. For example, in Southampton, 
England, the increase of serotype 6C pneumococci in carriage was due to the clonal 
expansion of CC395 (Loman et al., 2013). In Spain, the authors associated the 
increase of serotype 6C isolates with spread of CC1150 (Rolo et al., 2011b), 
although isolates of CC315 emerged in 2007, coinciding with the data from IPD and 
carriage in Portugal. 
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Table 7.4 – No. of isolates of STs and CCs of serogroup 6 responsible for invasive infections 
in children (<18 years) in Portugal between 1999 and 2012. 
 
Pre-vaccine PCV7  PCV13 
 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
CC176 - - - 1 - 1 - 1 - 2 2 1 2 2 12 
    ST176 - - - 1 - 1 - - - 1 2 1 - 1 7 
    ST138 - - - - - - - 1 - - - - 1 - 2 
    ST469 - - - - - - - - - - - - 1 1 2 
    ST8136 - - - - - - - - - 1 - - - - 1 
CC65 - - - 1 - - - - 2 2 2 2 1 1 11 
    ST460 - - - 1 - - - - 1 - 2 1 - 1 6 
    ST65 - - - - - - - - 1 2 - 1 1 - 5 
CC273 2 1 3 - - - - 1 2 - 2 - - - 11 
    ST273 1 - 3 - - - - - 1 - 1 - - - 6 
    ST2016 - - - - - - - 1 1 - 1 - - - 3 
    ST90 1 - - - - - - - - - - - - - 1 
    ST1224 - 1 - - - - - - - - - - - - 1 
CC315 - 1 - - 1 - 1 1 1 - - 1 1 1 8 
    ST386 - - - - - - - 1 1 - - - - 1 3 
    ST315 - - - - 1 - 1 - - - - - - - 2 
    ST887 - 1 - - - - - - - - - - 1 - 2 
    ST9985 - - - - - - - - - - - 1 - - 1 
CC1876 - - - - - - - - 2 2 - - 3 - 7 
    ST1876 - - - - - - - - 2 2 - - - - 4 
    ST473 - - - - - - - - - - - - 1 - 1 
    ST5679 - - - - - - - - - - - - 1 - 1 
    ST9988 - - - - - - - - - - - - 1 - 1 
CC395 - - - - 1 - 1 1 - - 3 - - - 6 
    ST327 - - - - 1 - - - - - 3 - - - 4 
    ST395 - - - - - - 1 1 - - - - - - 2 
CC681 - - - - - - - - - - 1 - - - 1 
    ST3403 - - - - - - - - - - 1 - - - 1 
CC1150 - - - - - - - - - - - 1 - - 1 
    ST1150 - - - - - - - - - - - 1 - - 1 
CC4248 - 1 - - - - - - - - - - - - 1 
    ST4248 - 1 - - - - - - - - - - - - 1 
ST1648 - - - - 1 - - - - - - - - - 1 
ST1662 - - - - - - - 1 - - - - - - 1 
ST3324 - - - - - - - - - - - - - 1 1 
ST8137 - - - - - - - - - 1 - - - - 1 
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Table 7.5 – No. of isolates of STs and CCs of serogroup 6 responsible for invasive infections 
in adults (≥18 years) in Portugal between 1999 and 2012. 
 
Pre-vaccine PCV7  PCV13 
 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
CC315 - - 1 1 - 2 3 2 1 1 8 7 9 4 39 
    ST386 - - - - - 2 1 1 1 1 4 6 5 3 24 
    ST887 - - 1 1 - - 1 - - - - 1 1 - 5 
    ST3396 - - - - - - - - - - 3 - 1 1 5 
    ST315 - - - - - - 1 1 - - - - 1 - 3 
    ST4310 - - - - - - - - - - 1 - 1 - 2 
CC395 1 - - 3 2 3 5 2 3 - 3 5 3 1 31 
    ST395 1 - - 1 2 2 2 - - - 2 2 3 - 15 
    ST1692 - - - - - - - 2 - - 1 2 - - 5 
    ST1714 - - - - - - 2 - 2 - - - - 1 5 
    ST327 - - - 2 - 1 - - - - - 1 - - 4 
    ST8145 - - - - - - 1 - - - - - - - 1 
    ST8745 - - - - - - - - 1 - - - - - 1 
CC65 - - - - 2 2 3 3 4 3 2 1 1 3 24 
    ST460 - - - - 2 2 3 1 3 2 - - - 3 16 
    ST65 - - - - - - - 2 1 - 2 1 1 - 7 
    ST9961 - - - - - - - - - 1 - - - - 1 
CC1150 1 - - - 1 - 2 1 1 2 2 2 1 3 16 
    ST1150 1 - - - 1 - 2 1 1 1 2 2 1 2 14 
    ST224 - - - - - - - - - - - - - 1 1 
    ST2667 - - - - - - - - - 1 - - - - 1 
CC273 - - 3 1 2 2 - 2 3 - 1 - 1 - 15 
    ST273 - - 2 1 1 2 - 1 3 - - - 1 - 11 
    ST1369 - - 1 - - - - - - - - - - - 1 
    ST1624 - - - - 1 - - - - - - - - - 1 
    ST3207 - - - - - - - - - - 1 - - - 1 
    ST8144 - - - - - - - 1 - - - - - - 1 
CC1876 - - 1 - 3 - 1 3 - 2 3 - - 2 15 
    ST1876 - - 1 - 1 - - 2 - 1 1 - - - 6 
    ST473 - - - - - - - - - 1 1 - - - 2 
    ST8140 - - - - 1 - 1 - - - - - - - 2 
    ST1135 - - - - - - - - - - - - - 1 1 
    ST1647 - - - - 1 - - - - - - - - - 1 
    ST1879 - - - - - - - 1 - - - - - - 1 
    ST9974 - - - - - - - - - - - - - 1 1 
    ST10055 - - - - - - - - - - 1 - - - 1 
CC176 - - - - 1 - - 2 2 - 4 - 2 3 14 
    ST176 - - - - 1 - - 2 1 - 3 - 2 2 11 
    ST469 - - - - - - - - 1 - - - - 1 2 
    ST138 - - - - - - - - - - 1 - - - 1 
CC2611 - - - - 1 1 1 1 - - 1 - - - 5 
    ST2611 - - - - 1 1 1 - - - 1 - - - 4 
    ST4580 - - - - - - - 1 - - - - - - 1 
CC681 - - - - - - - 1 - - 1 - - - 2 
    ST681 - - - - - - - 1 - - 1 - - - 2 
CC4248 - - 1 - - - 1 - - - - - - - 2 
    ST4248 - - 1 - - - - - - - - - - - 1 
    ST8141 - - - - - - 1 - - - - - - - 1 
ST1715 - - - - - - 1 - - - - 1 - - 2 
ST2185 1 - - - 1 - - - - - - - - - 2 
ST42 - - - - - - - - - 1 - - - - 1 
ST123 - - - 1 - - - - - - - - - - 1 
ST179 - 1 - - - - - - - - - - - - 1 
ST1390 - - - - - - - - - 1 - - - - 1 
ST1518 - - - - - - - - - - - - 1 - 1 
ST4246 1 - - - - - - - - - - - - - 1 
ST4252 - - - - - - - - 1 - - - - - 1 
ST4255 - - - - - - - - 1 - - - - - 1 
ST6175 - - - - - - - - - 1 - - - - 1 
ST9957 - - - - - - - - - - - 1 - - 1 
ST9965 - - - - - - - - - - - - 1 - 1 
ST9970 - - - - - - - - - - - 1 - - 1 
ST10051 - - - - - - - - - - 1 - - - 1 
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Figure 7.4 – Evolution among all invasive pneumococci of the proportion of CC273 and 
CC315 before vaccine introduction (1999-2002), in the early PCV7 use (2003-2006) period 
and following years. 
 
7.2.3. Diversity of the wciP and wciN genes  
 
Sequencing of the capsular genes wciN and wciP identified 5 and 14 alleles, 
respectively (Table 7.6). There was a strong correspondence between the alleles at 
these loci and serotype and locus type but two isolates of ST460 presented unusual 
capsular loci. In one isolate (presenting wciP-24 allele) a point mutation seems to 
have occurred in an allele characteristic of serotype 6A switching it to 6B (6B-1). 
The other possibly resulted from horizontal DNA transfer, presenting a hybrid 
locus including class 1 sequences associated with 6A and 6B-1 (wciN-1) and class 2 
sequences (wciP-8). These observations confirm that serotype switching within 
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Table 7.6 – Allelic profiles of genes wciN and wciP and respective serotype and CC/ST.  
Allelic profile Serotype  Clonal complex 
wciNa wciPb 6A 6B-1 6B-2 6C  CC315 CC395 CC65 CC273 CC176 CC1876 CC1150 CC2611 Otherc 
1 1 33 - - -  - - 32 - - - - - 1 
4 1 1 - - -  - - 1 - - - - - - 
1 2 24 - - -  - - - - 1 15 - - 8 
3 2 14 - - -  - 8 - - - - - 5 1 
5 2 1 - - -  - 1 - - - - - - - 
1 4 - 25 - -  - - - - 25 - - - - 
1 8 - 1 - -  - - 1 - - - - - - 
2 8 - - 51 -  17 - - 25 - 1 - - 8 
wciNβ 9 - - - 60  28 27 - - - 1 - - 4 
wciNβ 13 - - - 18  - - - - - - 16 - 2 
1 14 5 - - -  - - - 1 - 4 - - - 
1 22 1 - - -  - - - - - 1 - - - 
1 23 1 - - -  - - - - - - - - 1 
1 24 - 1 - -  - - 1 - - - - - - 
wciNβ 25 - - - 1  - 1 - - - - - - - 
wciNβ 26 - - - 1  1 - - - - - - - - 
wciNβ 27 - - - 1  - - - - - - - - 1 
2 28 - - 1 -  - - - - - - - - 1 
aSince the changes leading to the expression of serotypes 6F e 6G were identified in wciNα variants, only these 
were sequenced for the identification of allelic variants. wciNβ variants detected by PCR (all found in serotype 6C 
isolates) are indicated as such in the table. The sequence of each allele is available at 
https://dx.doi.org/10.6084/m9.figshare.3437429.v1. 
bIn two isolates serotype 6C it was not possible to determine the allele of the wciP gene. The sequence of each 
allele is available at https://dx.doi.org/10.6084/m9.figshare.3437429.v1. 
cOther CCs or STs not included in those discriminated. These were (wciN-wciP) – (1-1): ST4255, n=1; (1-2): CC681, 
n=3; CC4248, n=3; ST3324, n=1; ST4252, n=1; (3-2): ST42, n=1; (2-8): ST123, n=1; ST1518, n=1; ST1662, n=1; 
ST8137, n=1; ST9957, n=1; ST9965, n=1; ST9970, n=1; ST10051, n=1; (wciNβ-9): ST1715, n=2; ST179, n=1; 
ST4246, n=1; (wciNβ-13): ST2185, n=2; (1-23): ST1648, n=1; (wciNβ-27): ST1390, n=1; (2-28): ST6175, n=1. 
 
7.2.4. Antimicrobial susceptibility 
 
The antimicrobial susceptibility of the isolates is indicated in Table 7.7. 
Serotype 6B-2 presented the highest proportion of multidrug resistant isolates (67 
%) followed by 6C (36 %) (MDR, defined as non-susceptibility to at least 3 
antimicrobial classes). The majority of isolates non-susceptible to penicillin (PNSP) 
(C.L.S.I., 2007) expressed low level resistance (MIC=0.12-1 μg/mL), with the 
exception of a single 6B-2 isolate that expressed high level resistance (MIC=2 
μg/mL). None of the PNSP isolates was 6B-1. Considering the current CLSI 
guidelines (C.L.S.I., 2014), 6 cerebrospinal fluid isolates (6B-2, n=3; 6C, n=2; 6A, 
n=1) would be considered resistant and all remaining isolates would be considered 
fully susceptible to penicillin using the non-meningitis breakpoints. Erythromycin 
resistance (ERP) was identified in 77 isolates and 53 isolates were simultaneously 
PNSP and ERP (serotype 6C, n=29; serotype 6B-2, n=20; and serotype 6A, n=4). 
CC315 and CC273 presented the highest proportions of non-susceptible isolates 
(Table 7.7). The proportion of isolates representing these CCs changed over time 
and this was the basis of changes in resistance within serotypes 6C and 6B-2. 
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Among 6C, the proportions of PNSP (p<0.001), ERP (p=0.001), clindamycin 
(p=0.001), tetracycline (p<0.001) and MDR (p=0.001) increased (CA, all significant 
after FDR), changes driven mostly by increases in CC315. In fact, the remaining 
two CCs representing almost all serotype 6C isolates were CC1150, including 
mostly PNSP, and CC395 including mostly susceptible isolates. In 6B-2, decreases 
of ERP (p=0.014), clindamycin (p=0.005), tetracycline (p=0.031) and MDR (p=0.024) 
resistance were observed (CA, all significant after FDR correction), reflecting the 
decrease in CC273. 
 
Table 7.7 – Antimicrobial resistance of the serogroup 6 isolates responsible for invasive 
infections in Portugal (1999-2012).   
 No. of non-susceptible isolates (%) 
 Serotype Clonal complex 
Antimicrobiala 6A 6B-1 6B-2 6C CC315 CC395 CC65 CC273 CC176 CC1876 CC1150 Otherb 
MDR 4 (5.0) 3 (11.1) 35 (67.3) 30 (36.1) 47 (100.0) 0 (0) 1 (2.9) 17 (65.4) 3 (12.0) 1 (4.5) 0 (0) 3 (9.4) 
PEN 10 (12.5) 0 (0) 26 (50.0) 42 (50.6) 45 (95.7) 1 (2.7) 2 (5.7) 9 (34.6) 0 (0) 4 (18.2) 13 (76.5) 4 (12.5) 
MIC50 0.023 0.016 0.047 0.064 0.125 0.016 0.023 0.023 0.016 0.016 0.094 0.023 
MIC90 0.064 0.032 0.19 0.19 0.19 0.032 0.047 0.38 0.023 0.19 0.125 0.064 
ERY 4 (5.0) 9 (33.3) 34 (65.4) 30 (36.1) 47 (100.0) 0 (0) 0 (0) 16 (61.5) 9 (34.6) 3 (13.6) 0 (0) 2 (6.3) 
CLI 1 (1.3) 4 (14.8) 33 (63.5) 30 (36.1) 47 (100.0) 0 (0) 0 (0) 16 (61.5) 4 (15.4) 0 (0) 0 (0) 1 (3.1) 
LEV 0 (0) 0 (0) 0 (0) 1 (1.2) 1 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
SXT 10 (12.5) 6 (22.2) 27 (51.9) 3 (3.6) 6 (12.8) 3 (8.1) 4 (11.4) 16 (61.5) 5 (19.2) 1 (4.5) 2 (11.8) 9 (26.1) 
TET 5 (6.3) 3 (11.1) 34 (65.4) 32 (38.6) 44 (93.6) 0 (0) 1 (2.9) 21 (80.8) 3 (11.5) 0 (0) 1 (5.9) 4 (12.5) 
CHL 1 (1.3) 0 (0) 7 (13.5) 2 (2.4) 2 (4.3) 0 (0) 1 (2.9) 6 (23.1) 0 (0) 0 (0) 0 (0) 1 (3.1) 
aAll isolates were susceptible to cefotaxime, vancomycin and linezolid. MDR: multidrug resistance, PEN: penicillin, 
MIC: minimum inhibitory concentration, ERY: erythromycin, CLI: clindamycin, LEV: levofloxacin, SXT: 
trimethoprim-sulfamethoxazole, TET: tetracycline, CHL: chloramphenicol. Isolates presenting PEN 
MIC≥0.12μg/ml were considered resistant and isolates presenting PEN MIC<0.12μg/ml were considered 
susceptible. 
bOther CC/ST – MDR: CC4248 (n=1), ST1518 (n=1), ST1662 (n=1); PEN: CC4248 (n=1), ST1518 (n=1), ST1662 
(n=1), ST4255 (n=1); ERY: ST1518 (n=1), ST1662 (n=1); CLI: ST1662 (n=1); SXT: CC681 (n=1), CC4248 (n=1), 
ST42 (n=1), ST1518 (n=1), ST1662 (n=1), ST3324 (n=1), ST9957 (n=1), ST9965 (n=1), ST9970 (n=1); TET: CC4248 
(n=2), ST1715 (n=1), ST3324 (n=1); CHL: ST1662 (n=1). 
 
7.2.5. Pherotype and influence on genetic recombination 
 
The pherotype of serogroup 6 isolates was identified (Table 7.8). Taking into 
consideration only the serogroup 6 isolates, serotype 6A and 6C isolates were 
associated with CSP2 (FET, p<0.001 and p=0.007, respectively, significant after 
FDR correction) and serotype 6B-1 and 6B-2 with CSP1 (FET, p<0.001, significant 
after FDR correction for both). These associations led us to choose serogroup 6 as a 
case-study of the influence of pherotype on genetic recombination. 
Although pherotype was observed to be a clonal property, ST273 (n=17) 
presented a CSP2 isolate (n=1) whereas the remaining isolates were CSP1 (n=16) 
(all serotype 6B-2) and ST473 (n=3) presented two CSP2 (serotype 6A) and one 
CSP1 (serotype 6B-2) isolate. 
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A total of 5 STs presented more than a single serogroup 6 serotype (Figure 
7.3c) reflecting possible capsular switching events: 
 
- ST176 (n=18): all the isolates were CSP1 (Table 7.9) and it could be 
assumed that the capsular switch was from 6B-1 (n=17) to 6A (n=1), namely by the 
exchange of a wciP-4 for wciP-2 allele. These alleles have 3 nucleotide differences, 
suggesting that the capsular switch was not driven by point mutations. The allele 
wciP-2 (n=39) was identified both in CSP1 (n=6) and CSP2 isolates (n=33), whereas 
wciP-4 (n=25) was identified only in isolates with CSP1 pherotype. Thus, although 
the donor strain could have been a CSP2 strain, the hypothesis that the exchange 
occurred between two CSP1 isolates cannot be ruled out. 
 
- ST386 (n=26): this ST presented isolates of serotype 6C (n=22) and serotype 
6B-2 (n=4) which means the capsular switch was between class 1 and class 2 
capsular sequences. All these isolates presented pherotype CSP2 (Table 7.9) and, 
in this case, it is not completely clear which serotype was that of the recipient 
strain. However, it was reported in this thesis that CC315 increased driven by an 
increase of serotype 6C isolates (see 7.2.2. Serogroup 6 genetic diversity). It is 
possible that this genetic lineage was 6B-2 to start with and then switched to 6C, 
enabling it to escape vaccine conferred immunity. If that was the case, 
recombination could have occurred between two CSP2 strains because the wciP-9 
allele, the allele found in ST386 6C isolates, was also found in other 6C isolates 
presenting the CSP2 pherotype, namely CC395, which could have acted as donors 
(Tables 7.6 and 7.9). 
 
- ST395 (n=17): the isolates of this ST were all CSP2 (Table 7.9) and a 
capsular switch could have occurred between 6C (n=16) and 6A (n=1). The serotype 
6A isolate presented the wciN-3 and wciP-2 alleles that were also identified in 
ST327, a SLV of ST395, and in CC2611 (Table 7.6). These genetic lineages also 
presented the pherotype CSP2 (Table 7.9), indicating that the recombination event 
could have occurred between two CSP2 strains. 
 
- ST460 (n=22): all the isolates were CSP2 (Table 7.9) and the majority of the 
isolates presented serotype 6A (n=20), whereas the serotype 6B of the two 
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remaining isolates was originated by a point mutation and by recombination with a 
wciP allele typical of class 2 capsular sequences (6B-2), as described above (see 
7.2.3. Diversity of the wciP and wciN genes). Although serotype 6B-2 was associated 
with CSP1, an important fraction of the isolates of this serotype was CSP2 and the 
horizontal gene transfer could have occurred between CSP2 strains. 
 
- ST473 (n=3): two isolates presented pherotype CSP2 and serotype 6A with 
the wciP-14 allele, an allele present mostly in isolates of CC1876 (Table 7.6). The 
other isolate was serotype 6B-2 and pherotype CSP1. Given the small number of 
isolates it is difficult to say which is the most frequent combination and horizontal 
gene transfer in these isolates could have occurred both with capsular and 
competence genes. 
 
In summary, the capsular switching events identified among serogroup 6 
isolates were: 
- 6A and 6B-1: 1 recombination event (ST176); 
- 6A and 6B-2: 2 recombination events (ST460, ST463); 
- 6A and 6C: 1 recombination event (ST395); 
- 6B-2 and 6C: 1 recombination event (ST386). 
 
Table 7.8 – Pherotype of serogroup 6 isolates. 
Serotype CSP1 CSP2 CSP3 Total 
6A 7 (8.75 %) 73 (91.25 %) - 80 
6B 56 (70.89 %) 21 (26.58 %) 2 (2.53 %) 79 
  6B-1   25 (92.59 %)   2 (7.41 %)   - 27 
  6B-2   31 (59.62 %)   19 (36.54 %)   2 (3.85 %) 52 
6Ca 19 (23.17 %) 63 (76.83 %) - 82 
aOne isolate presented a PCR product with a size higher than expected indicating the presence of an insertion 
sequence somewhere between the comC and comD genes. This isolate was not taken into account in pherotype 
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Table 7.9 – Pherotype of clonal complexes and STs. 
CC/ST CSP1 CSP2 CSP3 
CC315 1 45 - 
  ST386 - 26 - 
  ST887 - 7 - 
  ST315 - 5 - 
  ST3396 - 5 - 
  ST4310 -  2 - 
  ST9985 1 - - 
CC395 - 37 - 
  ST395 - 17 - 
  ST327 - 8 - 
  ST1692 - 5 - 
  ST1714 - 5 - 
  ST8145 - 1 - 
  ST8745 - 1 - 
CC65 - 35 - 
  ST460 - 22 - 
  ST65 - 12 - 
  ST9961 - 1 - 
CC176 26 - - 
  ST176 18 - - 
  ST469 4 - - 
  ST138 3 - - 
  ST8136 1 - - 
CC273 25 1 - 
  ST273 16 1 - 
  ST2016 3 - - 
  ST90 1 - - 
  ST1224 1 - - 
  ST1369 1 - - 
  ST1624 1 - - 
  ST3207 1 - - 
  ST8144 1 - - 
CC1876 1 21 - 
  ST1876 - 10 - 
  ST473 1 2 - 
  ST8140 - 2 - 
  ST1135 - 1 - 
  ST1647 - 1 - 
  ST1879 - 1 - 
  ST5679 - 1 - 
  ST9974 - 1 - 
  ST9988 - 1 - 
  ST10055 - 1 - 
CC1150 17 - - 
  ST1150 15 - - 
  ST224 1 - - 
  ST2667 1 - - 
CC2611 - 5 - 
  ST2611 - 4 - 
  ST4580 - 1 - 
CC681 3 - - 
  ST681 2 - - 
  ST3403 1 - - 
CC4248 - 3 - 
  ST4248 - 2 - 
  ST8141 - 1 - 
ST1715 2 - - 
ST2185 - 2 - 
ST42 1 - - 
ST123 1 - - 
ST179 - 1 - 
ST1390 - 1 - 
ST1518 1 - - 
ST1648 - 1 - 
ST1662 - 1 - 
ST3324 - 1 - 
ST4246 - 1 - 
ST4252 1 - - 
ST4255 - 1 - 
ST6175 - - 1 
ST8137 - 1 - 
ST9957 - - 1 
ST9970 1 - - 
ST9965 1 - - 
ST10051 1 - - 
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The capsular switching events identified on our isolates were not enough to 
extract any conclusions about a possible pherotype influence on recombination. For 
that reason, we used the isolate data deposited on the MLST database (downloaded 
on 16th December 2015) to check how many STs presented two or more serogroup 6 
serotypes. The isolate data were filtered by serotype to match exactly 6A, 6B or 6C. 
Serotype 6D was not taken into account because it was not found in our study and 
an association with pherotype could not be established. A total of 3955 isolates and 
1952 STs were obtained. Then, the STs presenting two or more serogroup 6 
serotypes were selected resulting in a total of 95 STs reflecting possible capsular 
switching events (Table 7.10). STs presenting a capsular switch between serotypes 
6A and 6B were the most frequent (n=45), followed by the capsular switch between 
serotypes 6A and 6C (n=32), whereas STs sharing serotypes 6B and 6C were less 
common (n=7). This may suggest that horizontal gene transfer could occur 
frequently between CSP1 and CSP2 isolates since serotype 6B isolates were 
associated with the former pherotype while serotype 6A with the latter. However, 
it would be important to distinguish between 6B-1 and 6B-2 isolates because the 
latter presented several CSP2 isolates and maybe the majority of the 
recombination events could have been between isolates of the same pherotype. 
 
The serogroup 6 isolates characterized in this thesis were divided into 
subpopulations considering both their serotype and pherotype. An estimation of the 
gene flow between these subpopulations was performed using the classical FST 
parameter (Hudson et al., 1992b) calculated with the concatenated sequence of the 
MLST genes excluding ddl. Low values of FST represent higher gene flow between 
the populations, i.e., higher Nm values, where N is the number of individuals in 
each subpopulation and m is the fraction of migrants in each subpopulation in each 
generation. The subpopulations 6B-1 CSP2 and 6B-2 CSP3 were not included 
because they presented just 2 isolates (Table 7.8). The results of the estimations 
showed that the range of the level of gene flow between subpopulations of the same 
pherotype (CSP1: 0.20-1.71, CSP2: 0.53-1.80) is similar to the level estimated for 
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Table 7.10 – No. of STs presenting two or more serogroup 6 serotypes on the MLST isolate 
database. 
Serotype No. of STs 
6A, 6B 45 
6A, 6C 32 
6A, 6B, 6C 11 
6B, 6C 7 
 
Table 7.11 – Gene flow between serogroup 6 subpopulations. 




6A CSP1 (n=7) 6B-2 CSP1 (n=31) 0.22601 1.71 
6A CSP1 (n=7) 6B-1 CSP1 (n=25) 0.49898 0.50 
6A CSP1 (n=7) 6C CSP1 (n=19) 0.54933 0.41 
6B-1 CSP1 (n=25) 6B-2 CSP1 (n=31) 0.68763 0.23 
6B-2 CSP1 (n=31) 6C CSP1 (n=19) 0.69869 0.22 




6B-2 CSP2 (n=19) 6C CSP2 (n=63) 0.21784 1.80 
6A CSP2 (n=73) 6C CSP2 (n=63) 0.23343 1.64 




6A CSP1 (n=7) 6C CSP2 (n=63) 0.21026 1.88 
6B-2 CSP1 (n=31) 6C CSP2 (n=63) 0.28067 1.28 
6A CSP1 (n=7) 6B-2 CSP2 (n=19) 0.29402 1.20 
6A CSP1 (n=7) 6A CSP2 (n=73) 0.31865 1.07 
6B-2 CSP1 (n=31) 6A CSP2 (n=73) 0.39235 0.77 
6B-2 CSP1 (n=31) 6B-2 CSP2 (n=19) 0.42847 0.67 
6B-1 CSP1 (n=25) 6C CSP2 (n=63) 0.50661 0.49 
6C CSP1 (n=19) 6C CSP2 (n=63) 0.52256 0.46 
6B-1 CSP1 (n=25) 6A CSP2 (n=73) 0.54957 0.41 
6C CSP1 (n=19) 6A CSP2 (n=73) 0.61838 0.31 
6B-1 CSP1 (n=25) 6B-2 CSP2 (n=19) 0.63801 0.28 
6C CSP1 (n=19) 6B-2 CSP2 (n=19) 0.69149 0.22 
Serogroup 6 CSP1 Serogroup 6 CSP2 0.15065 2.82 
 
Since poor evidence of pherotype influence on the genetic structure was 
obtained from serogroup 6 isolates, a further analysis was performed using the 
MLST data of the children invasive collection (n=903) studied in detail in Chapter 
5. For this analysis, the serotype 25A/38-ST393 isolates and the 6C isolate with an 
insertion in the comC gene (see 5.2.1. Pherotype abundance and evolution) were 
excluded because their pherotype was not determined, giving a total of n=893 
sequences for this analysis. 
A similar approach as described in Carrolo et al. (Carrolo et al., 2009) was 
followed using the FST parameter (Hudson et al., 1992b) to estimate the level of 
gene flow and the K*ST (Hudson et al., 1992a) and Snn (Hudson, 2000) statistics to 
evaluate genetic differentiation between pherotype subpopulations. However, in 
addition to the analysis using all strains (All dataset, n=893, Table 7.12), another 
two analyses were performed with smaller datasets. One of these datasets was 
formed by non-duplicate sequences within each pherotype subpopulation (Unique 
dataset, n=199, Table 7.12). This corresponds almost to using a single sequence 
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per ST, but a single sequence was kept in the cases when two STs differed only in 
the ddl gene, since this gene was not included in this analysis. It also means that 
unique sequences presenting different pherotypes were duplicated because they 
were included in different subpopulations. The use of non-duplicated sequences 
reduced a potential bias of sampling which could have altered the frequency of each 
ST in the sample relative to the one actually found in the pneumococcal population. 
The other dataset used contained just the sequences of the founder STs of the CCs 
presented in Chapter 5 defined by the software PHYLOViZ (CC founders dataset, 
n=71, Table 7.12) (see Table 5.3 and Figure 5.9). If a founder ST presented two 
pherotypes, its sequence was included in the dominant pherotype of its CC (a 
pherotype was considered dominant if expressed by >50 % of the isolates of that 
CC). With this approach, I attempted to reduce the effect of the clonal structure of 
the pneumococcal population but this came with the cost of dismissing all the 
information provided by the evolution within the CCs. 
Regarding the genetic analyses including all isolates (All dataset) and all 
pherotype populations (CSP1, CSP2 and CSP3) of each of the MLST genes 
separately and the sequence that resulted from their concatenation, it could be 
observed that statistically significant K*ST and Snn values were obtained in all the 
tests performed, indicating that pherotype populations were genetically distinct 
(Table 7.13). A rather low gene flow between the pherotype populations was also 
seen when considering the FST and Nm parameters and, as expected due to its 
hitchhiking effect with pbp2b and penicillin resistance, ddl presented the highest 
gene flow (Table 7.13). The analysis between each population (CSP1 vs. CSP2, 
CSP1 vs. CSP3 and CSP2 vs. CSP3) with all the sequences also produced 
significant results regarding genetic differentiation (Table 7.14, All dataset). The 
highest differentiation was obtained when comparing CSP1 and CSP3 populations. 
When I minimized the effect of the frequency of each ST, the pherotype populations 
were still considered genetically different, with the exception of CSP2 and CSP3 
populations regarding the K*ST statistic, but the gene flow became higher (Table 
7.14, Unique dataset). However, by removing the influence of the intrinsic 
pneumococcal clonal structure in these tests the populations were no longer 
considered to be genetically different (Table 7.14, CC founders dataset). The 
smaller number of sequences included in the analyses of Unique and CC founders 
datasets could have reduced the power of the tests, although, at least for the 
statistic Snn, it was proven by previous literature to retain its power even when 
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using sequences from few individuals (Hudson, 2000), so it is unlikely that this is 
the only explanation. 
The pherotype distribution among the pneumococcal genetic lineages was 
evaluated by constructing a minimum spanning tree (MST) using PHYLOViZ 
online tool (Ribeiro-Gonçalves et al., 2016) (Figure 7.5). Pherotype was evenly 
distributed through the MST and genetic subpopulations could not be identified 
regarding pherotype. 
 
Table 7.12 – Number of sequences per population in the datasets used in gene flow and 
genetic differentiation analyses. 
Dataset CSP1 CSP2 CSP3 Total 
All 681 192 20 893 
Unique 127 63 9 199 
CC founders 40 24 7 71 
 
 
Table 7.13 – Gene flow and genetic differentiation of MLST genes and the concatenated 
sequence of them, with the exception of ddl, using all the isolates and all pherotype 
populations. 
Dataset: All Populations:   CSP1, CSP2, CSP3 
Allele π FST Nm K*ST p (K*ST) Snn p (Snn) 
aroE 0.00466 0.21766 1.80 0.07097 <0.001 0.74358 <0.001 
ddl 0.00922 0.06180 7.59 0.03778 <0.001 0.75812 <0.001 
gdh 0.00803 0.16990 2.44 0.05818 <0.001 0.83261 <0.001 
gki 0.01880 0.12372 3.54 0.04209 <0.001 0.75104 <0.001 
recP 0.00497 0.09893 4.55 0.04652 <0.001 0.78980 <0.001 
spi 0.00798 0.07396 6.26 0.03160 <0.001 0.71080 <0.001 
xpt 0.00821 0.10782 4.14 0.05144 <0.001 0.79408 <0.001 
concatenated 0.00894 0.12523 3.49 0.04043 <0.001 0.94655 <0.001 
 
 
Table 7.14 – Gene flow and genetic differentiation between pherotype populations using 
the concatenated sequence of the MLST genes, with exception of ddl, and the datasets All, 
Unique and CC founders. 
Dataset Populations n π FST Nm K*ST p (K*ST) Snn p (Snn) 
Alla CSP1, CSP2, CSP3 893 0,00894 0,12523 3,49 0,04043 <0.001 0,94655 <0.001 
 CSP1, CSP2 873 0,00894 0,12383 3,54 0,03629 <0.001 0,96400 <0.001 
 CSP1, CSP3 701 0,00869 0,14248 3,01 0,00787 <0.001 0,99061 <0.001 
 CSP2, CSP3 212 0,00817 0,10816 4,12 0,02062 <0.001 0,92396 <0.001 
Uniqueb CSP1, CSP2, CSP3 199 0,01007 0,03047 15,91 0,00943 <0.001 0,72822 <0.001 
 CSP1, CSP2 190 0,01004 0,04900 9,70 0,00867 <0.001 0,77588 <0.001 
 CSP1, CSP3 136 0,01013 0,04399 10,87 0,00276 0,0180 0,93382 <0.001 
 CSP2, CSP3 72 0,00947 <0 <0 0,00200 0,1880 0,84722 0,0460 
CC foundersc CSP1, CSP2, CSP3 71 0,00990 <0 <0 0,00151 0,2340 0,44601 0,4450 
 CSP1, CSP2 64 0,00979 0,00356 139,87 0,00071 0,2600 0,51823 0,5500 
 CSP1, CSP3 43 0,00976 0,00870 56,98 0,00231 0,1750 0,78723 0,2740 
 CSP2, CSP3 31 0,01030 <0 <0 -0,00039 0,5040 0,67742 0,3300 
aAll the sequences. 
bNon-duplicated sequences within each pherotype population. 
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 Red: CSP1, Blue: CSP2, Green: CSP3 and Pink: Unidentified pherotype. 
Figure 7.5 – Pherotype distribution among the STs connected in a minimum spanning tree 
(MST) constructed from the MLST data of a collection of pneumococci causing IPD in 
children (n=903). The MST was constructed by using PHYLOViZ online (Ribeiro-Gonçalves et al., 
2016). Each circle represents a ST colored by the pherotype identified in its isolates. These data are 
available at http://bit.do/children_invasive.  
  
III. Pherotype specificity and influence on the genetic 
structure 






The recent identification of new serotypes (6D, 6F, 6G and 6H) in serogroup 6 
prompted us to re-evaluate our collection of invasive isolates. However, these new 
serotypes were not present among our collection and their rarity indicates that 
currently available phenotypic or simple genotypic assays remain adequate for 
distinguishing serotypes within serogroup 6 isolates. The data presented here also 
revealed that 66 % (52/79) of the 6B isolates presented class 2 capsular sequences 
and the observed decline was due to these isolates. In fact, the decrease of serotype 
6B was the result of the reduction of one major genetic lineage, the CC273, both in 
children and in adults. 
 
Serotype 6B-2 isolates were confirmed to produce the same capsule as 
serotype 6B-1 pneumococci (Burton et al., 2016), so it is reasonable to think that 
PCV7 confers the same protection against them. In fact, killing of serotype 6B-2 
pneumococci mediated by vaccine-induced serotype 6B antibodies was shown in 
vitro (van Tonder et al., 2015). However, the data reported here only indicate a 
decrease of serotype 6B-2 isolates after PCV7 introduction in Portugal, especially 
from the CC273, while serotype 6B-1 isolates did not present a significant change. 
In South Korea a similar situation was reported but in this country it was the 
frequency of serotype 6B-1 pneumococci that decreased after introduction of PCV7, 
while the observed increase of serotype 6B-2 isolates was not statistically 
supported (Baek et al., 2014b). Conjugate vaccine protection against both types of 
serotype 6B could be similar and the fact that this protection against serotype 6B-1 
and serotype 6B-2 pneumococci was not seen in Portugal and South Korea, 
respectively, could be because the prevalence of these serotypes was already low 
before introduction of PCV7 in the respective countries. The universal uptake of 
PCV13 by children, expected with the introduction of this vaccine in the National 
Immunization Plan in 2015 in Portugal, could reduce the prevalence of serotype 
6B-1 pneumococci in the next years. Regarding data of pneumococcal carriage in 
children in Portugal, a decrease of not only isolates belonging to CC273 but also of 
CC315 was observed after introduction of PCV7 (Simões et al., 2011). In the study 
reported here, CC315 presented mostly serotype 6B-2 isolates in children, so the 
observed decrease in carriage of this clonal complex could have been due to the 
reduction of serotype 6B-2 and not serotype 6C pneumococci. A decrease of serotype 
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6B-2 pneumococci was also observed in San Sebastian, Spain, and CC273 and 
CC315 lineages were identified in this region (Marimon et al., 2016). A decrease of 
isolates of CC273 was also reported in Barcelona, Spain, during 1994-2008 (Rolo et 
al., 2011a), confirming the reduction of this genetic lineage in Spain. In a whole 
genome genetic screen of serogroup 6 isolates from diverse regions of the world, the 
majority of serotype 6B pneumococci were revealed to present class 2 capsular 
sequences and they were worldwide distributed (van Tonder et al., 2015). Thus, a 
decrease of serotype 6B-2 pneumococci is expected to have occurred in the countries 
that implemented conjugate vaccination. The antibiotic resistance profile of 
serotype 6B-1 and 6B-2 pneumococci was distinct, with serotype 6B-2 isolates 
presenting a higher degree of MDR than serotype 6B-1 pneumococci. This could be 
one of the reasons for the selection and expansion of serotype 6B-2 prior to the 
availability of conjugate vaccines. However, further studies are necessary to clarify 
potential differences between 6B-1 and 6B-2 and their response to vaccination. 
 
Following the reduction of serotype 6B invasive infections, serotype 6A 
isolates became the most frequently found among serogroup 6 pneumococci after 
the introduction of PCV7 in Portugal suggesting that a cross-protection of PCV7 
against these pneumococci did not occur. Thus, the introduction of PCV13, which 
includes serotype 6A polysaccharides in its formulation, was expected to reduce the 
proportion of invasive cases caused by serotype 6A pneumococci. However, this 
reduction was observed only in adults and not in children who were directly 
vaccinated. The stabilization of the number of isolates received by our laboratory 
from 2007 onwards made it possible to calculate the incidence of IPD in children 
and a reduction of the total invasive cases was observed after the introduction of 
PCV13 (Aguiar et al., 2014). Thus, analysis of the proportions of infections in 
children in the post-PCV13 period (2010-2012) needs to be carefully done since it 
may be misleading. For example, the increase of the proportion of serotype 6A 
isolates seen in 2011 in children does not correspond to an increase of the number 
of cases caused by isolates expressing this serotype comparing with the period 
2007-2009 (Table 7.2). In fact, the number of infections caused by serotype 6A 
pneumococci decreased from 14 to 8 comparing this period with the period after 
PCV13 introduction. Thus, a protection of PCV13 against serotype 6A pneumococci 
cannot be discarded. 
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The prevalence of serogroup 6 isolates in Portugal was higher in children 
than in adults. However, serotype 6C pneumococci were responsible for a small 
proportion of IPD cases in children. Several countries also reported infrequent 
cases of invasive infections by serotype 6C pneumococci among children (du Plessis 
et al., 2008, Millar et al., 2010, Rolo et al., 2011b, van der Linden et al., 2013a). The 
proportion of serotype 6C pneumococci among isolates recovered from carriage in 
children during the years 1999-2007 in Portugal was 3.0 % (Nunes et al., 2009), 
contrasting with the prevalence of just 0.4 % (2/457, Table 7.2) in IPD in children 
of these pneumococci during the same period. This could mean that serotype 6C 
isolates could have a decreased ability to cause invasive disease in this age group, 
although some clones may be more successful than others and its prevalence could 
rise in children IPD. In fact, although not seen in this study, a rise in IPD cases of 
serotype 6C pneumococci was observed in 2009 in Spain (Rolo et al., 2011b). On the 
other side, the proportion of serotype 6C pneumococci infections in adults was 
completely different. These pneumococci became the most prevalent of the invasive 
serogroup 6 isolates recovered from adults and were mainly distributed between 
three major genetic lineages (CC315, CC395 and CC1150). Although an increase of 
serotype 6C isolates in adults was not statistically supported, expansion of CC315 
due to serotype 6C pneumococci occurred in this age group starting around 2008. In 
children’s carriage in Portugal, isolates of ST3396 (CC315) were recovered only in 
the last years of the study (2006-2007) and isolates of CC395 and CC1150 were 
already present before introduction of conjugate vaccine (Nunes et al., 2009). 
Increase of the prevalence of serotype 6C pneumococci was reported in several 
regions (Loman et al., 2013, Millar et al., 2010, Nahm et al., 2009, Rolo et al., 
2011b, van der Linden et al., 2013a). However, the genetic lineage that increased 
was not always the CC315. For example, in Southampton, England, the increase of 
serotype 6C pneumococci in carriage was due to the clonal expansion of CC395 
(Loman et al., 2013). In Spain, the authors associated the increase of serotype 6C 
isolates with spread of CC1150 (Rolo et al., 2011b), although isolates of CC315 
emerged in 2007, coinciding with the data from IPD and carriage in Portugal. 
Expansion of just CC315 from the three major serotype 6C genetic lineages present 
in Portugal could have occurred due to selection by antibiotics consumption, since 
CC315 presented MDR and CC1150 and CC395 were more susceptible to 
antimicrobials. Thus, expansion of resistant 6C lineages in adults, but not in 
children where the same lineages express other serogroup 6 serotypes, may be a 
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hallmark of the post-PCV period and suggest that vaccination and antimicrobial 
use are the two major forces currently shaping pneumococcal populations. 
 
Capsular switching events are relatively common in serogroup 6 (Mavroidi et 
al., 2004). In this study, five STs suggested that a capsular switch has occurred in 
some of their isolates. In serogroup 6, capsular switching may occur by horizontal 
transfer (whole capsular loci or part of it) or by a spontaneous mutation in a single 
nucleotide, namely in the amino acid position 195 of WciP. Although capsular 
switch by horizontal transfer appeared to be the most common mechanism, one 
isolate in this study was confirmed to switch its capsule by a point mutation like 
the case described by Mavroidi and colleagues (Mavroidi et al., 2004). Another 
characteristic of serogroup 6 is the occurrence of hybrid capsular sequences, 
particularly between class 1 and class 2 sequences (Mavroidi et al., 2004). This was 
recently highlighted in a whole genome screen of serogroup 6 isolates that reported 
a hybrid between serotype 6C and serotype 6B-2 capsular loci (van Tonder et al., 
2015). In this study, a ST460 isolate also presented a hybrid sequence between 
classes 1 and 2 sequences. It remains unclear if some cases of hybrid capsular loci 
in serogroup 6 represent new serotypes but the hybrid described here should be 
serotype 6B since the genetic sequences are from two classes of serotype 6B 
capsular sequences. 
 
A decline of serotype 6B-2 pneumococci, particularly of CC273, and not of 
serotype 6B-1 pneumococci was observed in Portugal. Along with this decline, 
expansion of CC315 due to serotype 6C isolates was also observed. This suggested 
that introduction of PCV7 protected against serotype 6B-2 pneumococci infections, 
while this protection should not be discarded in serotype 6B-1 pneumococci and, 
with introduction of PCV13, in serotype 6A isolates.  
 
Expansion of CC315 was not responsible for the increase of serotype 6C 
pneumococci in some regions, so genetic surveillance either by MLST or whole 
genome sequencing is important to perform along with serotyping and 
determination of the antimicrobial resistance profiles. 
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The pherotype influence on the pneumococcal genetic structure was also 
explored in this chapter. The serogroup 6 collection was used as a case-study in a 
first approach to this subject under the premise that serogroup 6 serotypes were 
associated to different pherotypes and the capsular switching events occurring 
between them would be representative of intra- and inter-pherotype genetic 
recombination. A total of 5 cases of probable capsular switching events were 
identified among serogroup 6 isolates, a low number that did not allow any solid 
conclusions. In most of these cases, a dominant serotype was identified, and the 
capsular switch was initially assumed to have been from the dominant serotype to 
the least commonly found serotype in a given ST. By taking ST386 isolates (n=26) 
as an example, where most of them were serotype 6C (n=22) while serotype 6B-2 
was identified in fewer isolates (n=4), the capsular switch could have been from 6C 
to 6B-2. However, a careful interpretation should be done because the capsular 
switch could have been exactly in the opposite direction. In fact, it may have been 
from 6B-2 to 6C, followed by an increase of 6C ST386 isolates, an interpretation 
supported by the observed increase of CC395 due to 6C isolates documented in this 
thesis. The MLST isolate database was also used to further explore if pherotype 
influence on recombination could be inferred from serogroup 6 capsular switching 
events. Most of the capsular switching events identified using this database were 
between serotype 6A and 6B, which, under the premise of this study, would mean 
recombination between pherotype CSP2 and CSP1. However, in addition to the fact 
that a significant proportion of 6B-2 isolates presented CSP2 pherotype, the 
difficulty to quantify the expected capsular switching rate between serogroup 6 
serotypes under different scenarios have not allowed any conclusion to be drawn 
from this analysis. Thus, pherotype influence on capsular switching events and 
hence in genetic recombination could not be properly evaluated using serogroup 6 
isolates. 
 
Pherotype influence on the genetic recombination was further explored by 
using a collection of pneumococcal isolates causing IPD in children between 1999 
and 2012, which was studied in Chapter 5. By using this large collection (n=903), it 
was expected to elucidate if pherotype was really defining genetically different 
subpopulations as was found in previous work from our lab (Carrolo et al., 2009) or 
if it did not have an effect on recombination between populations of different 
pherotypes as was suggested by Cornejo et al. (Cornejo et al., 2010). These studies 
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used rather small collections so the analyses performed here with a larger 
collection could shed light on the subject. The results obtained here showed that 
pherotype populations were indeed genetically different even when the frequency of 
each ST was not taken into account. However, this result could be expected because 
of the clonal structure of the pneumococcal population. For example, if two 
subpopulations were chosen from the CSP2 population and if the STs belonging to 
the same CC were kept together in the same subpopulation, the genetic 
differentiation tests would also report those subpopulations as genetically 
different, despite all being CSP2 strains. By using the CC founder dataset, we tried 
to eliminate the effect of the clonal structure on the results obtained from the 
genetic differentiation tests using the All and Unique datasets. In this case, a 
genetic differentiation between CSP1 and CSP2 populations could no longer be 
seen. Moreover, the analysis of the pherotype distribution through the genetic 
backgrounds connected between them in a minimum spanning tree failed to 
identify subpopulations segregated by pherotype. However, these results do not 
unequivocally prove that pherotype does not restrict recombination between 
pherotypes and further analyses should be performed. Recently, a study using 
whole genome data from a total of 4089 isolates was unable to find an effect of 
pherotype on genetic structure and recombination (Miller et al., 2017). Their 
results showed that pherotype does not restrict recombination between strains 
presenting a different pherotype and they even suggested that recombination 
between those strains could be slightly facilitated. Definitively, their results should 
be taken into account in the scope of the work performed in this chapter. Thus, the 
influence of the pherotype on the genetic structure of S. pneumoniae was not clear 




















 IV. Final remarks and future perspectives 
 
157 
IV. FINAL REMARKS AND FUTURE PERSPECTIVES 
 
The work performed under the scope of this thesis aimed to strengthen the 
knowledge on horizontal gene transfer and its importance for the evolution of S. 
pneumoniae. To achieve this goal it was proposed to: 
- Study the genetic diversity of the pherotype-defining region comCDE, 
which was done by sequencing this region from a collection of n=89 
pneumococcal isolates causing IPD in Portugal during 1999-2001; 
-  Evaluate pherotype abundance and its evolution and the pherotypes 
that could be identified in the pneumococcal population. This goal was 
accomplished by studying a large collection of invasive pneumococci 
recovered from children IPD during a period of 14 years when conjugate 
vaccines were introduced. 
- Explore pherotype specificity by identifying the structural determinants 
responsible for this putative lock-and-key mechanism. Here the strategy 
followed was to determine the 3D structure of the ComD sensor in 
complex with the respective CSP. Although several experiments were 
performed, this goal was not achieved. 
- Further study the influence of pherotype on genetic structure, which was 
explored by using a serogroup 6 pneumococci collection and also a large 
collection of isolates causing IPD in children. 
 
The main findings of this thesis were: 
- Pherotype abundance remained stable in a period when extensive 
changes occurred in serotype distribution and in frequency of some 
pneumococcal clones;  
- Recognition of CSP3 as a pneumococcal pherotype by identification of 
CSP3 strains circulating in Portugal and quantification of the CSP3 
pherotype abundance; 
- ComD could be a membrane-embedded sensor making it difficult the 
production of this protein; 
- Influence of the pherotype on the genetic structure of S. pneumoniae is 
not clear. 
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S. pneumoniae presents polymorphism in the comCD genes and the 
interaction between their products could function like a lock-and-key mechanism. 
These genes were observed to be under positive selection (Ichihara et al., 2006), 
indicating that there is a high probability that mutations in this region cause a 
decrease of the efficiency of competence induction and hence of fitness. 
Pneumococci enter in the competent state in response to cell density and 
environmental conditions such as pH and antibiotic stress (Moreno-Gámez et al., 
2017, Weyder et al., 2018). In this state, pneumococci are not only able to undergo 
genetic recombination but they also express other genes. Fratricide was identified 
as a molecular mechanism induced during competence and the lysis of non-
competent cells was proposed to increase the homologous DNA available for genetic 
transformation. The main benefit of pneumococcal transformation was suggested to 
be gene repair instead of the acquisition of new traits (Ambur et al., 2016). 
Naturally, genetic recombination proved to be extremely beneficial in some cases 
where strong selective pressures existed, as for example in recombination events 
involving the acquisition of antimicrobial resistance genes or capsular switching 
events enabling the evasion of vaccine protection. Inter-pherotype recombination 
could theoretically be more advantageous because pneumococci would have a 
bigger reservoir of genetic diversity than if they were restricted to exchange 
information with just strains of the same pherotype. However, it can be also the 
case that the specificity between some ComD variants and their cognate CSPs may 
be not so strict, allowing responses to heterologous CSPs further confusing the 
issue of the potential genetic segregation mediated by the pherotypes. Moreover, it 
was also suggested that the main reservoir of genetic variability of S. pneumoniae 
resides in other streptococcal species, namely Streptococcus mitis (Donati et al., 
2010) which do not share the same CSP alleles of S. pneumoniae.  
Pherotype proportions of approximately 70:28:2 (CSP1:CSP2:CSP3) seem to 
be maintained in pneumococcal populations from diverse geographic sites and 
isolation dates, suggesting that a mechanism enforcing these proportions could 
exist, although it is still not clear which are the forces behind it. The possibility of a 
yet undiscovered mechanism that could contribute to stabilize pherotype 
abundance could exist because up to 124 genes are induced during competence and 
only a small set of them were identified to be directly involved in genetic 
transformation. Thus, like the discovery of fratricide, there could be still 
unrevealed phenotypes induced during competence which could also be under 
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selection. However, a bigger temporal scale may be needed to evaluate if pherotype 
abundance is indeed being actively stabilized by selection or if it is slowly changing 
at a pace not measurable by the temporal scale of 14 years used in this work, 
although the introduction of the vaccine would be expected to have been a 
sufficiently strong perturbation to cause changes in the absence of other stabilizing 
selective forces. The pneumococcal pherotypes exhibit different phenotypes as 
observed by a previous study performed by our laboratory with mutants lacking the 
comC gene which indicated that CSP1 strains were able to respond much better to 
their cognate peptide than CSP2 strains, resulting in a better capacity to form 
biofilms and a higher transformation efficiency of CSP1 in relation to CSP2 strains 
(Carrolo et al., 2014). These results suggested either a stronger binding of CSP1 to 
its receptor or an amplification of the response in the CSP1 genetic background and 
could explain the higher prevalence of the comC1 allele in the pneumococcal 
population. 
It is difficult to state if there was an original pneumococcal pherotype, but it 
is likely that it was either CSP1 or CSP2, or maybe an ancestor of both pherotypes. 
CSP3 seems to have been acquired from a Streptococcus mitis strain because the 
comC3 allele and the intergenic space between comC and comD presented sequence 
lengths different from CSP1 and CSP2 strains whereas that intergenic space was 
of the same length as that seen in a sequence of the comCDE operon from an S. 
mitis strain (Whatmore et al., 1999).  
 
Future work should focus on the evaluation of pherotype abundance in the 
period after introduction of PCV13 to ascertain if pherotype abundance really 
remained stable or an increase of CSP2 has occurred. The pherotype of non-
invasive isolates and of adult isolates could also be identified to check possible 
differences in comparison to invasive isolates causing IPD in children. The 
structural determination of the specificity between ComD and CSP should consider 
that ComD may be a membrane-embedded sensor and production of this protein 
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Abstract
Although serogroup 6 was among the first to be recognized among Streptococcus pneumo-
niae, several new serotypes were identified since the introduction of pneumococcal conju-
gate vaccines (PCVs). A decrease of the 6B-2 variant among invasive pneumococcal dise-
ase (IPD), but not 6B-1, was noted post conjugate vaccine introduction, underpinned by a
decrease of CC273 isolates. Serotype 6C was associated with adult IPD and increased in
this age group representing two lineages (CC315 and CC395), while the same lineages
expressed other serogroup 6 serotypes in children. Taken together, these findings suggest
a potential cross-protection of PCVs against serotype 6C IPD among vaccinated children
but not among adults. Serotype 6A became the most important serogroup 6 serotype in chil-
dren but it decreased in adult IPD. No other serogroup 6 serotypes were detected, so avail-
able phenotypic or simple genotypic assays remain adequate for distinguishing serotypes
within serogroup 6 isolates.
Introduction
Although historically only two serotypes were recognized within serogroup 6 (6A, 6B), five
more were recently discovered (6C, 6D, 6F, 6G and 6H) and shown to be the result of alter-
ations in the wciN and wciP genes [1,2]. An additional serotype “6E” was proposed based on
divergent capsular loci (including SNPs and indels), most frequently of serotype 6B isolates.
However, the polysaccharide of this putative serotype, henceforth designated 6B-2, was
recently shown to be identical of that of isolates with canonical serotype 6B loci (designated
6B-1) [2].
The 7-valent PCV (PCV7), which includes serotype 6B, was introduced in Portugal in 2001.
However, PCV7 was not included in the National Immunization Plan so its uptake increased
slowly. Previous work from our laboratory identified a period when no PCV7 attributable
changes in serotypes causing invasive pneumococcal disease (IPD) occurred (Pre-PCV7,
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1999–2002), early-PCV7 (2003–2006) and late-PCV7 (2007–2009) periods [3–8]. By mid-2009
and start of 2010, 10-valent (PCV10) and 13-valent (PCV13) PCVs were introduced replacing
PCV7. While PCV10 was used only briefly and does not include additional serogroup 6 sero-
types, PCV13 includes serotype 6A. This study aimed to evaluate which serogroup 6 serotypes
were causing IPD in Portugal, the genetic lineages associated and their antimicrobial resistance
as well as any changes during a period when PCVs were being introduced.
Materials and methods
Isolates and serotyping
In 1999–2012, n = 4812 isolates causing IPD (n = 985 in children <18 yrs and n = 3847 in
adults18 yrs) were identified and characterized regarding serotype and antimicrobial sus-
ceptibility [3–8]. Isolates were serotyped by the standard capsular reaction test (Statens Serum
Institut, Copenhagen, Denmark). Only isolates expressing serogroup 6 (n = 242, 5%) were
retained for further study. To confirm the phenotypically determined serotypes and to identify
the most recent serotypes and locus class, three PCR reactions were used (Table 1), comple-
mented by sequencing of wciN and wciP.
Multilocus Sequence Typing (MLST)
MLST was performed as previously described [11]. Briefly, seven housekeeping genes
were sequenced and compared to the pneumococcal MLST database (http://pubmlst.org/
spneumoniae) to identify the alleles and respective sequence types (STs). PHYLOViZ [12]
was used to define clonal complexes (CCs) at double locus variant (DLV) level using only
the STs found in this study.
Antimicrobial susceptibility testing
Etest strips (AB Biodisk, Solna, Sweden) were used to determine the minimal inhibitory con-
centration (MIC) for penicillin, cefotaxime and levofloxacin. Susceptibility to erythromycin,
clindamycin, vancomycin, linezolid, trimethoprim-sulfamethoxazole, tetracycline and chlor-
amphenicol was tested by the Kirby-Bauer disk diffusion technique according to CLSI proce-
dures. Unless otherwise stated, the interpretative criteria prior to 2008 [13] were used. These
criteria were selected to enable comparison with previous studies. Multidrug resistance
(MDR) was defined by non-susceptibility to at least three classes of antibiotics.
Statistical analysis
Genetic diversity was evaluated using Simpson’s index of diversity (SID) and respective 95%
confidence intervals (CI95%) [14]. The Cochran-Armitage test (CA) was used to evaluate the
temporal trends of serotypes, STs and CCs. Only STs and CCs with5 isolates were consid-
ered for the CA analysis. Fisher’s exact test (FET) was used to test association of serotypes, STs
and CCs with age group. The false discovery rate (FDR) correction for multiple testing [15]
was used in both tests. A p<0.05 was considered significant for all tests.
Results and discussion
The serotypes identified were 6A (n = 80), 6B (n = 79) and 6C (n = 83). All class 2 loci were
identified among serotype 6B isolates (6B-2, n = 52; 6B-1, n = 27). No representatives of sero-
types 6D, 6F, 6G and 6H were found, confirming their rarity in Europe [16,17]. The propor-
tion of serogroup 6 isolates was higher in children than in adults [6.4% and 4.7%, respectively,
FET p = 0.032] and differences in serotype distribution were also observed (Fig 1 and S1 and
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S2 Tables). Most 6C pneumococci were recovered from adults (n = 79/83) resulting in an asso-
ciation with this age group [FET p<0.001, significant after FDR correction]. There was no
association between serotype and isolate source. Despite no overall change in frequency of ser-
ogroup 6 pneumococci following the introduction of PCVs, there were changes in proportion
of serotypes (Fig 1). In the pre-PCV7 period, serotype 6B (6B-2) was the most frequent in con-
trast to neighboring Spain where 6B-1 predominated [16], but it subsequently decreased in
both adults and children, similarly to Spain [supported only in children: CA p<0.001, signifi-
cant after FDR; CA p = 0.160, in adults]. Class 6B-1 accounted for a small proportion of IPD in
both age groups before vaccine introduction and, although there was an increase in the pro-
portion of 6B-1 isolates in both age groups, this was supported only in adults and before FDR
correction (CA p = 0.041). So although both 6B-1 and 6B-2 express the same polysaccharide,
they showed different dynamics following vaccination. It was hypothesized that the two classes
could present differences in capsule expression [2] potentially explaining their contrasting var-
iations seen here. Serotype 6A increased to become the most frequent serotype in children in
late-PCV7 and PCV13 periods. In adults, although 6A was an important serotype up to 2009, a
decrease was seen afterwards (CA p = 0.006, significant after FDR), coinciding with PCV13
introduction in children (Fig 1B). While the proportion of isolates expressing serotype 6C
remained low and stable in children, in adults an increase in serotype 6C was noted after 2008,
although not statistically supported (CA p = 0.392), establishing it as the most frequent sero-
type of serogroup 6 in adults.
All isolates were characterized by multilocus sequence typing (MLST) to complement the
information already available [18] and PHYLOViZ was used to define CCs (Fig 1C). Serotype
6A was the most diverse (27 STs and 13 CCs) followed by 6B-2 (21 STs and 12 CCs), 6C (17
STs and 9 CCs) and 6B-1 (5 STs and 2 CCs). Still, the majority of serogroup 6 isolates (n = 210,
87%) were distributed into only 7 genetic lineages, three of which included PMEN clones [19]:
Table 1. PCRs used for serotype and class identification.
Purpose of the PCR Target
gene
Primer Sequence (5’-3’) Target
serotype
Product size Reference
Multiplex PCR for identification of 6A,
6B, 6C and 6D serotypes
wzy wzy-f CGACGTAACAAAGAACTAGGTGCTGAAAC Serogroup 6 220 bp [9]
wzy-r AAGTATATAACCACGCTGTAAAACTCTGAC


















wciN sequencing wciN wciN-
f2






GTT TTTCTTTCAATATCTTTA 1.7 kb (6B-2)
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CC315 (Poland6B315, n = 47), CC395 (Portugal6A327, n = 37), CC65 (n = 35), CC176 (n = 26),
CC273 (Greece6B273 and Spain6B90, n = 26), CC1876 (n = 22) and CC1150 (n = 17) (S3 and
S4 Tables). Mostly, each ST presented only one serotype, with the exception of STs ST176,
ST460, ST473, ST386 and ST395, possibly reflecting capsular switching events (Fig 1C). The
6B-2 ST90 lineage dominant in Asia [10,20] was represented by a single isolate.
The genetic diversity of serogroup 6 isolates recovered from both children and adults was
similar when considering both STs and CCs, with all seven major lineages present in both age
Fig 1. Clonal composition and changes in serogroup 6 serotypes among invasive pneumococci recovered in Portugal (1999–2012).
(A) Shows the variations of the serotypes and serotype classes in children and (B) in adults. The years before PCV7 introduction (1999–2002)
and subsequent periods were defined as described in the text. (C) shows STs and CCs identified colored by serotype. Each circle represents
an ST and the diameter represents its frequency in a logarithmic scale. Grey lines connect STs that are double-locus variants, while lines of
other colors connect STs that are single-locus variants according to the PHYLOViZ tie-break rule reached. STs that are linked belong to the
same CC. This data set can be explored online at http://bit.do/PHYLOViZ_sero6.
doi:10.1371/journal.pone.0170354.g001
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groups (S3 and S4 Tables). Although CC176 was found more frequently in children (FET
p = 0.017, not supported after FDR), no association of particular STs or CCs with age group
was observed. While in adults the majority of CC315 and CC395 isolates expressed serotype
6C (n = 28/39 and n = 27/31, respectively), in children these lineages expressed mostly other
serotypes: CC315/6B-2 (n = 6/8) and CC395/6A (n = 5/6). Serotype 6C was found in 3.0% of
carriage isolates in children [21] but in only 0.4% of IPD (S1 Table). Taken together these
observations suggest that children may be particularly protected against serotype 6C IPD,
potentially through cross-protection due to the presence of polysaccharides 6A and 6B in
PCV13. CC315 increased in adults (CA p = 0.012, significant after FDR). This CC included
both 6C and 6B-2 isolates but only the 6C drove the increase (CA p = 0.001). In contrast, and
in agreement with the decrease of 6B-2, there was a decrease in the major lineage expressing
this class (CC273) in both children and adults (CA p<0.001 and p = 0.002, respectively, both
significant after FDR) (S1 Fig and S3 and S4 Tables). Increase of the prevalence of serotype 6C
pneumococci was reported in several regions [17,22,23]. However, the genetic lineage that
increased was not always CC315. For example, in Southampton, England, the increase of sero-
type 6C pneumococci in carriage was due to the clonal expansion of CC395 [22]. In Spain, the
authors associated the increase of serotype 6C isolates with spread of CC1150 [23], although
isolates of CC315 emerged in 2007, coinciding with the data from IPD and carriage in
Portugal.
Sequencing of the capsular genes wciN and wciP identified 5 and 14 alleles, respectively (S5
Table). There was a strong correspondence between the alleles at these loci and serotype
and locus type but two isolates of ST460 presented unusual capsular loci. In one isolate a
point mutation seems to have occurred in an allele characteristic of serotype 6A switching
it to 6B (6B-1). The other possibly resulted from horizontal DNA transfer, presenting a
hybrid locus including class 1 sequences associated with 6A and 6B-1 (wciN-1) and class 2
sequences (wciP-8). These observations confirm that serotype switching within serogroup
6 may occur in the wild by both point mutation and recombination.
The antimicrobial susceptibility of the isolates is indicated in Table 2. Serotype 6B-2 presented
the highest proportion of multidrug resistant isolates (67%) followed by 6C (36%) (MDR, defined
as non-susceptibility to at least 3 antimicrobial classes). The majority of isolates non-susceptible
to penicillin (PNSP) [13] expressed low level resistance (MIC = 0.12–1 μg/mL), with the excep-
tion of a single 6B-2 isolate that expressed high level resistance (MIC = 2 μg/mL). None of the
PNSP isolates was 6B-1. Considering the current CLSI guidelines [24], 6 cerebrospinal fluid iso-
lates (6B-2, n = 3; 6C, n = 2; 6A, n = 1) would be considered resistant and all remaining isolates
would be considered fully susceptible to penicillin using the non-meningitis breakpoints. Eryth-
romycin resistance (ERP) was identified in 77 isolates and 53 isolates were simultaneously PNSP
and ERP (serotype 6C, n = 29; serotype 6B-2, n = 20; and serotype 6A, n = 4). CC315 and CC273
presented the highest proportions of non-susceptible isolates (Table 2). The proportion of isolates
representing these CCs changed over time and this was the basis of changes in resistance within
serotypes 6C and 6B-2. Among 6C, the proportions of PNSP (p<0.001), ERP (p = 0.001), clinda-
mycin (p = 0.001), tetracycline (p<0.001) and MDR (p = 0.001) increased (CA, all significant
after FDR), changes driven mostly by increases in CC315. In fact, the remaining two CCs repre-
senting almost all serotype 6C isolates were CC1150, including mostly PNSP, and CC395 includ-
ing mostly susceptible isolates. In 6B-2, decreases of ERP (p = 0.014), clindamycin (p = 0.005),
tetracycline (p = 0.031) and MDR (p = 0.024) resistance were observed (CA, all significant after
FDR correction), reflecting the decrease in CC273.
The rarity of serotypes 6D, 6F, 6G and 6H indicates that currently available phenotypic
or simple genotypic assays remain adequate for distinguishing serotypes within serogroup 6
isolates. Although the 6B-2 class seems to have been preferentially affected by vaccination in
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Portugal, this was in contrast to what was documented elsewhere [20]. Further studies are neces-
sary to clarify potential differences between the two classes and their response to vaccination.
Expansion of resistant 6C lineages in adults, but not in children where the same lineages express
other serogroup 6 serotypes, may be a hallmark of the post-PCV period and suggest that vaccina-
tion and antimicrobial use are the two major forces currently shaping pneumococcal populations.
Supporting information
S1 Fig. Temporal changes of the proportion of CC273 and CC315 among all invasive pneu-
mococci in Portugal (1999–2012).
(PDF)
S1 Table. No. of isolates of each serotype of serogroup 6 responsible for invasive infections
in children (<18 years) in Portugal (1999–2012).
(PDF)
S2 Table. No. of isolates of each serotype of serogroup 6 responsible for invasive infections
in adults (18 years) in Portugal (1999–2012).
(PDF)
S3 Table. No. of isolates of STs and CCs of serogroup 6 responsible for invasive infections
in children (<18 years) in Portugal (1999–2012).
(PDF)
S4 Table. No. of isolates of STs and CCs of serogroup 6 responsible for invasive infections
in adults (18 years) in Portugal (1999–2012).
(PDF)
Table 2. Antimicrobial resistance of serogroup 6 isolates responsible for invasive infections in Portugal (1999–2012).
No. of non-susceptible isolates (%)
Serotype Clonal complex
Antimicrobial a 6A 6B-1 6B-2 6C CC315 CC395 CC65 CC273 CC176 CC1876 CC1150 Otherb
MDR 4 (5.0) 3 (11.1) 35 (67.3) 30 (36.1) 47 (100.0) 0 (0) 1 (2.9) 17 (65.4) 3 (12.0) 1 (4.5) 0 (0) 3 (9.4)
PEN 10 (12.5) 0 (0) 26 (50.0) 42 (50.6) 45 (95.7) 1 (2.7) 2 (5.7) 9 (34.6) 0 (0) 4 (18.2) 13 (76.5) 4 (12.5)
MIC50 0.023 0.016 0.047 0.064 0.125 0.016 0.023 0.023 0.016 0.016 0.094 0.023
MIC90 0.064 0.032 0.19 0.19 0.19 0.032 0.047 0.38 0.023 0.19 0.125 0.064
ERY 4 (5.0) 9 (33.3) 34 (65.4) 30 (36.1) 47 (100.0) 0 (0) 0 (0) 16 (61.5) 9 (34.6) 3 (13.6) 0 (0) 2 (6.3)
CLI 1 (1.3) 4 (14.8) 33 (63.5) 30 (36.1) 47 (100.0) 0 (0) 0 (0) 16 (61.5) 4 (15.4) 0 (0) 0 (0) 1 (3.1)
LEV 0 (0) 0 (0) 0 (0) 1 (1.2) 1 (2.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
SXT 10 (12.5) 6 (22.2) 27 (51.9) 3 (3.6) 6 (12.8) 3 (8.1) 4 (11.4) 16 (61.5) 5 (19.2) 1 (4.5) 2 (11.8) 9 (26.1)
TET 5 (6.3) 3 (11.1) 34 (65.4) 32 (38.6) 44 (93.6) 0 (0) 1 (2.9) 21 (80.8) 3 (11.5) 0 (0) 1 (5.9) 4 (12.5)
CHL 1 (1.3) 0 (0) 7 (13.5) 2 (2.4) 2 (4.3) 0 (0) 1 (2.9) 6 (23.1) 0 (0) 0 (0) 0 (0) 1 (3.1)
aAll isolates were susceptible to cefotaxime, vancomycin and linezolid. MDR: multidrug resistance, PEN: penicillin, MIC: minimum inhibitory concentration,
ERY: erythromycin, CLI: clindamycin, LEV: levofloxacin, SXT: trimethoprim-sulfamethoxazole, TET: tetracycline, CHL: chloramphenicol. Isolates
presenting PEN MIC0.12μg/ml were considered resistant and isolates presenting PEN MIC<0.12μg/ml were considered susceptible.
bOther CCs or STs not included in those discriminated. MDR: CC4248 (n = 1), ST1518 (n = 1), ST1662 (n = 1); PEN: CC4248 (n = 1), ST1518 (n = 1),
ST1662 (n = 1), ST4255 (n = 1); ERY: ST1518 (n = 1), ST1662 (n = 1); CLI: ST1662 (n = 1); SXT: CC681 (n = 1), CC4248 (n = 1), ST42 (n = 1), ST1518
(n = 1), ST1662 (n = 1), ST3324 (n = 1), ST9957 (n = 1), ST9965 (n = 1), ST9970 (n = 1); TET: CC4248 (n = 2), ST1715 (n = 1), ST3324 (n = 1); CHL:
ST1662 (n = 1).
doi:10.1371/journal.pone.0170354.t002
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S5 Table. Allelic profiles of genes wciN and wciP and respective serotype and CC/ST.
(PDF)
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17. van der Linden M, Winkel N, Küntzel S, Farkas A, Perniciaro SR, Reinert RR, et al. Epidemiology of
Streptococcus pneumoniae serogroup 6 isolates from IPD in children and adults in Germany. PloS
One. 2013; 8: e60848. doi: 10.1371/journal.pone.0060848 PMID: 23593324
18. Horácio AN, Silva-Costa C, Diamantino-Miranda J, Lopes JP, Ramirez M, Melo-Cristino J, et al. Popula-
tion structure of Streptococcus pneumoniae causing invasive disease in adults in Portugal before
PCV13 availability for adults: 2008–2011. PloS One. 2016; 11: e0153602. doi: 10.1371/journal.pone.
0153602 PMID: 27168156
19. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, et al. Nomenclature of major antimi-
crobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemi-
ology network. J Clin Microbiol. 2001; 39: 2565–71. doi: 10.1128/JCM.39.7.2565-2571.2001 PMID:
11427569
20. Baek JY, Park IH, Song J-H, Ko KS. Prevalence of isolates of Streptococcus pneumoniae putative sero-
type 6E in South Korea. J Clin Microbiol. 2014; 52: 2096–2099. doi: 10.1128/JCM.00228-14 PMID:
24719436
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